SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '3mws'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_1 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ALA A 28 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.76A	1c6yA-3mwsA: 18.8	1c6yA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_1 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.65A	1c6yA-3mwsA: 18.8	1c6yA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.45A	1c6yB-3mwsA: 18.3	1c6yB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 ILE A 84	None	0.43A	1c6yB-3mwsA: 18.3	1c6yB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 THR A 80 ILE A 84	None	0.55A	1c6yB-3mwsA: 18.3	1c6yB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 THR A 80 PRO A 81	None	0.67A	1c6yB-3mwsA: 18.3	1c6yB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Y_B_MK1B524_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 50 THR A 80 ILE A 84	None	0.69A	1c6yB-3mwsA: 18.3	1c6yB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_1 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.71A	1c6zA-3mwsA: 18.6	1c6zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_1 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.56A	1c6zA-3mwsA: 18.6	1c6zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_1 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 ILE A 84	None	0.41A	1c6zA-3mwsA: 18.6	1c6zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50	None	0.53A	1c6zB-3mwsA: 18.6	1c6zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 ILE A 84	None	0.43A	1c6zB-3mwsA: 18.6	1c6zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1C6Z_B_ROCB505_2 (PROTEIN (PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 PRO A 81	None	0.59A	1c6zB-3mwsA: 18.6	1c6zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4S_A_TPVA201_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.02A	1d4sA-3mwsA: 19.6	1d4sA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4S_A_TPVA201_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81	None	0.52A	1d4sA-3mwsA: 19.6	1d4sA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4Y_A_TPVA501_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.88A	1d4yA-3mwsA: 19.9	1d4yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4Y_A_TPVA501_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 ILE A 47 ILE A 50 VAL A 82	None	0.77A	1d4yA-3mwsA: 19.9	1d4yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4Y_A_TPVA501_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.46A	1d4yA-3mwsA: 19.9	1d4yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4Y_A_TPVA501_1 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.60A	1d4yA-3mwsA: 19.9	1d4yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1D4Y_A_TPVA501_2 (PROTEIN (HIV-1 PROTEASE))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 8	LEU A 23 ASP A 25 ALA A 28 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.61A	1d4yB-3mwsA: 19.5	1d4yB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1FB7_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 THR A 80 PRO A 81 VAL A 82	None	0.76A	1fb7A-3mwsA: 19.3	1fb7A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1FB7_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.61A	1fb7A-3mwsA: 19.3	1fb7A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1FB7_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 THR A 80 VAL A 82 ILE A 84	None	0.54A	1fb7A-3mwsA: 19.3	1fb7A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1FB7_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.59A	1fb7A-3mwsA: 19.3	1fb7A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HPV_B_478B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	LEU A 23 ASP A 25 GLY A 27 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.56A	1hpvA-3mwsA: 19.7	1hpvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HPV_B_478B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 GLY A 27 VAL A 32 ILE A 47 GLY A 48 PRO A 81 ILE A 84	None	0.93A	1hpvA-3mwsA: 19.7	1hpvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HPV_B_478B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.80A	1hpvB-3mwsA: 19.7	1hpvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HPV_B_478B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.56A	1hpvB-3mwsA: 19.7	1hpvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSG_B_MK1B902_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82	None	0.87A	1hsgA-3mwsA: 19.7	1hsgA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSG_B_MK1B902_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.51A	1hsgA-3mwsA: 19.7	1hsgA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSG_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.86A	1hsgB-3mwsA: 19.5	1hsgB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSG_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.42A	1hsgB-3mwsA: 19.5	1hsgB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSG_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.37A	1hsgB-3mwsA: 19.5	1hsgB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_A_MK1A401_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.85A	1hshA-3mwsA: 19.0	1hshA-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_A_MK1A401_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.39A	1hshA-3mwsA: 19.0	1hshA-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_A_MK1A401_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 ILE A 84	None	0.55A	1hshA-3mwsA: 19.0	1hshA-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_A_MK1A401_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.64A	1hshA-3mwsA: 19.0	1hshA-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_A_MK1A401_2 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.70A	1hshB-3mwsA: 19.2	1hshB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_C_MK1C402_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.53A	1hshC-3mwsA: 19.3	1hshC-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HSH_C_MK1C402_1 (HIV-II PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.56A	1hshC-3mwsA: 19.3	1hshC-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.89A	1hxbA-3mwsA: 19.6	1hxbA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.61A	1hxbA-3mwsA: 19.6	1hxbA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 48 GLY A 49 ILE A 50 ILE A 84	None	0.41A	1hxbA-3mwsA: 19.6	1hxbA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 48 GLY A 49 PRO A 81 ILE A 84	None	0.44A	1hxbA-3mwsA: 19.6	1hxbA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 THR A 80 VAL A 82	None	0.55A	1hxbA-3mwsA: 19.6	1hxbA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82	None	0.88A	1hxbB-3mwsA: 19.6	1hxbB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.39A	1hxbB-3mwsA: 19.6	1hxbB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.55A	1hxbB-3mwsA: 19.6	1hxbB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	1hxbB-3mwsA: 19.6	1hxbB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXB_A_ROCA100_4 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 4	GLY A 27 ASP A 29 GLY A 48 THR A 80	None	0.31A	1hxbB-3mwsA: 19.6	1hxbB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXW_B_RITB301_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.18A	1hxwA-3mwsA: 20.2	1hxwA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXW_B_RITB301_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 GLY A 27 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.99A	1hxwA-3mwsA: 20.2	1hxwA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXW_B_RITB301_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 GLY A 27 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.46A	1hxwA-3mwsA: 20.2	1hxwA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXW_B_RITB301_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82	None	1.06A	1hxwB-3mwsA: 19.4	1hxwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1HXW_B_RITB301_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.59A	1hxwB-3mwsA: 19.4	1hxwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1K6C_B_MK1B902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 48 GLY A 49 PRO A 81	None	0.47A	1k6cA-3mwsA: 19.5	1k6cA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1K6C_B_MK1B902_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.92A	1k6cB-3mwsA: 19.5	1k6cB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1K6C_B_MK1B902_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.60A	1k6cB-3mwsA: 19.5	1k6cB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.47A	1muiA-3mwsA: 19.3	1muiA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.84A	1muiA-3mwsA: 19.3	1muiA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.64A	1muiA-3mwsA: 19.3	1muiA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.32A	1muiB-3mwsA: 19.6	1muiB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.56A	1muiB-3mwsA: 19.6	1muiB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	1muiB-3mwsA: 19.6	1muiB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1MUI_B_AB1B100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.78A	1muiB-3mwsA: 19.6	1muiB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_B_RITB301_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.46A	1n49A-3mwsA: 19.7	1n49A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_B_RITB301_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.13A	1n49B-3mwsA: 19.2	1n49B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_B_RITB301_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.78A	1n49B-3mwsA: 19.2	1n49B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_D_RITD401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.70A	1n49C-3mwsA: 19.2	1n49C-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_D_RITD401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 6	ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	0.42A	1n49D-3mwsA: 19.6	1n49D-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1N49_D_RITD401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 6	ASP A 29 ILE A 50 PRO A 81 ILE A 84	None	0.61A	1n49D-3mwsA: 19.6	1n49D-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_1 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.88A	1ohrA-3mwsA: 20.0	1ohrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_1 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.47A	1ohrA-3mwsA: 20.0	1ohrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_1 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.60A	1ohrA-3mwsA: 20.0	1ohrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_1 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.62A	1ohrA-3mwsA: 20.0	1ohrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_2 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.57A	1ohrB-3mwsA: 19.0	1ohrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_2 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.68A	1ohrB-3mwsA: 19.0	1ohrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1OHR_A_1UNA201_2 (ASPARTYLPROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.88A	1ohrB-3mwsA: 19.0	1ohrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	1.01A	1rl8A-3mwsA: 20.0	1rl8A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.16A	1rl8A-3mwsA: 20.0	1rl8A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.73A	1rl8A-3mwsA: 20.0	1rl8A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.56A	1rl8A-3mwsA: 20.0	1rl8A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 GLY A 27 ASP A 30 ILE A 50 PRO A 81	None	0.91A	1rl8B-3mwsA: 20.1	1rl8B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.43A	1rl8B-3mwsA: 20.1	1rl8B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	1.37A	1rl8B-3mwsA: 20.1	1rl8B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.61A	1rl8B-3mwsA: 20.1	1rl8B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1RL8_A_RITA9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 24 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ALA A 22	None	1.38A	1rl8B-3mwsA: 20.1	1rl8B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 LEU A 23 ASP A 25 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.51A	1sdtA-3mwsA: 20.3	1sdtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 GLY A 49 VAL A 82 ILE A 84	None	0.83A	1sdtA-3mwsA: 20.3	1sdtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.57A	1sdtB-3mwsA: 19.5	1sdtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	1sdtB-3mwsA: 19.5	1sdtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	1sdtB-3mwsA: 19.5	1sdtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDT_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.02A	1sdtB-3mwsA: 19.5	1sdtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDU_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ILE A 47 GLY A 48 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.53A	1sduA-3mwsA: 19.5	1sduA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDU_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.61A	1sduA-3mwsA: 19.5	1sduA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDU_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.47A	1sduB-3mwsA: 19.9	1sduB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDU_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.37A	1sduB-3mwsA: 19.9	1sduB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDU_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.48A	1sduB-3mwsA: 19.9	1sduB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDV_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.48A	1sdvA-3mwsA: 20.3	1sdvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDV_B_MK1B902_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ASP A 25 ALA A 28 GLY A 49 PRO A 81 ILE A 84	None	0.90A	1sdvA-3mwsA: 20.3	1sdvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDV_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	1.11A	1sdvB-3mwsA: 19.5	1sdvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDV_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.61A	1sdvB-3mwsA: 19.5	1sdvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SDV_B_MK1B902_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.50A	1sdvB-3mwsA: 19.5	1sdvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SGU_B_MK1B2632_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81	None	0.57A	1sguB-3mwsA: 19.9	1sguB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SGU_B_MK1B2632_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81	None	0.54A	1sguB-3mwsA: 19.9	1sguB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SGU_B_MK1B2632_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 GLY A 49 ILE A 50 PRO A 81	None	0.59A	1sguB-3mwsA: 19.9	1sguB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SGU_B_MK1B2632_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ALA A 22	None	1.31A	1sguB-3mwsA: 19.9	1sguB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SH9_B_RITB301_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 GLY A 27 ASP A 30 ILE A 47 GLY A 49 PRO A 81	None	0.51A	1sh9B-3mwsA: 19.7	1sh9B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1SH9_B_RITB301_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 GLY A 27 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.48A	1sh9B-3mwsA: 19.7	1sh9B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.74A	1t3rA-3mwsA: 20.1	1t3rA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.20A	1t3rA-3mwsA: 20.1	1t3rA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 VAL A 82	None	0.57A	1t3rA-3mwsA: 20.1	1t3rA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.44A	1t3rA-3mwsA: 20.1	1t3rA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ALA A 28 ASP A 29 PRO A 81 VAL A 82 ILE A 84	None	1.49A	1t3rB-3mwsA: 20.0	1t3rB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.48A	1t3rB-3mwsA: 20.0	1t3rB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T3R_A_017A1200_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.97A	1t3rB-3mwsA: 20.0	1t3rB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7I_A_017A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.24A	1t7iA-3mwsA: 19.8	1t7iA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7I_A_017A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47	None	0.60A	1t7iA-3mwsA: 19.8	1t7iA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7I_A_017A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50	None	0.39A	1t7iA-3mwsA: 19.8	1t7iA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7I_A_017A200_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 7	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50	None	0.26A	1t7iB-3mwsA: 19.8	1t7iB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7J_A_478A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 50 THR A 80	None	1.44A	1t7jA-3mwsA: 19.6	1t7jA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7J_A_478A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.26A	1t7jA-3mwsA: 19.6	1t7jA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7J_A_478A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50	None	0.60A	1t7jA-3mwsA: 19.6	1t7jA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7J_A_478A200_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	LEU A 23 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.76A	1t7jA-3mwsA: 19.6	1t7jA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1T7J_A_478A200_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 7	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50	None	0.29A	1t7jB-3mwsA: 19.6	1t7jB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOF_C_FRDC305_1 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	ASP A 25 GLY A 49 PRO A 81 ILE A 84	None	0.37A	2aofA-3mwsA: 20.3	2aofA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOF_C_FRDC305_2 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	LEU A 23 ASP A 25 PRO A 81 ILE A 84	None	0.26A	2aofB-3mwsA: 19.7	2aofB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOH_C_FRDC305_1 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	LEU A 23 ASP A 25 GLY A 49 PRO A 81	None	0.28A	2aohA-3mwsA: 20.3	2aohA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOH_C_FRDC305_2 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	LEU A 23 ASP A 25 GLY A 49 ILE A 84	None	0.33A	2aohB-3mwsA: 19.6	2aohB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOI_C_FRDC305_1 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 5	ASP A 25 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.41A	2aoiA-3mwsA: 20.3	2aoiA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOI_C_FRDC305_1 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.98A	2aoiA-3mwsA: 20.3	2aoiA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOI_C_FRDC305_2 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 5	LEU A 23 ASP A 25 PRO A 81 VAL A 82 ILE A 84	None	0.28A	2aoiB-3mwsA: 19.6	2aoiB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AOJ_C_FRDC305_1 (POL POLYPROTEIN PEPTIDE INHIBITOR)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 5	LEU A 23 ASP A 25 GLY A 49 PRO A 81 VAL A 82	None	0.49A	2aojA-3mwsA: 20.2	2aojA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.95A	2aquA-3mwsA: 19.9	2aquA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 PRO A 81	None	0.63A	2aquA-3mwsA: 19.9	2aquA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	2aquA-3mwsA: 19.9	2aquA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.94A	2aquB-3mwsA: 19.7	2aquB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	0.60A	2aquB-3mwsA: 19.7	2aquB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AQU_B_DR7B300_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.49A	2aquB-3mwsA: 19.7	2aquB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVO_B_MK1B902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ARG A 8 LEU A 23 ASP A 25 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.68A	2avoA-3mwsA: 19.4	2avoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVO_B_MK1B902_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.02A	2avoB-3mwsA: 19.9	2avoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVO_B_MK1B902_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.65A	2avoB-3mwsA: 19.9	2avoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVO_B_MK1B902_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.59A	2avoB-3mwsA: 19.9	2avoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVS_B_MK1B902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ALA A 28 ASP A 29 GLY A 48 GLY A 49	None	1.44A	2avsA-3mwsA: 19.6	2avsA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVS_B_MK1B902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 ILE A 84	None	0.56A	2avsA-3mwsA: 19.6	2avsA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVS_B_MK1B902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 48 GLY A 49 ILE A 84	None	0.40A	2avsA-3mwsA: 19.6	2avsA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVS_B_MK1B902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81 ILE A 84	None	0.51A	2avsB-3mwsA: 19.8	2avsB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVS_B_MK1B902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.42A	2avsB-3mwsA: 19.8	2avsB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 82 ILE A 84	None	0.48A	2avvA-3mwsA: 19.6	2avvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 48 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.43A	2avvA-3mwsA: 19.6	2avvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 29 GLY A 48 GLY A 49 ILE A 50	None	1.21A	2avvA-3mwsA: 19.6	2avvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 VAL A 32 PRO A 81	None	0.41A	2avvA-3mwsA: 19.6	2avvA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.43A	2avvB-3mwsA: 19.4	2avvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.54A	2avvB-3mwsA: 19.4	2avvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	2avvB-3mwsA: 19.4	2avvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_A_MK1A901_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.89A	2avvB-3mwsA: 19.4	2avvB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.74A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 48 GLY A 49	None	1.39A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.39A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.63A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 48 GLY A 49 ILE A 84	None	0.39A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.54A	2avvD-3mwsA: 19.4	2avvD-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82	None	0.84A	2avvE-3mwsA: 19.5	2avvE-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.49A	2avvE-3mwsA: 19.5	2avvE-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.44A	2avvE-3mwsA: 19.5	2avvE-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2AVV_E_MK1E902_3 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.45A	2avvE-3mwsA: 19.5	2avvE-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B60_B_RITB100_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	2b60A-3mwsA: 19.9	2b60A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B60_B_RITB100_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.51A	2b60A-3mwsA: 19.9	2b60A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B60_B_RITB100_2 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	2b60B-3mwsA: 19.9	2b60B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81	None	0.89A	2b7zA-3mwsA: 20.1	2b7zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 ASP A 25 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.28A	2b7zA-3mwsA: 20.1	2b7zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81	None	0.50A	2b7zA-3mwsA: 20.1	2b7zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.46A	2b7zA-3mwsA: 20.1	2b7zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ALA A 22	None	1.29A	2b7zA-3mwsA: 20.1	2b7zA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81	None	0.88A	2b7zB-3mwsA: 19.8	2b7zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81	None	0.55A	2b7zB-3mwsA: 19.8	2b7zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.53A	2b7zB-3mwsA: 19.8	2b7zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2B7Z_B_MK1B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ALA A 22	None	1.31A	2b7zB-3mwsA: 19.8	2b7zB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2BPX_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.81A	2bpxB-3mwsA: 18.9	2bpxB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2BPX_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.69A	2bpxB-3mwsA: 18.9	2bpxB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2BPX_B_MK1B902_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.65A	2bpxB-3mwsA: 18.9	2bpxB-3mwsA: 78.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2F78_A_BEZA1003_0 (HTH-TYPE TRANSCRIPTIONAL REGULATOR BENM)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 7	VAL A 13 LEU A 24 PHE A 89 THR A 31	None	1.09A	2f78A-3mwsA: undetectable	2f78A-3mwsA: 19.55
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2F78_B_BEZB1004_0 (HTH-TYPE TRANSCRIPTIONAL REGULATOR BENM)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 7	VAL A 13 LEU A 24 PHE A 89 THR A 31	None	1.10A	2f78B-3mwsA: undetectable	2f78B-3mwsA: 19.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F80_B_017B301_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 GLY A 48 PRO A 81 ILE A 84	None	0.94A	2f80A-3mwsA: 20.2	2f80A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F80_B_017B301_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.40A	2f80A-3mwsA: 20.2	2f80A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F80_B_017B301_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.24A	2f80B-3mwsA: 19.6	2f80B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.96A	2f81A-3mwsA: 20.3	2f81A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.46A	2f81A-3mwsA: 20.3	2f81A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.32A	2f81A-3mwsA: 20.3	2f81A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.75A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.53A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F81_A_017A302_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.37A	2f81B-3mwsA: 19.7	2f81B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.72A	2f8gA-3mwsA: 20.3	2f8gA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49	None	1.39A	2f8gA-3mwsA: 20.3	2f8gA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.49A	2f8gA-3mwsA: 20.3	2f8gA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 VAL A 82 ILE A 84	None	0.40A	2f8gA-3mwsA: 20.3	2f8gA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.96A	2f8gB-3mwsA: 19.7	2f8gB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2F8G_B_017B401_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.33A	2f8gB-3mwsA: 19.7	2f8gB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXD_A_DR7A102_1 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.28A	2fxdA-3mwsA: 19.4	2fxdA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXD_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 7	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	0.40A	2fxdB-3mwsA: 20.0	2fxdB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_1 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 GLY A 27 GLY A 48 GLY A 49 ILE A 50 PHE A 53 PRO A 81	None	0.76A	2fxeA-3mwsA: 19.6	2fxeA-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_1 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 GLY A 49 VAL A 82 ILE A 84	None	0.90A	2fxeA-3mwsA: 19.6	2fxeA-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_1 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 48 GLY A 49 ILE A 50 PHE A 53 PRO A 81 VAL A 82 ILE A 84	None	0.61A	2fxeA-3mwsA: 19.6	2fxeA-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_1 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	GLY A 27 ALA A 28 ASP A 29 GLY A 48 PRO A 81 ILE A 84	None	0.95A	2fxeA-3mwsA: 19.6	2fxeA-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.94A	2fxeB-3mwsA: 19.9	2fxeB-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.44A	2fxeB-3mwsA: 19.9	2fxeB-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ILE A 47 PRO A 81 VAL A 82	None	0.61A	2fxeB-3mwsA: 19.9	2fxeB-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	1.33A	2fxeB-3mwsA: 19.9	2fxeB-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2FXE_A_DR7A102_2 (POL PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.42A	2fxeB-3mwsA: 19.9	2fxeB-3mwsA: 81.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 ILE A 84	None	0.66A	2hs1A-3mwsA: 18.6	2hs1A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.50A	2hs1A-3mwsA: 18.6	2hs1A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.77A	2hs1B-3mwsA: 20.0	2hs1B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.50A	2hs1B-3mwsA: 20.0	2hs1B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.57A	2hs1B-3mwsA: 20.0	2hs1B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS1_B_017B203_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	TRP A 42 PRO A 44 MET A 46 ARG A 57 GLY A 78	None	0.34A	2hs1B-3mwsA: 20.0	2hs1B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.87A	2hs2A-3mwsA: 18.6	2hs2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.65A	2hs2A-3mwsA: 18.6	2hs2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	2hs2A-3mwsA: 18.6	2hs2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.87A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.83A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.26A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.54A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.46A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2HS2_B_017B203_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 6	TRP A 42 PRO A 44 ARG A 57 GLY A 78	None	0.23A	2hs2B-3mwsA: 20.1	2hs2B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.02A	2idwA-3mwsA: 19.5	2idwA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.59A	2idwA-3mwsA: 19.5	2idwA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 ILE A 84	None	0.71A	2idwB-3mwsA: 19.7	2idwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.21A	2idwB-3mwsA: 19.7	2idwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None	0.41A	2idwB-3mwsA: 19.7	2idwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IDW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	0.40A	2idwB-3mwsA: 19.7	2idwB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEN_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.35A	2ienA-3mwsA: 20.3	2ienA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEN_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.48A	2ienA-3mwsA: 20.3	2ienA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEN_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.97A	2ienA-3mwsA: 20.3	2ienA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEN_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.43A	2ienB-3mwsA: 19.7	2ienB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81	None	1.07A	2ieoA-3mwsA: 20.3	2ieoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82	None	1.45A	2ieoA-3mwsA: 20.3	2ieoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.39A	2ieoA-3mwsA: 20.3	2ieoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.73A	2ieoB-3mwsA: 19.7	2ieoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.26A	2ieoB-3mwsA: 19.7	2ieoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82	None	0.50A	2ieoB-3mwsA: 19.7	2ieoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2IEO_A_017A402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.32A	2ieoB-3mwsA: 19.7	2ieoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81 ILE A 84	None	1.00A	2nmyA-3mwsA: 18.8	2nmyA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 THR A 80 PRO A 81 ILE A 84	None	0.67A	2nmyA-3mwsA: 18.8	2nmyA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 PRO A 81 ILE A 84	None	0.45A	2nmyA-3mwsA: 18.8	2nmyA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.97A	2nmyB-3mwsA: 18.5	2nmyB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	0.57A	2nmyB-3mwsA: 18.5	2nmyB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMY_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.36A	2nmyB-3mwsA: 18.5	2nmyB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.00A	2nmzA-3mwsA: 19.5	2nmzA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.38A	2nmzA-3mwsA: 19.5	2nmzA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.38A	2nmzA-3mwsA: 19.5	2nmzA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.64A	2nmzA-3mwsA: 19.5	2nmzA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	2nmzA-3mwsA: 19.5	2nmzA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 50	None	1.46A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	0.76A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 50 PRO A 81 ILE A 84	None	0.65A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.35A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 47 PRO A 81 ILE A 84	None	0.70A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NMZ_B_ROCB401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	2nmzB-3mwsA: 19.6	2nmzB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82	None	0.97A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.33A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82	None	0.66A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.42A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 PRO A 81 VAL A 82	None	0.45A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 VAL A 32 THR A 80	None	0.66A	2nnkA-3mwsA: 19.7	2nnkA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 LEU A 23 ASP A 30 PRO A 81 VAL A 82	None	0.71A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 LEU A 23 ILE A 50 PRO A 81 VAL A 82	None	0.85A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	GLY A 27 ASP A 29 ASP A 30 GLY A 48 PRO A 81	None	0.94A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.24A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ASP A 29 ASP A 30 ILE A 47 PRO A 81 VAL A 82	None	0.66A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNK_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.54A	2nnkB-3mwsA: 19.4	2nnkB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.96A	2nnpA-3mwsA: 19.5	2nnpA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 ASP A 29 GLY A 48 THR A 80 PRO A 81 VAL A 82	None	0.98A	2nnpA-3mwsA: 19.5	2nnpA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81	None	0.66A	2nnpA-3mwsA: 19.5	2nnpA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 VAL A 82	None	0.70A	2nnpA-3mwsA: 19.5	2nnpA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 THR A 80 PRO A 81 VAL A 82	None	0.63A	2nnpA-3mwsA: 19.5	2nnpA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2NNP_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.57A	2nnpB-3mwsA: 19.7	2nnpB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4K_A_DR7A301_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.36A	2o4kA-3mwsA: 20.1	2o4kA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4K_A_DR7A301_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 ALA A 28 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PHE A 53 PRO A 81 ILE A 84	None	0.49A	2o4kA-3mwsA: 20.1	2o4kA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4K_A_DR7A301_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.03A	2o4kB-3mwsA: 19.6	2o4kB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4K_A_DR7A301_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 GLY A 27 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.67A	2o4kB-3mwsA: 19.6	2o4kB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4K_A_DR7A301_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.31A	2o4kB-3mwsA: 19.6	2o4kB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 LEU A 23 ASP A 30 PRO A 81 VAL A 82	None	0.71A	2o4lA-3mwsA: 20.0	2o4lA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ILE A 47 GLY A 49 PRO A 81 VAL A 82	None	0.65A	2o4lA-3mwsA: 20.0	2o4lA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82	None	0.85A	2o4lA-3mwsA: 20.0	2o4lA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.59A	2o4lA-3mwsA: 20.0	2o4lA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	2o4lA-3mwsA: 20.0	2o4lA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4L_A_TPVA403_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 VAL A 82 ILE A 84	None	0.52A	2o4lB-3mwsA: 19.4	2o4lB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4N_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.66A	2o4nA-3mwsA: 20.6	2o4nA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82	None	0.93A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81	None	0.72A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.61A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81 VAL A 82	None	0.62A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.40A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.48A	2o4pA-3mwsA: 20.0	2o4pA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.67A	2o4pB-3mwsA: 19.5	2o4pB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4P_A_TPVA300_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.49A	2o4pB-3mwsA: 19.5	2o4pB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4S_A_AB1A400_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81	None	0.60A	2o4sA-3mwsA: 20.2	2o4sA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4S_A_AB1A400_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	2o4sA-3mwsA: 20.2	2o4sA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4S_A_AB1A400_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 48 PRO A 81	None	0.88A	2o4sA-3mwsA: 20.2	2o4sA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4S_A_AB1A400_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.75A	2o4sA-3mwsA: 20.2	2o4sA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2O4S_A_AB1A400_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.54A	2o4sB-3mwsA: 19.5	2o4sB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYM_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81	None	0.89A	2pymA-3mwsA: 20.0	2pymA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYM_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.44A	2pymA-3mwsA: 20.0	2pymA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYM_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	2pymA-3mwsA: 20.0	2pymA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYM_A_1UNA1001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.44A	2pymB-3mwsA: 20.0	2pymB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYM_A_1UNA1001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.51A	2pymB-3mwsA: 20.0	2pymB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYN_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81	None	0.84A	2pynA-3mwsA: 20.1	2pynA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYN_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.45A	2pynA-3mwsA: 20.1	2pynA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYN_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.49A	2pynA-3mwsA: 20.1	2pynA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYN_A_1UNA1001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.45A	2pynB-3mwsA: 20.0	2pynB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2PYN_A_1UNA1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 THR A 80 PRO A 81	None	0.43A	2pynB-3mwsA: 20.0	2pynB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q5K_A_AB1A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.84A	2q5kA-3mwsA: 19.6	2q5kA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q5K_A_AB1A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.50A	2q5kA-3mwsA: 19.6	2q5kA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q5K_A_AB1A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.31A	2q5kA-3mwsA: 19.6	2q5kA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q5K_A_AB1A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.42A	2q5kB-3mwsA: 20.1	2q5kB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q63_A_1UNA1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.42A	2q63B-3mwsA: 19.9	2q63B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q63_A_1UNA1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.47A	2q63B-3mwsA: 19.9	2q63B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81	None	0.81A	2q64A-3mwsA: 19.8	2q64A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.49A	2q64A-3mwsA: 19.8	2q64A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 THR A 80 VAL A 82	None	0.38A	2q64A-3mwsA: 19.8	2q64A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 VAL A 32 GLY A 48 VAL A 82 ILE A 84	None	0.76A	2q64B-3mwsA: 19.8	2q64B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.41A	2q64B-3mwsA: 19.8	2q64B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Q64_B_1UNB1001_4 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 THR A 80 PRO A 81	None	0.37A	2q64B-3mwsA: 19.8	2q64B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QAK_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.87A	2qakA-3mwsA: 20.0	2qakA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QAK_A_1UNA1001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.51A	2qakA-3mwsA: 20.0	2qakA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QAK_A_1UNA1001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 THR A 80 VAL A 82	None	0.50A	2qakA-3mwsA: 20.0	2qakA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QAK_A_1UNA1001_3 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.45A	2qakB-3mwsA: 20.0	2qakB-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QAK_A_1UNA1001_4 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 THR A 80 PRO A 81	None	0.43A	2qakB-3mwsA: 20.0	2qakB-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	ARG A 8 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	2qhcA-3mwsA: 19.8	2qhcA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.80A	2qhcA-3mwsA: 19.8	2qhcA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.62A	2qhcB-3mwsA: 19.8	2qhcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.50A	2qhcB-3mwsA: 19.8	2qhcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	2qhcB-3mwsA: 19.8	2qhcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2QHC_B_AB1B9001_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	0.94A	2qhcB-3mwsA: 19.8	2qhcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ASP A 29 GLY A 48 GLY A 49 ILE A 50	None	1.29A	2r5pA-3mwsA: 20.7	2r5pA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.69A	2r5pA-3mwsA: 20.7	2r5pA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	2r5pA-3mwsA: 20.7	2r5pA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.03A	2r5pB-3mwsA: 20.0	2r5pB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.42A	2r5pB-3mwsA: 20.0	2r5pB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_B_MK1B902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.56A	2r5pB-3mwsA: 20.0	2r5pB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ASP A 29 GLY A 48 GLY A 49 ILE A 50	None	1.29A	2r5pC-3mwsA: 20.7	2r5pC-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.69A	2r5pC-3mwsA: 20.7	2r5pC-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 48 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	2r5pC-3mwsA: 20.7	2r5pC-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.96A	2r5pD-3mwsA: 20.0	2r5pD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.42A	2r5pD-3mwsA: 20.0	2r5pD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.54A	2r5pD-3mwsA: 20.0	2r5pD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5P_D_MK1D902_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	2r5pD-3mwsA: 20.0	2r5pD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ARG A 8 LEU A 23 ASP A 25 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.61A	2r5qA-3mwsA: 20.6	2r5qA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.89A	2r5qA-3mwsA: 20.6	2r5qA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.02A	2r5qB-3mwsA: 19.6	2r5qB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.46A	2r5qB-3mwsA: 19.6	2r5qB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.69A	2r5qB-3mwsA: 19.6	2r5qB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_B_1UNB900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.52A	2r5qB-3mwsA: 19.6	2r5qB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_D_1UND900_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ARG A 8 LEU A 23 ASP A 25 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.61A	2r5qC-3mwsA: 20.6	2r5qC-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_D_1UND900_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.89A	2r5qC-3mwsA: 20.6	2r5qC-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_D_1UND900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.05A	2r5qD-3mwsA: 19.6	2r5qD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_D_1UND900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.73A	2r5qD-3mwsA: 19.6	2r5qD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2R5Q_D_1UND900_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.54A	2r5qD-3mwsA: 19.6	2r5qD-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	2rkfA-3mwsA: 19.6	2rkfA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.49A	2rkfA-3mwsA: 19.6	2rkfA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.34A	2rkfA-3mwsA: 19.6	2rkfA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.38A	2rkfB-3mwsA: 19.6	2rkfB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.90A	2rkfB-3mwsA: 19.6	2rkfB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.41A	2rkfB-3mwsA: 19.6	2rkfB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	1.38A	2rkfB-3mwsA: 19.6	2rkfB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKF_A_AB1A501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.51A	2rkfB-3mwsA: 19.6	2rkfB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.38A	2rkgA-3mwsA: 19.6	2rkgA-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.90A	2rkgA-3mwsA: 19.6	2rkgA-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.33A	2rkgA-3mwsA: 19.6	2rkgA-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	1.37A	2rkgA-3mwsA: 19.6	2rkgA-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_1 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.52A	2rkgA-3mwsA: 19.6	2rkgA-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.46A	2rkgB-3mwsA: 19.5	2rkgB-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2RKG_B_AB1B501_2 (PROTEASE RETROPEPSIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.33A	2rkgB-3mwsA: 19.5	2rkgB-3mwsA: 70.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.81A	2z54A-3mwsA: 20.0	2z54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.53A	2z54A-3mwsA: 20.0	2z54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.49A	2z54A-3mwsA: 20.0	2z54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.36A	2z54B-3mwsA: 20.0	2z54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.55A	2z54B-3mwsA: 20.0	2z54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	2z54B-3mwsA: 20.0	2z54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2Z54_A_AB1A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.80A	2z54B-3mwsA: 20.0	2z54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_1 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.37A	3bvbA-3mwsA: 20.3	3bvbA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_1 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ILE A 54 GLY A 49 ILE A 50 VAL A 82	None	1.39A	3bvbA-3mwsA: 20.3	3bvbA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_1 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 GLY A 27 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.03A	3bvbA-3mwsA: 20.3	3bvbA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_2 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.80A	3bvbB-3mwsA: 19.6	3bvbB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_2 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.35A	3bvbB-3mwsA: 19.6	3bvbB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_2 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.54A	3bvbB-3mwsA: 19.6	3bvbB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3BVB_B_017B401_2 (PROTEASE (RETROPEPSIN))	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	3bvbB-3mwsA: 19.6	3bvbB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYW_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3cywA-3mwsA: 20.1	3cywA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYW_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.79A	3cywB-3mwsA: 19.7	3cywB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYW_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3cywB-3mwsA: 19.7	3cywB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYW_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.29A	3cywB-3mwsA: 19.7	3cywB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYX_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.66A	3cyxA-3mwsA: 20.1	3cyxA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYX_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3cyxA-3mwsA: 20.1	3cyxA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYX_A_ROCA201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.52A	3cyxB-3mwsA: 19.7	3cyxB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYX_A_ROCA201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 48 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.33A	3cyxB-3mwsA: 19.7	3cyxB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3CYX_A_ROCA201_4 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 4	LEU A 23 ASP A 29 VAL A 32 THR A 80	None	0.44A	3cyxB-3mwsA: 19.7	3cyxB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.04A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81 VAL A 82	None	1.02A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 VAL A 82 ILE A 84	None	1.47A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.77A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82	None	0.71A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 VAL A 82	None	0.55A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.55A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.61A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 THR A 80 PRO A 81 VAL A 82	None	0.56A	3d1xA-3mwsA: 19.8	3d1xA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.38A	3d1xB-3mwsA: 19.7	3d1xB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.57A	3d1xB-3mwsA: 19.7	3d1xB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1X_A_ROCA201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.46A	3d1xB-3mwsA: 19.7	3d1xB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.95A	3d1yA-3mwsA: 19.9	3d1yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.36A	3d1yA-3mwsA: 19.9	3d1yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.60A	3d1yA-3mwsA: 19.9	3d1yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.58A	3d1yA-3mwsA: 19.9	3d1yA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ARG A 8 LEU A 23 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.82A	3d1yB-3mwsA: 19.4	3d1yB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Y_A_ROCA201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.67A	3d1yB-3mwsA: 19.4	3d1yB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.94A	3d1zA-3mwsA: 20.1	3d1zA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.51A	3d1zA-3mwsA: 20.1	3d1zA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.56A	3d1zA-3mwsA: 20.1	3d1zA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.68A	3d1zB-3mwsA: 19.7	3d1zB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.34A	3d1zB-3mwsA: 19.7	3d1zB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.42A	3d1zB-3mwsA: 19.7	3d1zB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D1Z_B_017B201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.35A	3d1zB-3mwsA: 19.7	3d1zB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.86A	3d20A-3mwsA: 20.3	3d20A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.85A	3d20A-3mwsA: 20.3	3d20A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3d20A-3mwsA: 20.3	3d20A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.44A	3d20A-3mwsA: 20.3	3d20A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.69A	3d20B-3mwsA: 19.6	3d20B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	3d20B-3mwsA: 19.6	3d20B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.40A	3d20B-3mwsA: 19.6	3d20B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3D20_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.33A	3d20B-3mwsA: 19.6	3d20B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EBZ_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.45A	3ebzA-3mwsA: 19.3	3ebzA-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EBZ_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.27A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EBZ_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.48A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EBZ_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.27A	3ebzB-3mwsA: 19.4	3ebzB-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.84A	3ekpB-3mwsA: 19.2	3ekpB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.34A	3ekpB-3mwsA: 19.2	3ekpB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.48A	3ekpB-3mwsA: 19.2	3ekpB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.86A	3ekpC-3mwsA: 19.8	3ekpC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.31A	3ekpC-3mwsA: 19.8	3ekpC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	3ekpC-3mwsA: 19.8	3ekpC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ALA A 28 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.76A	3ekpD-3mwsA: 19.8	3ekpD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 84	None	1.26A	3ekpD-3mwsA: 19.8	3ekpD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKP_C_478C200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 ILE A 84	None	0.43A	3ekpD-3mwsA: 19.8	3ekpD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.99A	3ekqA-3mwsA: 19.6	3ekqA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.32A	3ekqA-3mwsA: 19.6	3ekqA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.65A	3ekqA-3mwsA: 19.6	3ekqA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.39A	3ekqA-3mwsA: 19.6	3ekqA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ARG A 8 LEU A 23 VAL A 32 ILE A 50 PRO A 81	None	0.95A	3ekqB-3mwsA: 19.2	3ekqB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKQ_A_ROCA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.63A	3ekqB-3mwsA: 19.2	3ekqB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.82A	3ektA-3mwsA: 19.8	3ektA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.26A	3ektA-3mwsA: 19.8	3ektA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50	None	0.46A	3ektA-3mwsA: 19.8	3ektA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.41A	3ektB-3mwsA: 19.8	3ektB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.87A	3ektB-3mwsA: 19.8	3ektB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_B_017B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	3ektB-3mwsA: 19.8	3ektB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_D_017D200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.84A	3ektC-3mwsA: 19.3	3ektC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_D_017D200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	1.22A	3ektC-3mwsA: 19.3	3ektC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_D_017D200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.43A	3ektC-3mwsA: 19.3	3ektC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_D_017D200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.76A	3ektD-3mwsA: 19.3	3ektD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKT_D_017D200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.38A	3ektD-3mwsA: 19.3	3ektD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.68A	3ekvA-3mwsA: 19.8	3ekvA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.27A	3ekvA-3mwsA: 19.8	3ekvA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.37A	3ekvA-3mwsA: 19.8	3ekvA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.41A	3ekvA-3mwsA: 19.8	3ekvA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.49A	3ekvB-3mwsA: 19.5	3ekvB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKV_A_478A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.92A	3ekvB-3mwsA: 19.5	3ekvB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKW_B_DR7B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ARG A 8 ASP A 25 ALA A 28 ILE A 47 PRO A 81	None	0.69A	3ekwA-3mwsA: 19.9	3ekwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKW_B_DR7B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 29 GLY A 48 PRO A 81 ILE A 84	None	0.92A	3ekwA-3mwsA: 19.9	3ekwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKW_B_DR7B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.37A	3ekwA-3mwsA: 19.9	3ekwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKW_B_DR7B100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.26A	3ekwA-3mwsA: 19.9	3ekwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKW_B_DR7B100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.48A	3ekwB-3mwsA: 19.4	3ekwB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 THR A 80 PRO A 81 ILE A 84	None	0.91A	3ekxA-3mwsA: 19.3	3ekxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 THR A 80 PRO A 81 ILE A 84	None	0.68A	3ekxA-3mwsA: 19.3	3ekxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 THR A 80 ILE A 84	None	0.55A	3ekxA-3mwsA: 19.3	3ekxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 THR A 80 PRO A 81 ILE A 84	None	0.65A	3ekxA-3mwsA: 19.3	3ekxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.70A	3ekxB-3mwsA: 19.9	3ekxB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.41A	3ekxB-3mwsA: 19.9	3ekxB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ARG A 8 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.60A	3ekxB-3mwsA: 19.9	3ekxB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKX_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ARG A 8 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.56A	3ekxB-3mwsA: 19.9	3ekxB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKY_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.93A	3ekyA-3mwsA: 19.9	3ekyA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKY_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.43A	3ekyA-3mwsA: 19.9	3ekyA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKY_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.56A	3ekyA-3mwsA: 19.9	3ekyA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EKY_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.60A	3ekyB-3mwsA: 19.2	3ekyB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL0_A_1UNA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 8	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 ILE A 84	None	0.50A	3el0A-3mwsA: 19.0	3el0A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL0_A_1UNA201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.55A	3el0B-3mwsA: 19.9	3el0B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL1_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.46A	3el1A-3mwsA: 19.5	3el1A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL1_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.53A	3el1A-3mwsA: 19.5	3el1A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL1_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.80A	3el1B-3mwsA: 19.8	3el1B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL1_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.69A	3el1B-3mwsA: 19.8	3el1B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL4_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.87A	3el4A-3mwsA: 19.2	3el4A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL4_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 THR A 80 PRO A 81	None	0.72A	3el4A-3mwsA: 19.2	3el4A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL4_A_ROCA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 PRO A 81	None	0.68A	3el4A-3mwsA: 19.2	3el4A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL4_A_ROCA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81	None	0.83A	3el4B-3mwsA: 19.6	3el4B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL4_A_ROCA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.44A	3el4B-3mwsA: 19.6	3el4B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ASP A 25 ALA A 28 ASP A 29 ILE A 50 THR A 80	None	1.14A	3el5A-3mwsA: 19.9	3el5A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.07A	3el5A-3mwsA: 19.9	3el5A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.29A	3el5A-3mwsA: 19.9	3el5A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81	None	0.63A	3el5A-3mwsA: 19.9	3el5A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.33A	3el5A-3mwsA: 19.9	3el5A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.39A	3el5B-3mwsA: 19.3	3el5B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 THR A 80 PRO A 81	None	0.57A	3el5B-3mwsA: 19.3	3el5B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 THR A 80 PRO A 81	None	0.52A	3el5B-3mwsA: 19.3	3el5B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL5_B_1UNB201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 THR A 80 PRO A 81	None	0.90A	3el5B-3mwsA: 19.3	3el5B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL9_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 8	ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	0.45A	3el9A-3mwsA: 19.2	3el9A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL9_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 48 PRO A 81	None	1.13A	3el9B-3mwsA: 20.1	3el9B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL9_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 PRO A 81	None	0.59A	3el9B-3mwsA: 20.1	3el9B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EL9_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.30A	3el9B-3mwsA: 20.1	3el9B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM3_B_478B200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 30 VAL A 32 GLY A 48 VAL A 82 ILE A 84	None	0.82A	3em3A-3mwsA: 19.9	3em3A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM3_B_478B200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 49 VAL A 82 ILE A 84	None	0.56A	3em3A-3mwsA: 19.9	3em3A-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM3_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.97A	3em3B-3mwsA: 20.0	3em3B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM3_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.43A	3em3B-3mwsA: 20.0	3em3B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM3_B_478B200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.44A	3em3B-3mwsA: 20.0	3em3B-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.95A	3em4A-3mwsA: 19.7	3em4A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_A_DR7A100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.43A	3em4A-3mwsA: 19.7	3em4A-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 29 GLY A 48 PRO A 81 VAL A 82	None	0.92A	3em4B-3mwsA: 19.6	3em4B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ARG A 8 ASP A 25 ALA A 28 GLY A 49 PRO A 81	None	0.64A	3em4B-3mwsA: 19.6	3em4B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_A_DR7A100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.51A	3em4B-3mwsA: 19.6	3em4B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_V_DR7V100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	1.28A	3em4U-3mwsA: 20.0	3em4U-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_V_DR7V100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.39A	3em4U-3mwsA: 20.0	3em4U-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_V_DR7V100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ASP A 25 ASP A 29 GLY A 49 VAL A 82 ILE A 84	None	1.00A	3em4V-3mwsA: 19.7	3em4V-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM4_V_DR7V100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 ASP A 29 ILE A 47 GLY A 48 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	3em4V-3mwsA: 19.7	3em4V-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM6_A_017A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.44A	3em6B-3mwsA: 19.9	3em6B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3EM6_A_017A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.99A	3em6B-3mwsA: 19.9	3em6B-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.92A	3gguA-3mwsA: 20.2	3gguA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.30A	3gguA-3mwsA: 20.2	3gguA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81	None	0.49A	3gguA-3mwsA: 20.2	3gguA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.28A	3gguA-3mwsA: 20.2	3gguA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.85A	3gguB-3mwsA: 20.1	3gguB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.23A	3gguB-3mwsA: 20.1	3gguB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3GGU_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	None	0.50A	3gguB-3mwsA: 20.1	3gguB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JVY_B_017B401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.83A	3jvyA-3mwsA: 20.0	3jvyA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JVY_B_017B401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.36A	3jvyA-3mwsA: 20.0	3jvyA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JVY_B_017B401_2 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.34A	3jvyB-3mwsA: 19.4	3jvyB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JW2_A_017A401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.35A	3jw2A-3mwsA: 20.3	3jw2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JW2_A_017A401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 VAL A 82 ILE A 84	None	1.03A	3jw2A-3mwsA: 20.3	3jw2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JW2_A_017A401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.97A	3jw2A-3mwsA: 20.3	3jw2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3JW2_A_017A401_1 (GAG-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.36A	3jw2A-3mwsA: 20.3	3jw2A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.96A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.48A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.41A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	1.34A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.63A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 VAL A 32 THR A 80	None	0.67A	3k4vA-3mwsA: 19.6	3k4vA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.89A	3k4vB-3mwsA: 19.6	3k4vB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.44A	3k4vB-3mwsA: 19.6	3k4vB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.57A	3k4vB-3mwsA: 19.6	3k4vB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_B_ROCB201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3k4vB-3mwsA: 19.6	3k4vB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.75A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 30 VAL A 32 PRO A 81 VAL A 82	None	0.59A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 VAL A 32 ILE A 50 PRO A 81 VAL A 82	None	0.78A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.28A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.54A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.52A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 4	GLY A 27 ASP A 29 GLY A 48 THR A 80	None	0.43A	3k4vC-3mwsA: 19.6	3k4vC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.31A	3k4vD-3mwsA: 19.5	3k4vD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.59A	3k4vD-3mwsA: 19.5	3k4vD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3K4V_D_ROCD201_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3k4vD-3mwsA: 19.5	3k4vD-3mwsA: 79.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3KEE_D_30BD500_2 (GENOME POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 4	PHE A 89 TYR A 59 VAL A 10 LEU A 23	None	1.49A	3keeD-3mwsA: undetectable	3keeD-3mwsA: 24.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZS_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3lzsA-3mwsA: 20.1	3lzsA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZS_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.29A	3lzsA-3mwsA: 20.1	3lzsA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZS_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.44A	3lzsB-3mwsA: 20.1	3lzsB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZS_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.25A	3lzsB-3mwsA: 20.1	3lzsB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.77A	3lzuA-3mwsA: 20.2	3lzuA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.42A	3lzuA-3mwsA: 20.2	3lzuA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.21A	3lzuA-3mwsA: 20.2	3lzuA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.95A	3lzuB-3mwsA: 20.1	3lzuB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.35A	3lzuB-3mwsA: 20.1	3lzuB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	1.33A	3lzuB-3mwsA: 20.1	3lzuB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZU_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.21A	3lzuB-3mwsA: 20.1	3lzuB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZV_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	GLY A 27 ALA A 28 ASP A 29 GLY A 48 VAL A 82	None	0.82A	3lzvA-3mwsA: 19.4	3lzvA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZV_A_017A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.51A	3lzvA-3mwsA: 19.4	3lzvA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZV_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ARG A 8 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	3lzvB-3mwsA: 19.2	3lzvB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3LZV_A_017A200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.98A	3lzvB-3mwsA: 19.2	3lzvB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3N3I_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.79A	3n3iA-3mwsA: 13.8	3n3iA-3mwsA: 39.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3N3I_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 82	None	0.62A	3n3iA-3mwsA: 13.8	3n3iA-3mwsA: 39.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3N3I_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 VAL A 82	None	0.43A	3n3iA-3mwsA: 13.8	3n3iA-3mwsA: 39.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.92A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.29A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.47A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 ILE A 50 VAL A 82 ILE A 84	None	0.67A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.67A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.42A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.53A	3ndtA-3mwsA: 19.4	3ndtA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.92A	3ndtB-3mwsA: 19.6	3ndtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.96A	3ndtB-3mwsA: 19.6	3ndtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.91A	3ndtB-3mwsA: 19.6	3ndtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.69A	3ndtB-3mwsA: 19.6	3ndtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_A_ROCA101_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.44A	3ndtB-3mwsA: 19.6	3ndtB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.29A	3ndtC-3mwsA: 19.6	3ndtC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.61A	3ndtC-3mwsA: 19.6	3ndtC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.38A	3ndtC-3mwsA: 19.6	3ndtC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.51A	3ndtC-3mwsA: 19.6	3ndtC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.95A	3ndtD-3mwsA: 19.5	3ndtD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.33A	3ndtD-3mwsA: 19.5	3ndtD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.61A	3ndtD-3mwsA: 19.5	3ndtD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDT_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.30A	3ndtD-3mwsA: 19.5	3ndtD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.31A	3nduA-3mwsA: 19.5	3nduA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.57A	3nduA-3mwsA: 19.5	3nduA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	3nduA-3mwsA: 19.5	3nduA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81	None	0.93A	3nduB-3mwsA: 19.7	3nduB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.34A	3nduB-3mwsA: 19.7	3nduB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.58A	3nduB-3mwsA: 19.7	3nduB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3nduB-3mwsA: 19.7	3nduB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.55A	3nduC-3mwsA: 19.6	3nduC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.51A	3nduC-3mwsA: 19.6	3nduC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.30A	3nduD-3mwsA: 19.1	3nduD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.60A	3nduD-3mwsA: 19.1	3nduD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.42A	3nduD-3mwsA: 19.1	3nduD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDU_D_ROCD100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.43A	3nduD-3mwsA: 19.1	3nduD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.80A	3ndwA-3mwsA: 19.5	3ndwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 50 VAL A 82 ILE A 84	None	0.54A	3ndwA-3mwsA: 19.5	3ndwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.42A	3ndwA-3mwsA: 19.5	3ndwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.65A	3ndwA-3mwsA: 19.5	3ndwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 29 GLY A 48 VAL A 82 ILE A 84	None	0.85A	3ndwB-3mwsA: 19.6	3ndwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.52A	3ndwB-3mwsA: 19.6	3ndwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDW_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 48 VAL A 82 ILE A 84	None	1.46A	3ndwB-3mwsA: 19.6	3ndwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None	0.50A	3ndxA-3mwsA: 19.5	3ndxA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.40A	3ndxA-3mwsA: 19.5	3ndxA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	0.69A	3ndxA-3mwsA: 19.5	3ndxA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.67A	3ndxA-3mwsA: 19.5	3ndxA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30	None	0.68A	3ndxB-3mwsA: 19.7	3ndxB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82 ILE A 84	None	0.84A	3ndxB-3mwsA: 19.7	3ndxB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ALA A 28 ASP A 30 GLY A 48 VAL A 82 ILE A 84	None	1.45A	3ndxB-3mwsA: 19.7	3ndxB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 VAL A 82 ILE A 84	None	0.72A	3ndxB-3mwsA: 19.7	3ndxB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NDX_A_RITA100_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.53A	3ndxB-3mwsA: 19.7	3ndxB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	3nu3A-3mwsA: 20.3	3nu3A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.92A	3nu3A-3mwsA: 20.3	3nu3A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ARG A 8 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81	None	0.81A	3nu3B-3mwsA: 19.2	3nu3B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.67A	3nu3B-3mwsA: 19.2	3nu3B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.30A	3nu3B-3mwsA: 19.2	3nu3B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.54A	3nu3B-3mwsA: 19.2	3nu3B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU3_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.44A	3nu3B-3mwsA: 19.2	3nu3B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU4_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.57A	3nu4A-3mwsA: 20.2	3nu4A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU4_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.92A	3nu4A-3mwsA: 20.2	3nu4A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU4_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.26A	3nu4B-3mwsA: 19.2	3nu4B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU4_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 84	None	0.52A	3nu4B-3mwsA: 19.2	3nu4B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU4_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 GLY A 49 ILE A 50 ILE A 84	None	0.38A	3nu4B-3mwsA: 19.2	3nu4B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.03A	3nu5A-3mwsA: 20.2	3nu5A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.48A	3nu5A-3mwsA: 20.2	3nu5A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81	None	0.51A	3nu5B-3mwsA: 19.5	3nu5B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49	None	1.37A	3nu5B-3mwsA: 19.5	3nu5B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.58A	3nu5B-3mwsA: 19.5	3nu5B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU5_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 84	None	0.38A	3nu5B-3mwsA: 19.5	3nu5B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.53A	3nu6A-3mwsA: 19.9	3nu6A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.61A	3nu6A-3mwsA: 19.9	3nu6A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.96A	3nu6A-3mwsA: 19.9	3nu6A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.31A	3nu6B-3mwsA: 19.6	3nu6B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 VAL A 82 ILE A 84	None	0.50A	3nu6B-3mwsA: 19.6	3nu6B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU6_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.47A	3nu6B-3mwsA: 19.6	3nu6B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU9_A_478A401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 8	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.46A	3nu9A-3mwsA: 19.8	3nu9A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU9_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50	None	1.01A	3nu9B-3mwsA: 19.7	3nu9B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU9_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 VAL A 82	None	0.53A	3nu9B-3mwsA: 19.7	3nu9B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NU9_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.46A	3nu9B-3mwsA: 19.7	3nu9B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	3nujA-3mwsA: 20.2	3nujA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.92A	3nujA-3mwsA: 20.2	3nujA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.83A	3nujB-3mwsA: 19.5	3nujB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	3nujB-3mwsA: 19.5	3nujB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.51A	3nujB-3mwsA: 19.5	3nujB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUJ_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.40A	3nujB-3mwsA: 19.5	3nujB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 9	ASP A 25 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.56A	3nuoA-3mwsA: 20.2	3nuoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.94A	3nuoA-3mwsA: 20.2	3nuoA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.86A	3nuoB-3mwsA: 19.3	3nuoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	3nuoB-3mwsA: 19.3	3nuoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.51A	3nuoB-3mwsA: 19.3	3nuoB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3NUO_B_478B478_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.41A	3nuoB-3mwsA: 19.3	3nuoB-3mwsA: 78.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_A_017A200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.60A	3ogpA-3mwsA: 15.8	3ogpA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_A_017A200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 49 ILE A 50	None	0.51A	3ogpB-3mwsA: 16.1	3ogpB-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_A_017A200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 ALA A 28 VAL A 32 VAL A 82	None	0.69A	3ogpB-3mwsA: 16.1	3ogpB-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_B_017B200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 ALA A 28 GLY A 48 VAL A 82	None	0.90A	3ogpA-3mwsA: 15.8	3ogpA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_B_017B200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 ALA A 28 GLY A 49 ILE A 50	None	0.57A	3ogpA-3mwsA: 15.8	3ogpA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_B_017B200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	LEU A 23 ASP A 25 ALA A 28 ILE A 50 VAL A 82	None	0.81A	3ogpA-3mwsA: 15.8	3ogpA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_B_017B200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 48	None	0.80A	3ogpB-3mwsA: 16.1	3ogpB-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGP_B_017B200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.36A	3ogpB-3mwsA: 16.1	3ogpB-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGQ_A_AB1A200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 48	None	0.93A	3ogqA-3mwsA: 15.9	3ogqA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGQ_A_AB1A200_1 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50	None	0.59A	3ogqA-3mwsA: 15.9	3ogqA-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGQ_A_AB1A200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 50	None	0.47A	3ogqB-3mwsA: 16.1	3ogqB-3mwsA: 28.45
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OGQ_A_AB1A200_2 (FIV PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.45A	3ogqB-3mwsA: 16.1	3ogqB-3mwsA: 28.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXC_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.88A	3oxcA-3mwsA: 18.5	3oxcA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXC_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.62A	3oxcA-3mwsA: 18.5	3oxcA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXC_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.37A	3oxcA-3mwsA: 18.5	3oxcA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXC_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.56A	3oxcB-3mwsA: 18.9	3oxcB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXC_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.48A	3oxcB-3mwsA: 18.9	3oxcB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_A_478A200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 6	TRP A 42 PRO A 44 ARG A 57 GLY A 78	None	0.40A	3oxvA-3mwsA: 19.9	3oxvA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_B_478B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 82 ILE A 84	None	0.48A	3oxvA-3mwsA: 19.9	3oxvA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_B_478B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 GLY A 49 VAL A 82 ILE A 84	None	0.33A	3oxvA-3mwsA: 19.9	3oxvA-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_B_478B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	3oxvB-3mwsA: 20.0	3oxvB-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_B_478B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.00A	3oxvB-3mwsA: 20.0	3oxvB-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_C_478C200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.44A	3oxvC-3mwsA: 19.8	3oxvC-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_C_478C200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 84	None	0.37A	3oxvC-3mwsA: 19.8	3oxvC-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_C_478C200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	ARG A 8 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.50A	3oxvD-3mwsA: 19.8	3oxvD-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXV_C_478C200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.00A	3oxvD-3mwsA: 19.8	3oxvD-3mwsA: 75.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_B_017B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 VAL A 82	None	0.89A	3oxwA-3mwsA: 20.0	3oxwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_B_017B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 VAL A 82	None	0.45A	3oxwA-3mwsA: 20.0	3oxwA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.92A	3oxwB-3mwsA: 20.0	3oxwB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.43A	3oxwB-3mwsA: 20.0	3oxwB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.44A	3oxwB-3mwsA: 20.0	3oxwB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_D_017D200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.87A	3oxwC-3mwsA: 20.1	3oxwC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_D_017D200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 GLY A 49 VAL A 82	None	0.52A	3oxwC-3mwsA: 20.1	3oxwC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_D_017D200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.96A	3oxwD-3mwsA: 20.1	3oxwD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_D_017D200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.38A	3oxwD-3mwsA: 20.1	3oxwD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXW_D_017D200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.53A	3oxwD-3mwsA: 20.1	3oxwD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_A_DR7A100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 PRO A 81 ILE A 84	None	0.28A	3oxxA-3mwsA: 19.7	3oxxA-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_A_DR7A100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3oxxB-3mwsA: 19.9	3oxxB-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_C_DR7C100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.46A	3oxxC-3mwsA: 19.5	3oxxC-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_C_DR7C100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ALA A 28 ASP A 29 GLY A 48 PRO A 81 ILE A 84	None	0.96A	3oxxD-3mwsA: 19.5	3oxxD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_C_DR7C100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.35A	3oxxD-3mwsA: 19.5	3oxxD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OXX_C_DR7C100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	1.49A	3oxxD-3mwsA: 19.5	3oxxD-3mwsA: 74.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ALA A 28 ASP A 29 PRO A 81 VAL A 82 ILE A 84	None	1.49A	3oy4A-3mwsA: 19.3	3oy4A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.60A	3oy4A-3mwsA: 19.3	3oy4A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.93A	3oy4A-3mwsA: 19.3	3oy4A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 VAL A 82	None	0.75A	3oy4B-3mwsA: 19.5	3oy4B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.23A	3oy4B-3mwsA: 19.5	3oy4B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82	None	0.58A	3oy4B-3mwsA: 19.5	3oy4B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3OY4_B_017B200_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.53A	3oy4B-3mwsA: 19.5	3oy4B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.94A	3pwmA-3mwsA: 20.2	3pwmA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49	None	1.43A	3pwmA-3mwsA: 20.2	3pwmA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.54A	3pwmA-3mwsA: 20.2	3pwmA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.35A	3pwmA-3mwsA: 20.2	3pwmA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.69A	3pwmB-3mwsA: 19.7	3pwmB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.27A	3pwmB-3mwsA: 19.7	3pwmB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.46A	3pwmB-3mwsA: 19.7	3pwmB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.44A	3pwmB-3mwsA: 19.7	3pwmB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWM_B_017B402_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.54A	3pwmB-3mwsA: 19.7	3pwmB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.34A	3pwrA-3mwsA: 19.8	3pwrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.65A	3pwrA-3mwsA: 19.8	3pwrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.35A	3pwrA-3mwsA: 19.8	3pwrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3pwrA-3mwsA: 19.8	3pwrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 VAL A 32 THR A 80	None	0.65A	3pwrA-3mwsA: 19.8	3pwrA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.36A	3pwrB-3mwsA: 19.6	3pwrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 VAL A 82 ILE A 84	None	0.52A	3pwrB-3mwsA: 19.6	3pwrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3PWR_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.37A	3pwrB-3mwsA: 19.6	3pwrB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S43_A_478A401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 ILE A 84	None	0.46A	3s43A-3mwsA: 20.1	3s43A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S43_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.27A	3s43B-3mwsA: 19.3	3s43B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S43_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 ILE A 84	None	0.55A	3s43B-3mwsA: 19.3	3s43B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S43_A_478A401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 GLY A 49 ILE A 50 ILE A 84	None	0.35A	3s43B-3mwsA: 19.3	3s43B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S45_B_478B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.05A	3s45A-3mwsA: 19.2	3s45A-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S45_B_478B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.56A	3s45A-3mwsA: 19.2	3s45A-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S45_B_478B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None	0.48A	3s45B-3mwsA: 19.1	3s45B-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S45_B_478B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	0.40A	3s45B-3mwsA: 19.1	3s45B-3mwsA: 48.48
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S53_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.72A	3s53A-3mwsA: 18.7	3s53A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S53_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.29A	3s53A-3mwsA: 18.7	3s53A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S53_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	3s53B-3mwsA: 20.0	3s53B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S53_B_017B203_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	TRP A 42 PRO A 44 ARG A 57 GLY A 78	None	0.27A	3s53B-3mwsA: 20.0	3s53B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	1.37A	3s54A-3mwsA: 20.1	3s54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.55A	3s54A-3mwsA: 20.1	3s54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.94A	3s54A-3mwsA: 20.1	3s54A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.37A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.89A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.24A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	1.38A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.57A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S54_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.31A	3s54B-3mwsA: 19.7	3s54B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81	None	0.60A	3s56A-3mwsA: 19.1	3s56A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 THR A 80 PRO A 81	None	0.49A	3s56A-3mwsA: 19.1	3s56A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.91A	3s56A-3mwsA: 19.1	3s56A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ASP A 25 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.84A	3s56B-3mwsA: 19.3	3s56B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.19A	3s56B-3mwsA: 19.3	3s56B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	LEU A 23 ASP A 25 ASP A 30 PRO A 81 ILE A 84	None	0.58A	3s56B-3mwsA: 19.3	3s56B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3S56_A_ROCA201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	3s56B-3mwsA: 19.3	3s56B-3mwsA: 76.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SM2_A_478A126_2 (GAG-PRO-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ASP A 25 ALA A 28 GLY A 48 LEU A 76 PRO A 81	None	1.02A	3sm2B-3mwsA: 11.7	3sm2B-3mwsA: 27.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SM2_A_478A126_2 (GAG-PRO-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ASP A 25 ALA A 28 VAL A 32 GLY A 49 LEU A 76	None	0.71A	3sm2B-3mwsA: 11.7	3sm2B-3mwsA: 27.41
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3SM2_A_478A126_2 (GAG-PRO-POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ASP A 25 ALA A 28 VAL A 32 LEU A 76 PRO A 81	None	0.74A	3sm2B-3mwsA: 11.7	3sm2B-3mwsA: 27.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SO9_A_017A100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.71A	3so9B-3mwsA: 18.9	3so9B-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SO9_A_017A100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.68A	3so9B-3mwsA: 18.9	3so9B-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_A_TPVA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ALA A 28 ASP A 29 ASP A 30 ILE A 47 PRO A 81	None	0.74A	3spkA-3mwsA: 19.7	3spkA-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_A_TPVA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ARG A 8 LEU A 23 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.42A	3spkA-3mwsA: 19.7	3spkA-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_A_TPVA100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ARG A 8 LEU A 23 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.75A	3spkA-3mwsA: 19.7	3spkA-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_B_TPVB100_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ARG A 8 LEU A 23 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81	None	0.78A	3spkA-3mwsA: 19.7	3spkA-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_B_TPVB100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.84A	3spkB-3mwsA: 19.8	3spkB-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_B_TPVB100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 PRO A 81	None	0.62A	3spkB-3mwsA: 19.8	3spkB-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_B_TPVB100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ARG A 8 LEU A 23 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.44A	3spkB-3mwsA: 19.8	3spkB-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3SPK_B_TPVB100_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 LEU A 23 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.60A	3spkB-3mwsA: 19.8	3spkB-3mwsA: 71.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3T3C_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 7	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.53A	3t3cA-3mwsA: 19.7	3t3cA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3T3C_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 50	None	0.31A	3t3cA-3mwsA: 19.7	3t3cA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3T3C_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.40A	3t3cB-3mwsA: 20.0	3t3cB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.33A	3tkgA-3mwsA: 19.6	3tkgA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.62A	3tkgA-3mwsA: 19.6	3tkgA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.38A	3tkgA-3mwsA: 19.6	3tkgA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 LEU A 23 ASP A 30 PRO A 81 VAL A 82	None	0.63A	3tkgB-3mwsA: 19.5	3tkgB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.31A	3tkgB-3mwsA: 19.5	3tkgB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.54A	3tkgB-3mwsA: 19.5	3tkgB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_B_ROCB801_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3tkgB-3mwsA: 19.5	3tkgB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.62A	3tkgC-3mwsA: 19.2	3tkgC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.50A	3tkgC-3mwsA: 19.2	3tkgC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.89A	3tkgC-3mwsA: 19.2	3tkgC-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 VAL A 82 ILE A 84	None	0.50A	3tkgD-3mwsA: 19.5	3tkgD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.29A	3tkgD-3mwsA: 19.5	3tkgD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKG_C_ROCC901_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 THR A 80 PRO A 81	None	0.30A	3tkgD-3mwsA: 19.5	3tkgD-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKW_B_017B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82 ILE A 84	None	0.50A	3tkwA-3mwsA: 20.1	3tkwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKW_B_017B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.41A	3tkwA-3mwsA: 20.1	3tkwA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.90A	3tkwB-3mwsA: 18.7	3tkwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.35A	3tkwB-3mwsA: 18.7	3tkwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TKW_B_017B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.44A	3tkwB-3mwsA: 18.7	3tkwB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.95A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.41A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.47A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	1.33A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.65A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.42A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ARG A 8 VAL A 32 THR A 80	None	0.69A	3tl9A-3mwsA: 19.8	3tl9A-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ALA A 28 VAL A 32 GLY A 49 PRO A 81 VAL A 82	None	0.63A	3tl9B-3mwsA: 18.7	3tl9B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	GLY A 27 ALA A 28 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.95A	3tl9B-3mwsA: 18.7	3tl9B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TL9_A_ROCA401_3 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.41A	3tl9B-3mwsA: 18.7	3tl9B-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.40A	3ttpA-3mwsA: 19.9	3ttpA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.34A	3ttpA-3mwsA: 19.9	3ttpA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.85A	3ttpA-3mwsA: 19.9	3ttpA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.37A	3ttpA-3mwsA: 19.9	3ttpA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.38A	3ttpB-3mwsA: 19.9	3ttpB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.36A	3ttpB-3mwsA: 19.9	3ttpB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.85A	3ttpB-3mwsA: 19.9	3ttpB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3TTP_A_017A201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.37A	3ttpB-3mwsA: 19.9	3ttpB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.83A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.47A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.31A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.42A	3u7sB-3mwsA: 20.2	3u7sB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ARG A 8 ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81	None	1.01A	3u7sB-3mwsA: 20.2	3u7sB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A201_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 ASP A 25 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.60A	3u7sB-3mwsA: 20.2	3u7sB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 ALA A 28 ASP A 30 ILE A 47 GLY A 48 PRO A 81	None	0.88A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81	None	1.25A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 30 ILE A 47 PRO A 81	None	0.49A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_1 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 ALA A 28 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.57A	3u7sA-3mwsA: 19.7	3u7sA-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.90A	3u7sB-3mwsA: 20.2	3u7sB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3U7S_A_017A202_2 (POL POLYPROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 ILE A 50	None	0.49A	3u7sB-3mwsA: 20.2	3u7sB-3mwsA: 69.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UCB_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.38A	3ucbA-3mwsA: 20.3	3ucbA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UCB_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.41A	3ucbB-3mwsA: 20.2	3ucbB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UCB_B_017B202_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 7	TRP A 42 PRO A 44 MET A 46 ARG A 57 GLY A 78 PRO A 79	None	0.43A	3ucbB-3mwsA: 20.2	3ucbB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UFN_A_ROCA401_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ALA A 28 ASP A 29 GLY A 48 THR A 80 PRO A 81	None	0.85A	3ufnA-3mwsA: 20.0	3ufnA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UFN_A_ROCA401_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 48 GLY A 49 ILE A 50 THR A 80 PRO A 81	None	0.40A	3ufnA-3mwsA: 20.0	3ufnA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UFN_A_ROCA401_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ASP A 25 GLY A 27 ALA A 28 GLY A 49 THR A 80	None	0.85A	3ufnA-3mwsA: 20.0	3ufnA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3UFN_A_ROCA401_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 7	ASP A 25 GLY A 49 ILE A 50 VAL A 82	None	0.45A	3ufnB-3mwsA: 19.7	3ufnB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WSJ_A_MK1A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 VAL A 32 LEU A 76 ILE A 84	None	0.81A	3wsjA-3mwsA: 13.1	3wsjA-3mwsA: 35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WSJ_A_MK1A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ILE A 84	None	0.52A	3wsjB-3mwsA: 13.1	3wsjB-3mwsA: 35.34
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3WSJ_A_MK1A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	ARG A 8 LEU A 23 ASP A 25 VAL A 56 ILE A 84	None	1.32A	3wsjB-3mwsA: 13.1	3wsjB-3mwsA: 35.34
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4AC9_B_DXCB1473_0 (MJ0495-LIKE PROTEIN)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ILE A 64 ASP A 65 ILE A 66 GLY A 68 GLY A 94	None	0.89A	4ac9B-3mwsA: undetectable 4ac9C-3mwsA: undetectable	4ac9B-3mwsA: 13.76 4ac9C-3mwsA: 13.76
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.49A	4dqbA-3mwsA: 19.7	4dqbA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.57A	4dqbA-3mwsA: 19.7	4dqbA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.94A	4dqbA-3mwsA: 19.7	4dqbA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.64A	4dqbB-3mwsA: 19.7	4dqbB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.18A	4dqbB-3mwsA: 19.7	4dqbB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82	None	0.48A	4dqbB-3mwsA: 19.7	4dqbB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQB_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.46A	4dqbB-3mwsA: 19.7	4dqbB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.54A	4dqcA-3mwsA: 19.4	4dqcA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.99A	4dqcA-3mwsA: 19.4	4dqcA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.63A	4dqcB-3mwsA: 19.9	4dqcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.19A	4dqcB-3mwsA: 19.9	4dqcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.39A	4dqcB-3mwsA: 19.9	4dqcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQC_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50	None	0.30A	4dqcB-3mwsA: 19.9	4dqcB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.45A	4dqeA-3mwsA: 19.6	4dqeA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	4dqeA-3mwsA: 19.6	4dqeA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.01A	4dqeA-3mwsA: 19.6	4dqeA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.70A	4dqeB-3mwsA: 19.9	4dqeB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.19A	4dqeB-3mwsA: 19.9	4dqeB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82	None	0.45A	4dqeB-3mwsA: 19.9	4dqeB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQE_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.44A	4dqeB-3mwsA: 19.9	4dqeB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	4dqfA-3mwsA: 18.6	4dqfA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.97A	4dqfA-3mwsA: 18.6	4dqfA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82 ILE A 84	None	0.71A	4dqfB-3mwsA: 19.6	4dqfB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.22A	4dqfB-3mwsA: 19.6	4dqfB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 82 ILE A 84	None	0.57A	4dqfB-3mwsA: 19.6	4dqfB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQF_B_017B101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.51A	4dqfB-3mwsA: 19.6	4dqfB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_1 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81	None	1.46A	4dqhA-3mwsA: 19.7	4dqhA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_1 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 11	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.58A	4dqhA-3mwsA: 19.7	4dqhA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_1 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.01A	4dqhA-3mwsA: 19.7	4dqhA-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_2 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.69A	4dqhB-3mwsA: 19.8	4dqhB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_2 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.20A	4dqhB-3mwsA: 19.8	4dqhB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_2 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82	None	0.44A	4dqhB-3mwsA: 19.8	4dqhB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4DQH_B_017B101_2 (WILD-TYPE HIV-1 PROTEASE DIMER)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.45A	4dqhB-3mwsA: 19.8	4dqhB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HLA_A_017A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.52A	4hlaA-3mwsA: 20.1	4hlaA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HLA_A_017A200_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.43A	4hlaA-3mwsA: 20.1	4hlaA-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HLA_A_017A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.47A	4hlaB-3mwsA: 20.1	4hlaB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4HLA_A_017A200_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.45A	4hlaB-3mwsA: 20.1	4hlaB-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4J5J_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 10	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82	None	0.97A	4j5jB-3mwsA: 20.2	4j5jB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4J5J_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ASP A 25 ALA A 28 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.55A	4j5jB-3mwsA: 20.2	4j5jB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4J5J_B_478B402_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 5	TRP A 42 PRO A 44 ARG A 57 PRO A 79	None	0.47A	4j5jB-3mwsA: 20.2	4j5jB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4JEC_B_478B401_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.44A	4jecB-3mwsA: 19.9	4jecB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4JEC_B_478B401_3 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	ASP A 29 LEU A 76 VAL A 82	None	0.52A	4jecB-3mwsA: 19.9	4jecB-3mwsA: 79.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4L1A_A_AB1A101_1 (MDR769 HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ARG A 8 GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.52A	4l1aA-3mwsA: 18.3	4l1aA-3mwsA: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4L1A_A_AB1A101_1 (MDR769 HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81	None	0.52A	4l1aA-3mwsA: 18.3	4l1aA-3mwsA: 72.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.88A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.25A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 48 ILE A 84	None	1.48A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.45A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.22A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.85A	4ll3A-3mwsA: 20.1	4ll3A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	1.21A	4ll3A-3mwsA: 20.1	4ll3A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.46A	4ll3A-3mwsA: 20.1	4ll3A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.21A	4ll3A-3mwsA: 20.1	4ll3A-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	ARG A 8 ASP A 25 ALA A 28 ASP A 29 GLY A 49 PRO A 81 ILE A 84	None	1.47A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 ASP A 25 ALA A 28 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.59A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 ASP A 25 ALA A 28 VAL A 32 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.47A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LL3_A_017A202_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.85A	4ll3B-3mwsA: 20.2	4ll3B-3mwsA: 78.79
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.95A	4njtA-3mwsA: 19.8	4njtA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.45A	4njtA-3mwsA: 19.8	4njtA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.77A	4njtB-3mwsA: 19.7	4njtB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.20A	4njtB-3mwsA: 19.7	4njtB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.49A	4njtB-3mwsA: 19.7	4njtB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_B_017B101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50	None	0.37A	4njtB-3mwsA: 19.7	4njtB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_D_017D101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	4njtC-3mwsA: 19.8	4njtC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_D_017D101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.97A	4njtC-3mwsA: 19.8	4njtC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_D_017D101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.47A	4njtD-3mwsA: 19.7	4njtD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJT_D_017D101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 50	None	0.44A	4njtD-3mwsA: 19.7	4njtD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_A_TPVA500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.92A	4njuA-3mwsA: 19.9	4njuA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_A_TPVA500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.60A	4njuA-3mwsA: 19.9	4njuA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_A_TPVA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ARG A 8 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.84A	4njuB-3mwsA: 19.7	4njuB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_A_TPVA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.64A	4njuB-3mwsA: 19.7	4njuB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_C_TPVC500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	0.92A	4njuC-3mwsA: 19.8	4njuC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_C_TPVC500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.60A	4njuC-3mwsA: 19.8	4njuC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_C_TPVC500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ARG A 8 ALA A 28 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.84A	4njuD-3mwsA: 19.7	4njuD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJU_C_TPVC500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ARG A 8 LEU A 23 ASP A 25 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.64A	4njuD-3mwsA: 19.7	4njuD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	4njvA-3mwsA: 19.7	4njvA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	GLY A 51 ILE A 50 PRO A 81 THR A 80 ILE A 54	None	1.01A	4njvA-3mwsA: 19.7	4njvA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ASP A 25 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	1.35A	4njvB-3mwsA: 19.3	4njvB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ASP A 29 ASP A 30 VAL A 32 GLY A 49 PRO A 81 ILE A 84	None	0.66A	4njvB-3mwsA: 19.3	4njvB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.63A	4njvB-3mwsA: 19.3	4njvB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_A_RITA500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 11	GLY A 27 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.96A	4njvB-3mwsA: 19.3	4njvB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_D_RITD500_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.46A	4njvC-3mwsA: 19.8	4njvC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_D_RITD500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 ILE A 84	None	0.30A	4njvD-3mwsA: 19.4	4njvD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4NJV_D_RITD500_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.54A	4njvD-3mwsA: 19.4	4njvD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.74A	4q1wA-3mwsA: 19.8	4q1wA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.24A	4q1wA-3mwsA: 19.8	4q1wA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 82	None	0.60A	4q1wA-3mwsA: 19.8	4q1wA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 VAL A 82	None	0.48A	4q1wA-3mwsA: 19.8	4q1wA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	LEU A 38 GLY A 73 GLY A 86 ILE A 85 VAL A 77	None	1.03A	4q1wA-3mwsA: 19.8	4q1wA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ARG A 8 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	4q1wB-3mwsA: 19.5	4q1wB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1W_A_017A104_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.06A	4q1wB-3mwsA: 19.5	4q1wB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.75A	4q1xA-3mwsA: 19.7	4q1xA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.24A	4q1xA-3mwsA: 19.7	4q1xA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 VAL A 82	None	0.63A	4q1xA-3mwsA: 19.7	4q1xA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.54A	4q1xA-3mwsA: 19.7	4q1xA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.57A	4q1xB-3mwsA: 19.6	4q1xB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ARG A 8 LEU A 23 ILE A 54 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	1.49A	4q1xB-3mwsA: 19.6	4q1xB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1X_A_017A101_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.93A	4q1xB-3mwsA: 19.6	4q1xB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 VAL A 82	None	0.77A	4q1yA-3mwsA: 20.0	4q1yA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.25A	4q1yA-3mwsA: 20.0	4q1yA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 82	None	0.60A	4q1yA-3mwsA: 20.0	4q1yA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_1 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 VAL A 82	None	0.47A	4q1yA-3mwsA: 20.0	4q1yA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.85A	4q1yB-3mwsA: 19.9	4q1yB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q1Y_A_017A106_2 (ASPARTYL PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.46A	4q1yB-3mwsA: 19.9	4q1yB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q5M_A_ROCA1101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	GLY A 27 ASP A 29 ILE A 47 ILE A 50 THR A 80 PRO A 81 VAL A 82	None	0.51A	4q5mA-3mwsA: 16.8	4q5mA-3mwsA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4Q5M_A_ROCA1101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	GLY A 27 ASP A 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.60A	4q5mA-3mwsA: 16.8	4q5mA-3mwsA: 39.90
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 VAL A 82	None	0.93A	4qgiA-3mwsA: 19.7	4qgiA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 47 THR A 80 VAL A 82	None	0.62A	4qgiA-3mwsA: 19.7	4qgiA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 VAL A 82	None	0.54A	4qgiA-3mwsA: 19.7	4qgiA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.67A	4qgiB-3mwsA: 19.3	4qgiB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.63A	4qgiB-3mwsA: 19.3	4qgiB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4QGI_A_ROCA101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 11	LEU A 23 ASP A 25 ALA A 28 VAL A 32 ILE A 47 GLY A 49 PRO A 81 VAL A 82 ILE A 84	None	0.72A	4qgiB-3mwsA: 19.3	4qgiB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.58A	4rvjA-3mwsA: 19.9	4rvjA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 GLY A 48 PRO A 81 ILE A 84	None	1.07A	4rvjA-3mwsA: 19.9	4rvjA-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.82A	4rvjB-3mwsA: 19.2	4rvjB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.28A	4rvjB-3mwsA: 19.2	4rvjB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.50A	4rvjB-3mwsA: 19.2	4rvjB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_B_478B101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.48A	4rvjB-3mwsA: 19.2	4rvjB-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 11	LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.57A	4rvjC-3mwsA: 19.9	4rvjC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ASP A 25 ALA A 28 GLY A 48 PRO A 81 ILE A 84	None	1.08A	4rvjC-3mwsA: 19.9	4rvjC-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 30 VAL A 32 GLY A 48 ILE A 84	None	0.81A	4rvjD-3mwsA: 19.3	4rvjD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.28A	4rvjD-3mwsA: 19.3	4rvjD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 84	None	0.49A	4rvjD-3mwsA: 19.3	4rvjD-3mwsA: 70.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4RVJ_D_478D101_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.47A	4rvjD-3mwsA: 19.3	4rvjD-3mwsA: 70.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5AJQ_A_DB8A800_2 (SERINE/THREONINE-PRO TEIN KINASE 10)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 4	VAL A 13 ILE A 33 ASN A 88 VAL A 62	None	1.25A	5ajqA-3mwsA: undetectable	5ajqA-3mwsA: 17.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5J_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 ILE A 84	None	0.43A	5e5jA-3mwsA: 19.5	5e5jA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5J_A_017A201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 ILE A 84	None	0.32A	5e5jA-3mwsA: 19.5	5e5jA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5J_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.42A	5e5jB-3mwsA: 19.9	5e5jB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5J_A_017A201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 GLY A 48 PRO A 81 ILE A 84	None	0.92A	5e5jB-3mwsA: 19.9	5e5jB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.42A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	0.83A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.21A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 PRO A 81 ILE A 84	None	1.43A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.54A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.41A	5e5kA-3mwsA: 19.5	5e5kA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5E5K_B_017B201_2 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.39A	5e5kB-3mwsA: 19.9	5e5kB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQX_A_ROCA101_1 (PROTEASE E35D-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.95A	5kqxA-3mwsA: 19.5	5kqxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQX_A_ROCA101_1 (PROTEASE E35D-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	GLY A 27 ALA A 28 ASP A 29 ASP A 30 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.69A	5kqxA-3mwsA: 19.5	5kqxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQX_A_ROCA101_1 (PROTEASE E35D-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	GLY A 27 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80 VAL A 82 ILE A 84	None	0.58A	5kqxA-3mwsA: 19.5	5kqxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQX_A_ROCA101_1 (PROTEASE E35D-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	GLY A 27 ALA A 28 ASP A 29 ILE A 47 THR A 80 PRO A 81 VAL A 82 ILE A 84	None	0.54A	5kqxA-3mwsA: 19.5	5kqxA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQX_A_ROCA101_2 (PROTEASE E35D-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ARG A 8 LEU A 23 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.74A	5kqxB-3mwsA: 19.3	5kqxB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQY_B_017B101_1 (PROTEASE E35D-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.97A	5kqyA-3mwsA: 19.9	5kqyA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQY_B_017B101_1 (PROTEASE E35D-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.51A	5kqyA-3mwsA: 19.9	5kqyA-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQY_B_017B101_2 (PROTEASE E35D-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 7	ALA A 28 ASP A 29 ASP A 30 GLY A 48	None	0.67A	5kqyB-3mwsA: 19.6	5kqyB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQY_B_017B101_2 (PROTEASE E35D-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	4 / 7	GLY A 27 ALA A 28 ASP A 29 ASP A 30	None	0.47A	5kqyB-3mwsA: 19.6	5kqyB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KQY_B_017B101_2 (PROTEASE E35D-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 7	GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	0.26A	5kqyB-3mwsA: 19.6	5kqyB-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_1 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 9	ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	5kr0A-3mwsA: 19.8	5kr0A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_1 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.93A	5kr0A-3mwsA: 19.8	5kr0A-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_2 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 30 VAL A 32 GLY A 48 VAL A 82	None	0.76A	5kr0B-3mwsA: 19.3	5kr0B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_2 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	LEU A 23 GLY A 27 ALA A 28 ASP A 30 VAL A 32 VAL A 82	None	0.53A	5kr0B-3mwsA: 19.3	5kr0B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_2 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 GLY A 27 ALA A 28 VAL A 32 GLY A 49 ILE A 50 VAL A 82	None	0.58A	5kr0B-3mwsA: 19.3	5kr0B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR0_A_478A101_2 (PROTEASE E35D-APV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	LEU A 38 GLY A 73 GLY A 86 ILE A 85 VAL A 77	None	1.01A	5kr0B-3mwsA: 19.3	5kr0B-3mwsA: 77.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_1 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ARG A 8 ALA A 28 ASP A 30 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.69A	5kr1A-3mwsA: 19.4	5kr1A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_1 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ARG A 8 LEU A 23 ASP A 30 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.37A	5kr1A-3mwsA: 19.4	5kr1A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_1 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 10	ARG A 8 LEU A 23 ILE A 54 GLY A 49 ILE A 50 ILE A 84	None	1.46A	5kr1A-3mwsA: 19.4	5kr1A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_2 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 8	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.62A	5kr1B-3mwsA: 19.7	5kr1B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_2 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 8	GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32	None	0.47A	5kr1B-3mwsA: 19.7	5kr1B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR1_B_017B101_2 (PROTEASE PR5-DRV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 8	GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50	None	0.46A	5kr1B-3mwsA: 19.7	5kr1B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.94A	5kr2A-3mwsA: 19.0	5kr2A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ALA A 28 ASP A 29 ASP A 30 ILE A 47 THR A 80 PRO A 81	None	0.81A	5kr2A-3mwsA: 19.0	5kr2A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80	None	0.59A	5kr2A-3mwsA: 19.0	5kr2A-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	ALA A 28 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.70A	5kr2B-3mwsA: 19.2	5kr2B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	ARG A 8 LEU A 23 ASP A 30 PRO A 81 VAL A 82	None	1.10A	5kr2B-3mwsA: 19.2	5kr2B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 11	LEU A 23 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.55A	5kr2B-3mwsA: 19.2	5kr2B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.57A	5kr2B-3mwsA: 19.2	5kr2B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_A_ROCA101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 11	LEU A 23 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.51A	5kr2B-3mwsA: 19.2	5kr2B-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_C_ROCC101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ALA A 28 ASP A 29 ASP A 30 GLY A 48 THR A 80 PRO A 81	None	0.94A	5kr2C-3mwsA: 19.2	5kr2C-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_C_ROCC101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 9	ALA A 28 ASP A 29 ASP A 30 ILE A 47 THR A 80	None	0.86A	5kr2C-3mwsA: 19.2	5kr2C-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_C_ROCC101_1 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 THR A 80	None	0.64A	5kr2C-3mwsA: 19.2	5kr2C-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_C_ROCC101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 9	ARG A 8 LEU A 23 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.65A	5kr2D-3mwsA: 19.5	5kr2D-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5KR2_C_ROCC101_2 (PROTEASE PR5-SQV)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 9	LEU A 23 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.44A	5kr2D-3mwsA: 19.5	5kr2D-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	LEU A 23 ASP A 25 ASP A 29 GLY A 49 PRO A 81	None	1.08A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.52A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.47A	5t2zA-3mwsA: 19.5	5t2zA-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	1.24A	5t2zB-3mwsA: 19.4	5t2zB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 ILE A 84	None	1.43A	5t2zB-3mwsA: 19.4	5t2zB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 ILE A 84	None	0.74A	5t2zB-3mwsA: 19.4	5t2zB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 49 PRO A 81 ILE A 84	None	0.51A	5t2zB-3mwsA: 19.4	5t2zB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T2Z_B_017B201_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.44A	5t2zB-3mwsA: 19.4	5t2zB-3mwsA: 73.74
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T8H_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 PRO A 81 ILE A 84	None	0.51A	5t8hA-3mwsA: 19.3	5t8hA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T8H_B_478B401_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.50A	5t8hA-3mwsA: 19.3	5t8hA-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T8H_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.40A	5t8hB-3mwsA: 20.0	5t8hB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5T8H_B_478B401_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 GLY A 48 PRO A 81 ILE A 84	None	0.95A	5t8hB-3mwsA: 20.0	5t8hB-3mwsA: 76.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.64A	6dgxA-3mwsA: 20.0	6dgxA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.19A	6dgxA-3mwsA: 20.0	6dgxA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82 ILE A 84	None	0.49A	6dgxA-3mwsA: 20.0	6dgxA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.53A	6dgxA-3mwsA: 20.0	6dgxA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.80A	6dgxB-3mwsA: 19.8	6dgxB-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DGX_A_017A101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 LEU A 76 PRO A 81 VAL A 82 ILE A 84	None	0.47A	6dgxB-3mwsA: 19.8	6dgxB-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.62A	6dh0A-3mwsA: 19.9	6dh0A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.20A	6dh0A-3mwsA: 19.9	6dh0A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 VAL A 82	None	0.57A	6dh0A-3mwsA: 19.9	6dh0A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82	None	0.53A	6dh0A-3mwsA: 19.9	6dh0A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 GLY A 49 ILE A 50 LEU A 76 PRO A 81 VAL A 82	None	0.38A	6dh0B-3mwsA: 20.0	6dh0B-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH0_A_017A101_2 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	3 / 3	LEU A 23 ASP A 29 ILE A 47	None	0.51A	6dh0B-3mwsA: 20.0	6dh0B-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.64A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 GLY A 49 ILE A 50	None	1.19A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 84	None	0.36A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 ILE A 84	None	0.40A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 ILE A 84	None	0.48A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	LEU A 23 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.50A	6dh3A-3mwsA: 19.9	6dh3A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH3_A_017A101_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 ILE A 84	None	0.44A	6dh3B-3mwsA: 19.8	6dh3B-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH6_A_017A104_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 VAL A 82 ILE A 84	None	0.54A	6dh6A-3mwsA: 19.9	6dh6A-3mwsA: 73.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH6_A_017A104_0 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 VAL A 82 ILE A 84	None	0.47A	6dh6A-3mwsA: 19.9	6dh6A-3mwsA: 73.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DH6_A_017A104_1 (PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 ASP A 30 VAL A 32 ILE A 47 GLY A 49 LEU A 76 PRO A 81 ILE A 84	None	0.49A	6dh6B-3mwsA: 19.8	6dh6B-3mwsA: 73.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIF_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ARG A 8 LEU A 23 GLY A 49 ILE A 50 PRO A 81	None	0.60A	6difA-3mwsA: 20.0	6difA-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIF_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 PRO A 81 VAL A 82 ILE A 84	None	0.60A	6difA-3mwsA: 20.0	6difA-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIF_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	6difA-3mwsA: 20.0	6difA-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIF_B_TPVB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	9 / 12	ARG A 8 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.67A	6difB-3mwsA: 19.5	6difB-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIF_B_TPVB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 VAL A 82 ILE A 84	None	0.56A	6difB-3mwsA: 19.5	6difB-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81 VAL A 82	None	0.97A	6dilA-3mwsA: 19.9	6dilA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81	None	0.73A	6dilA-3mwsA: 19.9	6dilA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	ARG A 8 LEU A 23 ASP A 25 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81	None	0.59A	6dilA-3mwsA: 19.9	6dilA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 ASP A 30 VAL A 32 PRO A 81 VAL A 82	None	0.66A	6dilA-3mwsA: 19.9	6dilA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 12	LEU A 23 ASP A 25 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.49A	6dilA-3mwsA: 19.9	6dilA-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 VAL A 32 GLY A 48 PRO A 81 VAL A 82	None	0.86A	6dilB-3mwsA: 19.5	6dilB-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DIL_B_TPVB201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 LEU A 23 ASP A 25 GLY A 27 ALA A 28 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.72A	6dilB-3mwsA: 19.5	6dilB-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 ALA A 28 ASP A 29 GLY A 48 GLY A 49 ILE A 50	None	1.38A	6dj1A-3mwsA: 20.1	6dj1A-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 VAL A 82	None	0.61A	6dj1A-3mwsA: 20.1	6dj1A-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	11 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 29 VAL A 32 GLY A 48 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.47A	6dj1A-3mwsA: 20.1	6dj1A-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ASP A 25 GLY A 27 ALA A 28 ASP A 30 GLY A 48 VAL A 82	None	0.72A	6dj1A-3mwsA: 20.1	6dj1A-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 12	ASP A 25 GLY A 27 ALA A 28 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.72A	6dj1A-3mwsA: 20.1	6dj1A-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	5 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48	None	0.80A	6dj1B-3mwsA: 19.6	6dj1B-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ1_B_AB1B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.54A	6dj1B-3mwsA: 19.6	6dj1B-3mwsA: 76.25
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ2_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	8 / 10	ASP A 25 ALA A 28 ASP A 29 VAL A 32 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	0.94A	6dj2A-3mwsA: 20.1	6dj2A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ2_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	10 / 10	ASP A 25 ALA A 28 ASP A 29 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82 ILE A 84	None	0.55A	6dj2A-3mwsA: 20.1	6dj2A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ2_B_AB1B201_0 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	7 / 10	ASP A 25 ALA A 28 ASP A 30 GLY A 48 PRO A 81 VAL A 82 ILE A 84	None	1.34A	6dj2A-3mwsA: 20.1	6dj2A-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ2_B_AB1B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	6 / 12	ALA A 28 ASP A 29 ASP A 30 VAL A 32 GLY A 48 PRO A 81	None	1.11A	6dj2B-3mwsA: 19.4	6dj2B-3mwsA: 75.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6DJ2_B_AB1B201_1 (HIV-1 PROTEASE)	3mws	HIV-1 PROTEASE (Human immunodeficiency virus 1)	12 / 12	ARG A 8 ASP A 25 GLY A 27 ALA A 28 ASP A 29 ASP A 30 VAL A 32 ILE A 47 GLY A 49 ILE A 50 PRO A 81 VAL A 82	None	0.57A	6dj2B-3mwsA: 19.4	6dj2B-3mwsA: 75.00

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1C6Y_B_MK1B524_1","PROTEIN (PROTEASE);PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.76A","1c6yA-3mwsA:18.8","1c6yA-3mwsA:74.75"],["1C6Y_B_MK1B524_1","PROTEIN (PROTEASE);PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.65A","1c6yA-3mwsA:18.8","1c6yA-3mwsA:74.75"],["1C6Y_B_MK1B524_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.45A","1c6yB-3mwsA:18.3","1c6yB-3mwsA:74.75"],["1C6Y_B_MK1B524_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;ILE A  84","None","0.43A","1c6yB-3mwsA:18.3","1c6yB-3mwsA:74.75"],["1C6Y_B_MK1B524_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;THR A  80;ILE A  84","None","0.55A","1c6yB-3mwsA:18.3","1c6yB-3mwsA:74.75"],["1C6Y_B_MK1B524_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;THR A  80;PRO A  81","None","0.67A","1c6yB-3mwsA:18.3","1c6yB-3mwsA:74.75"],["1C6Y_B_MK1B524_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  50;THR A  80;ILE A  84","None","0.69A","1c6yB-3mwsA:18.3","1c6yB-3mwsA:74.75"],["1C6Z_B_ROCB505_1","PROTEIN (PROTEASE);PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.71A","1c6zA-3mwsA:18.6","1c6zA-3mwsA:74.75"],["1C6Z_B_ROCB505_1","PROTEIN (PROTEASE);PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.56A","1c6zA-3mwsA:18.6","1c6zA-3mwsA:74.75"],["1C6Z_B_ROCB505_1","PROTEIN (PROTEASE);PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;ILE A  84","None","0.41A","1c6zA-3mwsA:18.6","1c6zA-3mwsA:74.75"],["1C6Z_B_ROCB505_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50","None","0.53A","1c6zB-3mwsA:18.6","1c6zB-3mwsA:74.75"],["1C6Z_B_ROCB505_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;ILE A  84","None","0.43A","1c6zB-3mwsA:18.6","1c6zB-3mwsA:74.75"],["1C6Z_B_ROCB505_2","PROTEIN (PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;PRO A  81","None","0.59A","1c6zB-3mwsA:18.6","1c6zB-3mwsA:74.75"],["1D4S_A_TPVA201_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.02A","1d4sA-3mwsA:19.6","1d4sA-3mwsA:76.77"],["1D4S_A_TPVA201_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81","None","0.52A","1d4sA-3mwsA:19.6","1d4sA-3mwsA:76.77"],["1D4Y_A_TPVA501_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.88A","1d4yA-3mwsA:19.9","1d4yA-3mwsA:78.79"],["1D4Y_A_TPVA501_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;ILE A  47;ILE A  50;VAL A  82","None","0.77A","1d4yA-3mwsA:19.9","1d4yA-3mwsA:78.79"],["1D4Y_A_TPVA501_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.46A","1d4yA-3mwsA:19.9","1d4yA-3mwsA:78.79"],["1D4Y_A_TPVA501_1","PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.60A","1d4yA-3mwsA:19.9","1d4yA-3mwsA:78.79"],["1D4Y_A_TPVA501_2","PROTEIN (HIV-1 PROTEASE);PROTEIN (HIV-1 PROTEASE)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.61A","1d4yB-3mwsA:19.5","1d4yB-3mwsA:78.79"],["1FB7_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;THR A  80;PRO A  81;VAL A  82","None","0.76A","1fb7A-3mwsA:19.3","1fb7A-3mwsA:75.76"],["1FB7_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.61A","1fb7A-3mwsA:19.3","1fb7A-3mwsA:75.76"],["1FB7_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;THR A  80;VAL A  82;ILE A  84","None","0.54A","1fb7A-3mwsA:19.3","1fb7A-3mwsA:75.76"],["1FB7_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.59A","1fb7A-3mwsA:19.3","1fb7A-3mwsA:75.76"],["1HPV_B_478B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.56A","1hpvA-3mwsA:19.7","1hpvA-3mwsA:78.79"],["1HPV_B_478B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;GLY A  27;VAL A  32;ILE A  47;GLY A  48;PRO A  81;ILE A  84","None","0.93A","1hpvA-3mwsA:19.7","1hpvA-3mwsA:78.79"],["1HPV_B_478B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.80A","1hpvB-3mwsA:19.7","1hpvB-3mwsA:78.79"],["1HPV_B_478B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.56A","1hpvB-3mwsA:19.7","1hpvB-3mwsA:78.79"],["1HSG_B_MK1B902_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82","None","0.87A","1hsgA-3mwsA:19.7","1hsgA-3mwsA:78.79"],["1HSG_B_MK1B902_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.51A","1hsgA-3mwsA:19.7","1hsgA-3mwsA:78.79"],["1HSG_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.86A","1hsgB-3mwsA:19.5","1hsgB-3mwsA:78.79"],["1HSG_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.42A","1hsgB-3mwsA:19.5","1hsgB-3mwsA:78.79"],["1HSG_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.37A","1hsgB-3mwsA:19.5","1hsgB-3mwsA:78.79"],["1HSH_A_MK1A401_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.85A","1hshA-3mwsA:19.0","1hshA-3mwsA:48.48"],["1HSH_A_MK1A401_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.39A","1hshA-3mwsA:19.0","1hshA-3mwsA:48.48"],["1HSH_A_MK1A401_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;ILE A  84","None","0.55A","1hshA-3mwsA:19.0","1hshA-3mwsA:48.48"],["1HSH_A_MK1A401_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.64A","1hshA-3mwsA:19.0","1hshA-3mwsA:48.48"],["1HSH_A_MK1A401_2","HIV-II PROTEASE;HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.70A","1hshB-3mwsA:19.2","1hshB-3mwsA:48.48"],["1HSH_C_MK1C402_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.53A","1hshC-3mwsA:19.3","1hshC-3mwsA:48.48"],["1HSH_C_MK1C402_1","HIV-II PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.56A","1hshC-3mwsA:19.3","1hshC-3mwsA:48.48"],["1HXB_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.89A","1hxbA-3mwsA:19.6","1hxbA-3mwsA:77.78"],["1HXB_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.61A","1hxbA-3mwsA:19.6","1hxbA-3mwsA:77.78"],["1HXB_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  48;GLY A  49;ILE A  50;ILE A  84","None","0.41A","1hxbA-3mwsA:19.6","1hxbA-3mwsA:77.78"],["1HXB_A_ROCA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  48;GLY A  49;PRO A  81;ILE A  84","None","0.44A","1hxbA-3mwsA:19.6","1hxbA-3mwsA:77.78"],["1HXB_A_ROCA100_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;THR A  80;VAL A  82","None","0.55A","1hxbA-3mwsA:19.6","1hxbA-3mwsA:77.78"],["1HXB_A_ROCA100_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82","None","0.88A","1hxbB-3mwsA:19.6","1hxbB-3mwsA:77.78"],["1HXB_A_ROCA100_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.39A","1hxbB-3mwsA:19.6","1hxbB-3mwsA:77.78"],["1HXB_A_ROCA100_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.55A","1hxbB-3mwsA:19.6","1hxbB-3mwsA:77.78"],["1HXB_A_ROCA100_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","1hxbB-3mwsA:19.6","1hxbB-3mwsA:77.78"],["1HXB_A_ROCA100_4","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"GLY A  27;ASP A  29;GLY A  48;THR A  80","None","0.31A","1hxbB-3mwsA:19.6","1hxbB-3mwsA:77.78"],["1HXW_B_RITB301_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.18A","1hxwA-3mwsA:20.2","1hxwA-3mwsA:78.79"],["1HXW_B_RITB301_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.99A","1hxwA-3mwsA:20.2","1hxwA-3mwsA:78.79"],["1HXW_B_RITB301_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.46A","1hxwA-3mwsA:20.2","1hxwA-3mwsA:78.79"],["1HXW_B_RITB301_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82","None","1.06A","1hxwB-3mwsA:19.4","1hxwB-3mwsA:78.79"],["1HXW_B_RITB301_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.59A","1hxwB-3mwsA:19.4","1hxwB-3mwsA:78.79"],["1K6C_B_MK1B902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  48;GLY A  49;PRO A  81","None","0.47A","1k6cA-3mwsA:19.5","1k6cA-3mwsA:74.75"],["1K6C_B_MK1B902_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.92A","1k6cB-3mwsA:19.5","1k6cB-3mwsA:74.75"],["1K6C_B_MK1B902_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.60A","1k6cB-3mwsA:19.5","1k6cB-3mwsA:74.75"],["1MUI_B_AB1B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.47A","1muiA-3mwsA:19.3","1muiA-3mwsA:78.79"],["1MUI_B_AB1B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.84A","1muiA-3mwsA:19.3","1muiA-3mwsA:78.79"],["1MUI_B_AB1B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.64A","1muiA-3mwsA:19.3","1muiA-3mwsA:78.79"],["1MUI_B_AB1B100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.32A","1muiB-3mwsA:19.6","1muiB-3mwsA:78.79"],["1MUI_B_AB1B100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.56A","1muiB-3mwsA:19.6","1muiB-3mwsA:78.79"],["1MUI_B_AB1B100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","1muiB-3mwsA:19.6","1muiB-3mwsA:78.79"],["1MUI_B_AB1B100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.78A","1muiB-3mwsA:19.6","1muiB-3mwsA:78.79"],["1N49_B_RITB301_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.46A","1n49A-3mwsA:19.7","1n49A-3mwsA:74.75"],["1N49_B_RITB301_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.13A","1n49B-3mwsA:19.2","1n49B-3mwsA:74.75"],["1N49_B_RITB301_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.78A","1n49B-3mwsA:19.2","1n49B-3mwsA:74.75"],["1N49_D_RITD401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.70A","1n49C-3mwsA:19.2","1n49C-3mwsA:74.75"],["1N49_D_RITD401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","0.42A","1n49D-3mwsA:19.6","1n49D-3mwsA:74.75"],["1N49_D_RITD401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"ASP A  29;ILE A  50;PRO A  81;ILE A  84","None","0.61A","1n49D-3mwsA:19.6","1n49D-3mwsA:74.75"],["1OHR_A_1UNA201_1","ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.88A","1ohrA-3mwsA:20.0","1ohrA-3mwsA:78.79"],["1OHR_A_1UNA201_1","ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.47A","1ohrA-3mwsA:20.0","1ohrA-3mwsA:78.79"],["1OHR_A_1UNA201_1","ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.60A","1ohrA-3mwsA:20.0","1ohrA-3mwsA:78.79"],["1OHR_A_1UNA201_1","ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.62A","1ohrA-3mwsA:20.0","1ohrA-3mwsA:78.79"],["1OHR_A_1UNA201_2","ASPARTYLPROTEASE;ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.57A","1ohrB-3mwsA:19.0","1ohrB-3mwsA:78.79"],["1OHR_A_1UNA201_2","ASPARTYLPROTEASE;ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.68A","1ohrB-3mwsA:19.0","1ohrB-3mwsA:78.79"],["1OHR_A_1UNA201_2","ASPARTYLPROTEASE;ASPARTYLPROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.88A","1ohrB-3mwsA:19.0","1ohrB-3mwsA:78.79"],["1RL8_A_RITA9001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","1.01A","1rl8A-3mwsA:20.0","1rl8A-3mwsA:77.78"],["1RL8_A_RITA9001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.16A","1rl8A-3mwsA:20.0","1rl8A-3mwsA:77.78"],["1RL8_A_RITA9001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.73A","1rl8A-3mwsA:20.0","1rl8A-3mwsA:77.78"],["1RL8_A_RITA9001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.56A","1rl8A-3mwsA:20.0","1rl8A-3mwsA:77.78"],["1RL8_A_RITA9001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;GLY A  27;ASP A  30;ILE A  50;PRO A  81","None","0.91A","1rl8B-3mwsA:20.1","1rl8B-3mwsA:77.78"],["1RL8_A_RITA9001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.43A","1rl8B-3mwsA:20.1","1rl8B-3mwsA:77.78"],["1RL8_A_RITA9001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","1.37A","1rl8B-3mwsA:20.1","1rl8B-3mwsA:77.78"],["1RL8_A_RITA9001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.61A","1rl8B-3mwsA:20.1","1rl8B-3mwsA:77.78"],["1RL8_A_RITA9001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  24;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ALA A  22","None","1.38A","1rl8B-3mwsA:20.1","1rl8B-3mwsA:77.78"],["1SDT_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.51A","1sdtA-3mwsA:20.3","1sdtA-3mwsA:79.80"],["1SDT_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;GLY A  49;VAL A  82;ILE A  84","None","0.83A","1sdtA-3mwsA:20.3","1sdtA-3mwsA:79.80"],["1SDT_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.57A","1sdtB-3mwsA:19.5","1sdtB-3mwsA:79.80"],["1SDT_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","1sdtB-3mwsA:19.5","1sdtB-3mwsA:79.80"],["1SDT_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","1sdtB-3mwsA:19.5","1sdtB-3mwsA:79.80"],["1SDT_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.02A","1sdtB-3mwsA:19.5","1sdtB-3mwsA:79.80"],["1SDU_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ILE A  47;GLY A  48;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.53A","1sduA-3mwsA:19.5","1sduA-3mwsA:78.79"],["1SDU_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.61A","1sduA-3mwsA:19.5","1sduA-3mwsA:78.79"],["1SDU_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.47A","1sduB-3mwsA:19.9","1sduB-3mwsA:78.79"],["1SDU_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.37A","1sduB-3mwsA:19.9","1sduB-3mwsA:78.79"],["1SDU_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.48A","1sduB-3mwsA:19.9","1sduB-3mwsA:78.79"],["1SDV_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.48A","1sdvA-3mwsA:20.3","1sdvA-3mwsA:78.79"],["1SDV_B_MK1B902_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;GLY A  49;PRO A  81;ILE A  84","None","0.90A","1sdvA-3mwsA:20.3","1sdvA-3mwsA:78.79"],["1SDV_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","1.11A","1sdvB-3mwsA:19.5","1sdvB-3mwsA:78.79"],["1SDV_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.61A","1sdvB-3mwsA:19.5","1sdvB-3mwsA:78.79"],["1SDV_B_MK1B902_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.50A","1sdvB-3mwsA:19.5","1sdvB-3mwsA:78.79"],["1SGU_B_MK1B2632_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81","None","0.57A","1sguB-3mwsA:19.9","1sguB-3mwsA:74.75"],["1SGU_B_MK1B2632_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81","None","0.54A","1sguB-3mwsA:19.9","1sguB-3mwsA:74.75"],["1SGU_B_MK1B2632_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;GLY A  49;ILE A  50;PRO A  81","None","0.59A","1sguB-3mwsA:19.9","1sguB-3mwsA:74.75"],["1SGU_B_MK1B2632_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ALA A  22","None","1.31A","1sguB-3mwsA:19.9","1sguB-3mwsA:74.75"],["1SH9_B_RITB301_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ASP A  30;ILE A  47;GLY A  49;PRO A  81","None","0.51A","1sh9B-3mwsA:19.7","1sh9B-3mwsA:74.75"],["1SH9_B_RITB301_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.48A","1sh9B-3mwsA:19.7","1sh9B-3mwsA:74.75"],["1T3R_A_017A1200_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.74A","1t3rA-3mwsA:20.1","1t3rA-3mwsA:76.77"],["1T3R_A_017A1200_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.20A","1t3rA-3mwsA:20.1","1t3rA-3mwsA:76.77"],["1T3R_A_017A1200_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;VAL A  82","None","0.57A","1t3rA-3mwsA:20.1","1t3rA-3mwsA:76.77"],["1T3R_A_017A1200_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.44A","1t3rA-3mwsA:20.1","1t3rA-3mwsA:76.77"],["1T3R_A_017A1200_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;PRO A  81;VAL A  82;ILE A  84","None","1.49A","1t3rB-3mwsA:20.0","1t3rB-3mwsA:76.77"],["1T3R_A_017A1200_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.48A","1t3rB-3mwsA:20.0","1t3rB-3mwsA:76.77"],["1T3R_A_017A1200_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.97A","1t3rB-3mwsA:20.0","1t3rB-3mwsA:76.77"],["1T7I_A_017A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.24A","1t7iA-3mwsA:19.8","1t7iA-3mwsA:74.75"],["1T7I_A_017A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47","None","0.60A","1t7iA-3mwsA:19.8","1t7iA-3mwsA:74.75"],["1T7I_A_017A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50","None","0.39A","1t7iA-3mwsA:19.8","1t7iA-3mwsA:74.75"],["1T7I_A_017A200_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50","None","0.26A","1t7iB-3mwsA:19.8","1t7iB-3mwsA:74.75"],["1T7J_A_478A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  50;THR A  80","None","1.44A","1t7jA-3mwsA:19.6","1t7jA-3mwsA:74.75"],["1T7J_A_478A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.26A","1t7jA-3mwsA:19.6","1t7jA-3mwsA:74.75"],["1T7J_A_478A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50","None","0.60A","1t7jA-3mwsA:19.6","1t7jA-3mwsA:74.75"],["1T7J_A_478A200_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.76A","1t7jA-3mwsA:19.6","1t7jA-3mwsA:74.75"],["1T7J_A_478A200_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50","None","0.29A","1t7jB-3mwsA:19.6","1t7jB-3mwsA:74.75"],["2AOF_C_FRDC305_1","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"ASP A  25;GLY A  49;PRO A  81;ILE A  84","None","0.37A","2aofA-3mwsA:20.3","2aofA-3mwsA:78.79"],["2AOF_C_FRDC305_2","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"LEU A  23;ASP A  25;PRO A  81;ILE A  84","None","0.26A","2aofB-3mwsA:19.7","2aofB-3mwsA:78.79"],["2AOH_C_FRDC305_1","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"LEU A  23;ASP A  25;GLY A  49;PRO A  81","None","0.28A","2aohA-3mwsA:20.3","2aohA-3mwsA:78.79"],["2AOH_C_FRDC305_2","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"LEU A  23;ASP A  25;GLY A  49;ILE A  84","None","0.33A","2aohB-3mwsA:19.6","2aohB-3mwsA:78.79"],["2AOI_C_FRDC305_1","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.41A","2aoiA-3mwsA:20.3","2aoiA-3mwsA:79.80"],["2AOI_C_FRDC305_1","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.98A","2aoiA-3mwsA:20.3","2aoiA-3mwsA:79.80"],["2AOI_C_FRDC305_2","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;PRO A  81;VAL A  82;ILE A  84","None","0.28A","2aoiB-3mwsA:19.6","2aoiB-3mwsA:79.80"],["2AOJ_C_FRDC305_1","POL POLYPROTEIN;PEPTIDE INHIBITOR","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;GLY A  49;PRO A  81;VAL A  82","None","0.49A","2aojA-3mwsA:20.2","2aojA-3mwsA:79.80"],["2AQU_B_DR7B300_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.95A","2aquA-3mwsA:19.9","2aquA-3mwsA:78.79"],["2AQU_B_DR7B300_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;PRO A  81","None","0.63A","2aquA-3mwsA:19.9","2aquA-3mwsA:78.79"],["2AQU_B_DR7B300_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","2aquA-3mwsA:19.9","2aquA-3mwsA:78.79"],["2AQU_B_DR7B300_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.94A","2aquB-3mwsA:19.7","2aquB-3mwsA:78.79"],["2AQU_B_DR7B300_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","0.60A","2aquB-3mwsA:19.7","2aquB-3mwsA:78.79"],["2AQU_B_DR7B300_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.49A","2aquB-3mwsA:19.7","2aquB-3mwsA:78.79"],["2AVO_B_MK1B902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.68A","2avoA-3mwsA:19.4","2avoA-3mwsA:78.79"],["2AVO_B_MK1B902_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.02A","2avoB-3mwsA:19.9","2avoB-3mwsA:78.79"],["2AVO_B_MK1B902_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.65A","2avoB-3mwsA:19.9","2avoB-3mwsA:78.79"],["2AVO_B_MK1B902_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.59A","2avoB-3mwsA:19.9","2avoB-3mwsA:78.79"],["2AVS_B_MK1B902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;GLY A  48;GLY A  49","None","1.44A","2avsA-3mwsA:19.6","2avsA-3mwsA:78.79"],["2AVS_B_MK1B902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;ILE A  84","None","0.56A","2avsA-3mwsA:19.6","2avsA-3mwsA:78.79"],["2AVS_B_MK1B902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  48;GLY A  49;ILE A  84","None","0.40A","2avsA-3mwsA:19.6","2avsA-3mwsA:78.79"],["2AVS_B_MK1B902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81;ILE A  84","None","0.51A","2avsB-3mwsA:19.8","2avsB-3mwsA:78.79"],["2AVS_B_MK1B902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.42A","2avsB-3mwsA:19.8","2avsB-3mwsA:78.79"],["2AVV_A_MK1A901_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  82;ILE A  84","None","0.48A","2avvA-3mwsA:19.6","2avvA-3mwsA:78.79"],["2AVV_A_MK1A901_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  48;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.43A","2avvA-3mwsA:19.6","2avvA-3mwsA:78.79"],["2AVV_A_MK1A901_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  29;GLY A  48;GLY A  49;ILE A  50","None","1.21A","2avvA-3mwsA:19.6","2avvA-3mwsA:78.79"],["2AVV_A_MK1A901_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;VAL A  32;PRO A  81","None","0.41A","2avvA-3mwsA:19.6","2avvA-3mwsA:78.79"],["2AVV_A_MK1A901_3","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.43A","2avvB-3mwsA:19.4","2avvB-3mwsA:78.79"],["2AVV_A_MK1A901_3","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.54A","2avvB-3mwsA:19.4","2avvB-3mwsA:78.79"],["2AVV_A_MK1A901_3","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","2avvB-3mwsA:19.4","2avvB-3mwsA:78.79"],["2AVV_A_MK1A901_3","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.89A","2avvB-3mwsA:19.4","2avvB-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.74A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  48;GLY A  49","None","1.39A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.39A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.63A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  48;GLY A  49;ILE A  84","None","0.39A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.54A","2avvD-3mwsA:19.4","2avvD-3mwsA:78.79"],["2AVV_E_MK1E902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82","None","0.84A","2avvE-3mwsA:19.5","2avvE-3mwsA:78.79"],["2AVV_E_MK1E902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.49A","2avvE-3mwsA:19.5","2avvE-3mwsA:78.79"],["2AVV_E_MK1E902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.44A","2avvE-3mwsA:19.5","2avvE-3mwsA:78.79"],["2AVV_E_MK1E902_3","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.45A","2avvE-3mwsA:19.5","2avvE-3mwsA:78.79"],["2B60_B_RITB100_1","GAG-POL POLYPROTEIN;GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","2b60A-3mwsA:19.9","2b60A-3mwsA:76.77"],["2B60_B_RITB100_1","GAG-POL POLYPROTEIN;GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.51A","2b60A-3mwsA:19.9","2b60A-3mwsA:76.77"],["2B60_B_RITB100_2","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","2b60B-3mwsA:19.9","2b60B-3mwsA:76.77"],["2B7Z_B_MK1B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81","None","0.89A","2b7zA-3mwsA:20.1","2b7zA-3mwsA:74.75"],["2B7Z_B_MK1B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;ASP A  25;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.28A","2b7zA-3mwsA:20.1","2b7zA-3mwsA:74.75"],["2B7Z_B_MK1B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81","None","0.50A","2b7zA-3mwsA:20.1","2b7zA-3mwsA:74.75"],["2B7Z_B_MK1B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.46A","2b7zA-3mwsA:20.1","2b7zA-3mwsA:74.75"],["2B7Z_B_MK1B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ALA A  22","None","1.29A","2b7zA-3mwsA:20.1","2b7zA-3mwsA:74.75"],["2B7Z_B_MK1B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81","None","0.88A","2b7zB-3mwsA:19.8","2b7zB-3mwsA:74.75"],["2B7Z_B_MK1B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81","None","0.55A","2b7zB-3mwsA:19.8","2b7zB-3mwsA:74.75"],["2B7Z_B_MK1B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.53A","2b7zB-3mwsA:19.8","2b7zB-3mwsA:74.75"],["2B7Z_B_MK1B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ALA A  22","None","1.31A","2b7zB-3mwsA:19.8","2b7zB-3mwsA:74.75"],["2BPX_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.81A","2bpxB-3mwsA:18.9","2bpxB-3mwsA:78.79"],["2BPX_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.69A","2bpxB-3mwsA:18.9","2bpxB-3mwsA:78.79"],["2BPX_B_MK1B902_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.65A","2bpxB-3mwsA:18.9","2bpxB-3mwsA:78.79"],["2F78_A_BEZA1003_0","HTH-TYPE TRANSCRIPTIONAL REGULATOR BENM","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"VAL A  13;LEU A  24;PHE A  89;THR A  31","None","1.09A","2f78A-3mwsA:undetectable","2f78A-3mwsA:19.55"],["2F78_B_BEZB1004_0","HTH-TYPE TRANSCRIPTIONAL REGULATOR BENM","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"VAL A  13;LEU A  24;PHE A  89;THR A  31","None","1.10A","2f78B-3mwsA:undetectable","2f78B-3mwsA:19.55"],["2F80_B_017B301_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;ILE A  84","None","0.94A","2f80A-3mwsA:20.2","2f80A-3mwsA:78.79"],["2F80_B_017B301_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.40A","2f80A-3mwsA:20.2","2f80A-3mwsA:78.79"],["2F80_B_017B301_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.24A","2f80B-3mwsA:19.6","2f80B-3mwsA:78.79"],["2F81_A_017A302_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.96A","2f81A-3mwsA:20.3","2f81A-3mwsA:78.79"],["2F81_A_017A302_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.46A","2f81A-3mwsA:20.3","2f81A-3mwsA:78.79"],["2F81_A_017A302_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.32A","2f81A-3mwsA:20.3","2f81A-3mwsA:78.79"],["2F81_A_017A302_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.75A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.53A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F81_A_017A302_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.37A","2f81B-3mwsA:19.7","2f81B-3mwsA:78.79"],["2F8G_B_017B401_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.72A","2f8gA-3mwsA:20.3","2f8gA-3mwsA:78.79"],["2F8G_B_017B401_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49","None","1.39A","2f8gA-3mwsA:20.3","2f8gA-3mwsA:78.79"],["2F8G_B_017B401_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.49A","2f8gA-3mwsA:20.3","2f8gA-3mwsA:78.79"],["2F8G_B_017B401_1","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;VAL A  82;ILE A  84","None","0.40A","2f8gA-3mwsA:20.3","2f8gA-3mwsA:78.79"],["2F8G_B_017B401_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.96A","2f8gB-3mwsA:19.7","2f8gB-3mwsA:78.79"],["2F8G_B_017B401_2","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.33A","2f8gB-3mwsA:19.7","2f8gB-3mwsA:78.79"],["2FXD_A_DR7A102_1","POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.28A","2fxdA-3mwsA:19.4","2fxdA-3mwsA:77.78"],["2FXD_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","0.40A","2fxdB-3mwsA:20.0","2fxdB-3mwsA:77.78"],["2FXE_A_DR7A102_1","POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;GLY A  27;GLY A  48;GLY A  49;ILE A  50;PHE A  53;PRO A  81","None","0.76A","2fxeA-3mwsA:19.6","2fxeA-3mwsA:81.82"],["2FXE_A_DR7A102_1","POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;VAL A  82;ILE A  84","None","0.90A","2fxeA-3mwsA:19.6","2fxeA-3mwsA:81.82"],["2FXE_A_DR7A102_1","POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  48;GLY A  49;ILE A  50;PHE A  53;PRO A  81;VAL A  82;ILE A  84","None","0.61A","2fxeA-3mwsA:19.6","2fxeA-3mwsA:81.82"],["2FXE_A_DR7A102_1","POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;GLY A  48;PRO A  81;ILE A  84","None","0.95A","2fxeA-3mwsA:19.6","2fxeA-3mwsA:81.82"],["2FXE_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.94A","2fxeB-3mwsA:19.9","2fxeB-3mwsA:81.82"],["2FXE_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.44A","2fxeB-3mwsA:19.9","2fxeB-3mwsA:81.82"],["2FXE_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ILE A  47;PRO A  81;VAL A  82","None","0.61A","2fxeB-3mwsA:19.9","2fxeB-3mwsA:81.82"],["2FXE_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","1.33A","2fxeB-3mwsA:19.9","2fxeB-3mwsA:81.82"],["2FXE_A_DR7A102_2","POL PROTEIN;POL PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.42A","2fxeB-3mwsA:19.9","2fxeB-3mwsA:81.82"],["2HS1_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;ILE A  84","None","0.66A","2hs1A-3mwsA:18.6","2hs1A-3mwsA:78.79"],["2HS1_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.50A","2hs1A-3mwsA:18.6","2hs1A-3mwsA:78.79"],["2HS1_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.77A","2hs1B-3mwsA:20.0","2hs1B-3mwsA:78.79"],["2HS1_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.50A","2hs1B-3mwsA:20.0","2hs1B-3mwsA:78.79"],["2HS1_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.57A","2hs1B-3mwsA:20.0","2hs1B-3mwsA:78.79"],["2HS1_B_017B203_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"TRP A  42;PRO A  44;MET A  46;ARG A  57;GLY A  78","None","0.34A","2hs1B-3mwsA:20.0","2hs1B-3mwsA:78.79"],["2HS2_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.87A","2hs2A-3mwsA:18.6","2hs2A-3mwsA:78.79"],["2HS2_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.65A","2hs2A-3mwsA:18.6","2hs2A-3mwsA:78.79"],["2HS2_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","2hs2A-3mwsA:18.6","2hs2A-3mwsA:78.79"],["2HS2_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.87A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2HS2_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.83A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2HS2_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.26A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2HS2_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.54A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2HS2_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.46A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2HS2_B_017B203_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"TRP A  42;PRO A  44;ARG A  57;GLY A  78","None","0.23A","2hs2B-3mwsA:20.1","2hs2B-3mwsA:78.79"],["2IDW_B_017B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.02A","2idwA-3mwsA:19.5","2idwA-3mwsA:78.79"],["2IDW_B_017B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.59A","2idwA-3mwsA:19.5","2idwA-3mwsA:78.79"],["2IDW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;ILE A  84","None","0.71A","2idwB-3mwsA:19.7","2idwB-3mwsA:78.79"],["2IDW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.21A","2idwB-3mwsA:19.7","2idwB-3mwsA:78.79"],["2IDW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None","0.41A","2idwB-3mwsA:19.7","2idwB-3mwsA:78.79"],["2IDW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","0.40A","2idwB-3mwsA:19.7","2idwB-3mwsA:78.79"],["2IEN_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.35A","2ienA-3mwsA:20.3","2ienA-3mwsA:79.80"],["2IEN_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.48A","2ienA-3mwsA:20.3","2ienA-3mwsA:79.80"],["2IEN_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.97A","2ienA-3mwsA:20.3","2ienA-3mwsA:79.80"],["2IEN_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.43A","2ienB-3mwsA:19.7","2ienB-3mwsA:79.80"],["2IEO_A_017A402_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81","None","1.07A","2ieoA-3mwsA:20.3","2ieoA-3mwsA:78.79"],["2IEO_A_017A402_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82","None","1.45A","2ieoA-3mwsA:20.3","2ieoA-3mwsA:78.79"],["2IEO_A_017A402_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.39A","2ieoA-3mwsA:20.3","2ieoA-3mwsA:78.79"],["2IEO_A_017A402_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.73A","2ieoB-3mwsA:19.7","2ieoB-3mwsA:78.79"],["2IEO_A_017A402_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.26A","2ieoB-3mwsA:19.7","2ieoB-3mwsA:78.79"],["2IEO_A_017A402_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82","None","0.50A","2ieoB-3mwsA:19.7","2ieoB-3mwsA:78.79"],["2IEO_A_017A402_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.32A","2ieoB-3mwsA:19.7","2ieoB-3mwsA:78.79"],["2NMY_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81;ILE A  84","None","1.00A","2nmyA-3mwsA:18.8","2nmyA-3mwsA:78.79"],["2NMY_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;THR A  80;PRO A  81;ILE A  84","None","0.67A","2nmyA-3mwsA:18.8","2nmyA-3mwsA:78.79"],["2NMY_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;PRO A  81;ILE A  84","None","0.45A","2nmyA-3mwsA:18.8","2nmyA-3mwsA:78.79"],["2NMY_A_ROCA401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.97A","2nmyB-3mwsA:18.5","2nmyB-3mwsA:78.79"],["2NMY_A_ROCA401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","0.57A","2nmyB-3mwsA:18.5","2nmyB-3mwsA:78.79"],["2NMY_A_ROCA401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.36A","2nmyB-3mwsA:18.5","2nmyB-3mwsA:78.79"],["2NMZ_B_ROCB401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.00A","2nmzA-3mwsA:19.5","2nmzA-3mwsA:78.79"],["2NMZ_B_ROCB401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.38A","2nmzA-3mwsA:19.5","2nmzA-3mwsA:78.79"],["2NMZ_B_ROCB401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.38A","2nmzA-3mwsA:19.5","2nmzA-3mwsA:78.79"],["2NMZ_B_ROCB401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.64A","2nmzA-3mwsA:19.5","2nmzA-3mwsA:78.79"],["2NMZ_B_ROCB401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","2nmzA-3mwsA:19.5","2nmzA-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  50","None","1.46A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","0.76A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  50;PRO A  81;ILE A  84","None","0.65A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.35A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  47;PRO A  81;ILE A  84","None","0.70A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NMZ_B_ROCB401_3","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","2nmzB-3mwsA:19.6","2nmzB-3mwsA:78.79"],["2NNK_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82","None","0.97A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.33A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82","None","0.66A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.42A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;PRO A  81;VAL A  82","None","0.45A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;VAL A  32;THR A  80","None","0.66A","2nnkA-3mwsA:19.7","2nnkA-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  30;PRO A  81;VAL A  82","None","0.71A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ILE A  50;PRO A  81;VAL A  82","None","0.85A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  27;ASP A  29;ASP A  30;GLY A  48;PRO A  81","None","0.94A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.24A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ASP A  29;ASP A  30;ILE A  47;PRO A  81;VAL A  82","None","0.66A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNK_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.54A","2nnkB-3mwsA:19.4","2nnkB-3mwsA:78.79"],["2NNP_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.96A","2nnpA-3mwsA:19.5","2nnpA-3mwsA:78.79"],["2NNP_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;GLY A  48;THR A  80;PRO A  81;VAL A  82","None","0.98A","2nnpA-3mwsA:19.5","2nnpA-3mwsA:78.79"],["2NNP_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81","None","0.66A","2nnpA-3mwsA:19.5","2nnpA-3mwsA:78.79"],["2NNP_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;VAL A  82","None","0.70A","2nnpA-3mwsA:19.5","2nnpA-3mwsA:78.79"],["2NNP_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;THR A  80;PRO A  81;VAL A  82","None","0.63A","2nnpA-3mwsA:19.5","2nnpA-3mwsA:78.79"],["2NNP_A_ROCA401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.57A","2nnpB-3mwsA:19.7","2nnpB-3mwsA:78.79"],["2O4K_A_DR7A301_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.36A","2o4kA-3mwsA:20.1","2o4kA-3mwsA:77.78"],["2O4K_A_DR7A301_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PHE A  53;PRO A  81;ILE A  84","None","0.49A","2o4kA-3mwsA:20.1","2o4kA-3mwsA:77.78"],["2O4K_A_DR7A301_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.03A","2o4kB-3mwsA:19.6","2o4kB-3mwsA:77.78"],["2O4K_A_DR7A301_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;GLY A  27;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.67A","2o4kB-3mwsA:19.6","2o4kB-3mwsA:77.78"],["2O4K_A_DR7A301_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.31A","2o4kB-3mwsA:19.6","2o4kB-3mwsA:77.78"],["2O4L_A_TPVA403_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  30;PRO A  81;VAL A  82","None","0.71A","2o4lA-3mwsA:20.0","2o4lA-3mwsA:76.77"],["2O4L_A_TPVA403_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ILE A  47;GLY A  49;PRO A  81;VAL A  82","None","0.65A","2o4lA-3mwsA:20.0","2o4lA-3mwsA:76.77"],["2O4L_A_TPVA403_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82","None","0.85A","2o4lA-3mwsA:20.0","2o4lA-3mwsA:76.77"],["2O4L_A_TPVA403_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.59A","2o4lA-3mwsA:20.0","2o4lA-3mwsA:76.77"],["2O4L_A_TPVA403_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","2o4lA-3mwsA:20.0","2o4lA-3mwsA:76.77"],["2O4L_A_TPVA403_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;VAL A  82;ILE A  84","None","0.52A","2o4lB-3mwsA:19.4","2o4lB-3mwsA:76.77"],["2O4N_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.66A","2o4nA-3mwsA:20.6","2o4nA-3mwsA:74.75"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82","None","0.93A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81","None","0.72A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.61A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81;VAL A  82","None","0.62A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.40A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.48A","2o4pA-3mwsA:20.0","2o4pA-3mwsA:77.78"],["2O4P_A_TPVA300_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.67A","2o4pB-3mwsA:19.5","2o4pB-3mwsA:77.78"],["2O4P_A_TPVA300_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.49A","2o4pB-3mwsA:19.5","2o4pB-3mwsA:77.78"],["2O4S_A_AB1A400_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81","None","0.60A","2o4sA-3mwsA:20.2","2o4sA-3mwsA:77.78"],["2O4S_A_AB1A400_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","2o4sA-3mwsA:20.2","2o4sA-3mwsA:77.78"],["2O4S_A_AB1A400_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  48;PRO A  81","None","0.88A","2o4sA-3mwsA:20.2","2o4sA-3mwsA:77.78"],["2O4S_A_AB1A400_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.75A","2o4sA-3mwsA:20.2","2o4sA-3mwsA:77.78"],["2O4S_A_AB1A400_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.54A","2o4sB-3mwsA:19.5","2o4sB-3mwsA:77.78"],["2PYM_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81","None","0.89A","2pymA-3mwsA:20.0","2pymA-3mwsA:76.77"],["2PYM_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.44A","2pymA-3mwsA:20.0","2pymA-3mwsA:76.77"],["2PYM_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","2pymA-3mwsA:20.0","2pymA-3mwsA:76.77"],["2PYM_A_1UNA1001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.44A","2pymB-3mwsA:20.0","2pymB-3mwsA:76.77"],["2PYM_A_1UNA1001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.51A","2pymB-3mwsA:20.0","2pymB-3mwsA:76.77"],["2PYN_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81","None","0.84A","2pynA-3mwsA:20.1","2pynA-3mwsA:76.77"],["2PYN_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.45A","2pynA-3mwsA:20.1","2pynA-3mwsA:76.77"],["2PYN_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.49A","2pynA-3mwsA:20.1","2pynA-3mwsA:76.77"],["2PYN_A_1UNA1001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.45A","2pynB-3mwsA:20.0","2pynB-3mwsA:76.77"],["2PYN_A_1UNA1001_3","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;THR A  80;PRO A  81","None","0.43A","2pynB-3mwsA:20.0","2pynB-3mwsA:76.77"],["2Q5K_A_AB1A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.84A","2q5kA-3mwsA:19.6","2q5kA-3mwsA:77.78"],["2Q5K_A_AB1A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.50A","2q5kA-3mwsA:19.6","2q5kA-3mwsA:77.78"],["2Q5K_A_AB1A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.31A","2q5kA-3mwsA:19.6","2q5kA-3mwsA:77.78"],["2Q5K_A_AB1A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.42A","2q5kB-3mwsA:20.1","2q5kB-3mwsA:77.78"],["2Q63_A_1UNA1001_3","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.42A","2q63B-3mwsA:19.9","2q63B-3mwsA:75.76"],["2Q63_A_1UNA1001_3","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.47A","2q63B-3mwsA:19.9","2q63B-3mwsA:75.76"],["2Q64_B_1UNB1001_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81","None","0.81A","2q64A-3mwsA:19.8","2q64A-3mwsA:77.78"],["2Q64_B_1UNB1001_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.49A","2q64A-3mwsA:19.8","2q64A-3mwsA:77.78"],["2Q64_B_1UNB1001_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;THR A  80;VAL A  82","None","0.38A","2q64A-3mwsA:19.8","2q64A-3mwsA:77.78"],["2Q64_B_1UNB1001_3","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;VAL A  32;GLY A  48;VAL A  82;ILE A  84","None","0.76A","2q64B-3mwsA:19.8","2q64B-3mwsA:77.78"],["2Q64_B_1UNB1001_3","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.41A","2q64B-3mwsA:19.8","2q64B-3mwsA:77.78"],["2Q64_B_1UNB1001_4","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;THR A  80;PRO A  81","None","0.37A","2q64B-3mwsA:19.8","2q64B-3mwsA:77.78"],["2QAK_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.87A","2qakA-3mwsA:20.0","2qakA-3mwsA:75.76"],["2QAK_A_1UNA1001_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.51A","2qakA-3mwsA:20.0","2qakA-3mwsA:75.76"],["2QAK_A_1UNA1001_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;THR A  80;VAL A  82","None","0.50A","2qakA-3mwsA:20.0","2qakA-3mwsA:75.76"],["2QAK_A_1UNA1001_3","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.45A","2qakB-3mwsA:20.0","2qakB-3mwsA:75.76"],["2QAK_A_1UNA1001_4","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;THR A  80;PRO A  81","None","0.43A","2qakB-3mwsA:20.0","2qakB-3mwsA:75.76"],["2QHC_B_AB1B9001_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","2qhcA-3mwsA:19.8","2qhcA-3mwsA:77.78"],["2QHC_B_AB1B9001_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.80A","2qhcA-3mwsA:19.8","2qhcA-3mwsA:77.78"],["2QHC_B_AB1B9001_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.62A","2qhcB-3mwsA:19.8","2qhcB-3mwsA:77.78"],["2QHC_B_AB1B9001_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.50A","2qhcB-3mwsA:19.8","2qhcB-3mwsA:77.78"],["2QHC_B_AB1B9001_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","2qhcB-3mwsA:19.8","2qhcB-3mwsA:77.78"],["2QHC_B_AB1B9001_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","0.94A","2qhcB-3mwsA:19.8","2qhcB-3mwsA:77.78"],["2R5P_B_MK1B902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ASP A  29;GLY A  48;GLY A  49;ILE A  50","None","1.29A","2r5pA-3mwsA:20.7","2r5pA-3mwsA:76.77"],["2R5P_B_MK1B902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.69A","2r5pA-3mwsA:20.7","2r5pA-3mwsA:76.77"],["2R5P_B_MK1B902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","2r5pA-3mwsA:20.7","2r5pA-3mwsA:76.77"],["2R5P_B_MK1B902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.03A","2r5pB-3mwsA:20.0","2r5pB-3mwsA:76.77"],["2R5P_B_MK1B902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.42A","2r5pB-3mwsA:20.0","2r5pB-3mwsA:76.77"],["2R5P_B_MK1B902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.56A","2r5pB-3mwsA:20.0","2r5pB-3mwsA:76.77"],["2R5P_D_MK1D902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ASP A  29;GLY A  48;GLY A  49;ILE A  50","None","1.29A","2r5pC-3mwsA:20.7","2r5pC-3mwsA:76.77"],["2R5P_D_MK1D902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.69A","2r5pC-3mwsA:20.7","2r5pC-3mwsA:76.77"],["2R5P_D_MK1D902_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  48;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","2r5pC-3mwsA:20.7","2r5pC-3mwsA:76.77"],["2R5P_D_MK1D902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.96A","2r5pD-3mwsA:20.0","2r5pD-3mwsA:76.77"],["2R5P_D_MK1D902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.42A","2r5pD-3mwsA:20.0","2r5pD-3mwsA:76.77"],["2R5P_D_MK1D902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.54A","2r5pD-3mwsA:20.0","2r5pD-3mwsA:76.77"],["2R5P_D_MK1D902_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","2r5pD-3mwsA:20.0","2r5pD-3mwsA:76.77"],["2R5Q_B_1UNB900_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.61A","2r5qA-3mwsA:20.6","2r5qA-3mwsA:76.77"],["2R5Q_B_1UNB900_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.89A","2r5qA-3mwsA:20.6","2r5qA-3mwsA:76.77"],["2R5Q_B_1UNB900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.02A","2r5qB-3mwsA:19.6","2r5qB-3mwsA:76.77"],["2R5Q_B_1UNB900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.46A","2r5qB-3mwsA:19.6","2r5qB-3mwsA:76.77"],["2R5Q_B_1UNB900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.69A","2r5qB-3mwsA:19.6","2r5qB-3mwsA:76.77"],["2R5Q_B_1UNB900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.52A","2r5qB-3mwsA:19.6","2r5qB-3mwsA:76.77"],["2R5Q_D_1UND900_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.61A","2r5qC-3mwsA:20.6","2r5qC-3mwsA:76.77"],["2R5Q_D_1UND900_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.89A","2r5qC-3mwsA:20.6","2r5qC-3mwsA:76.77"],["2R5Q_D_1UND900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.05A","2r5qD-3mwsA:19.6","2r5qD-3mwsA:76.77"],["2R5Q_D_1UND900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.73A","2r5qD-3mwsA:19.6","2r5qD-3mwsA:76.77"],["2R5Q_D_1UND900_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.54A","2r5qD-3mwsA:19.6","2r5qD-3mwsA:76.77"],["2RKF_A_AB1A501_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","2rkfA-3mwsA:19.6","2rkfA-3mwsA:70.71"],["2RKF_A_AB1A501_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.49A","2rkfA-3mwsA:19.6","2rkfA-3mwsA:70.71"],["2RKF_A_AB1A501_1","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.34A","2rkfA-3mwsA:19.6","2rkfA-3mwsA:70.71"],["2RKF_A_AB1A501_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.38A","2rkfB-3mwsA:19.6","2rkfB-3mwsA:70.71"],["2RKF_A_AB1A501_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.90A","2rkfB-3mwsA:19.6","2rkfB-3mwsA:70.71"],["2RKF_A_AB1A501_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.41A","2rkfB-3mwsA:19.6","2rkfB-3mwsA:70.71"],["2RKF_A_AB1A501_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","1.38A","2rkfB-3mwsA:19.6","2rkfB-3mwsA:70.71"],["2RKF_A_AB1A501_2","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.51A","2rkfB-3mwsA:19.6","2rkfB-3mwsA:70.71"],["2RKG_B_AB1B501_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.38A","2rkgA-3mwsA:19.6","2rkgA-3mwsA:70.00"],["2RKG_B_AB1B501_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.90A","2rkgA-3mwsA:19.6","2rkgA-3mwsA:70.00"],["2RKG_B_AB1B501_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.33A","2rkgA-3mwsA:19.6","2rkgA-3mwsA:70.00"],["2RKG_B_AB1B501_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","1.37A","2rkgA-3mwsA:19.6","2rkgA-3mwsA:70.00"],["2RKG_B_AB1B501_1","PROTEASE RETROPEPSIN;PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.52A","2rkgA-3mwsA:19.6","2rkgA-3mwsA:70.00"],["2RKG_B_AB1B501_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.46A","2rkgB-3mwsA:19.5","2rkgB-3mwsA:70.00"],["2RKG_B_AB1B501_2","PROTEASE RETROPEPSIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.33A","2rkgB-3mwsA:19.5","2rkgB-3mwsA:70.00"],["2Z54_A_AB1A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.81A","2z54A-3mwsA:20.0","2z54A-3mwsA:76.77"],["2Z54_A_AB1A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.53A","2z54A-3mwsA:20.0","2z54A-3mwsA:76.77"],["2Z54_A_AB1A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.49A","2z54A-3mwsA:20.0","2z54A-3mwsA:76.77"],["2Z54_A_AB1A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.36A","2z54B-3mwsA:20.0","2z54B-3mwsA:76.77"],["2Z54_A_AB1A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.55A","2z54B-3mwsA:20.0","2z54B-3mwsA:76.77"],["2Z54_A_AB1A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","2z54B-3mwsA:20.0","2z54B-3mwsA:76.77"],["2Z54_A_AB1A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.80A","2z54B-3mwsA:20.0","2z54B-3mwsA:76.77"],["3BVB_B_017B401_1","PROTEASE (RETROPEPSIN);PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.37A","3bvbA-3mwsA:20.3","3bvbA-3mwsA:78.79"],["3BVB_B_017B401_1","PROTEASE (RETROPEPSIN);PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ILE A  54;GLY A  49;ILE A  50;VAL A  82","None","1.39A","3bvbA-3mwsA:20.3","3bvbA-3mwsA:78.79"],["3BVB_B_017B401_1","PROTEASE (RETROPEPSIN);PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;GLY A  27;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.03A","3bvbA-3mwsA:20.3","3bvbA-3mwsA:78.79"],["3BVB_B_017B401_2","PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.80A","3bvbB-3mwsA:19.6","3bvbB-3mwsA:78.79"],["3BVB_B_017B401_2","PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.35A","3bvbB-3mwsA:19.6","3bvbB-3mwsA:78.79"],["3BVB_B_017B401_2","PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.54A","3bvbB-3mwsA:19.6","3bvbB-3mwsA:78.79"],["3BVB_B_017B401_2","PROTEASE (RETROPEPSIN)","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","3bvbB-3mwsA:19.6","3bvbB-3mwsA:78.79"],["3CYW_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3cywA-3mwsA:20.1","3cywA-3mwsA:78.79"],["3CYW_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.79A","3cywB-3mwsA:19.7","3cywB-3mwsA:78.79"],["3CYW_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3cywB-3mwsA:19.7","3cywB-3mwsA:78.79"],["3CYW_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.29A","3cywB-3mwsA:19.7","3cywB-3mwsA:78.79"],["3CYX_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.66A","3cyxA-3mwsA:20.1","3cyxA-3mwsA:78.79"],["3CYX_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3cyxA-3mwsA:20.1","3cyxA-3mwsA:78.79"],["3CYX_A_ROCA201_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.52A","3cyxB-3mwsA:19.7","3cyxB-3mwsA:78.79"],["3CYX_A_ROCA201_3","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  48;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.33A","3cyxB-3mwsA:19.7","3cyxB-3mwsA:78.79"],["3CYX_A_ROCA201_4","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"LEU A  23;ASP A  29;VAL A  32;THR A  80","None","0.44A","3cyxB-3mwsA:19.7","3cyxB-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.04A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81;VAL A  82","None","1.02A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;VAL A  82;ILE A  84","None","1.47A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.77A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82","None","0.71A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;VAL A  82","None","0.55A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.55A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.61A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;THR A  80;PRO A  81;VAL A  82","None","0.56A","3d1xA-3mwsA:19.8","3d1xA-3mwsA:78.79"],["3D1X_A_ROCA201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.38A","3d1xB-3mwsA:19.7","3d1xB-3mwsA:78.79"],["3D1X_A_ROCA201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.57A","3d1xB-3mwsA:19.7","3d1xB-3mwsA:78.79"],["3D1X_A_ROCA201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.46A","3d1xB-3mwsA:19.7","3d1xB-3mwsA:78.79"],["3D1Y_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.95A","3d1yA-3mwsA:19.9","3d1yA-3mwsA:78.79"],["3D1Y_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.36A","3d1yA-3mwsA:19.9","3d1yA-3mwsA:78.79"],["3D1Y_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.60A","3d1yA-3mwsA:19.9","3d1yA-3mwsA:78.79"],["3D1Y_A_ROCA201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.58A","3d1yA-3mwsA:19.9","3d1yA-3mwsA:78.79"],["3D1Y_A_ROCA201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.82A","3d1yB-3mwsA:19.4","3d1yB-3mwsA:78.79"],["3D1Y_A_ROCA201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.67A","3d1yB-3mwsA:19.4","3d1yB-3mwsA:78.79"],["3D1Z_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.94A","3d1zA-3mwsA:20.1","3d1zA-3mwsA:78.79"],["3D1Z_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.51A","3d1zA-3mwsA:20.1","3d1zA-3mwsA:78.79"],["3D1Z_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.56A","3d1zA-3mwsA:20.1","3d1zA-3mwsA:78.79"],["3D1Z_B_017B201_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.68A","3d1zB-3mwsA:19.7","3d1zB-3mwsA:78.79"],["3D1Z_B_017B201_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.34A","3d1zB-3mwsA:19.7","3d1zB-3mwsA:78.79"],["3D1Z_B_017B201_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.42A","3d1zB-3mwsA:19.7","3d1zB-3mwsA:78.79"],["3D1Z_B_017B201_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.35A","3d1zB-3mwsA:19.7","3d1zB-3mwsA:78.79"],["3D20_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.86A","3d20A-3mwsA:20.3","3d20A-3mwsA:78.79"],["3D20_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.85A","3d20A-3mwsA:20.3","3d20A-3mwsA:78.79"],["3D20_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3d20A-3mwsA:20.3","3d20A-3mwsA:78.79"],["3D20_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.44A","3d20A-3mwsA:20.3","3d20A-3mwsA:78.79"],["3D20_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.69A","3d20B-3mwsA:19.6","3d20B-3mwsA:78.79"],["3D20_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","3d20B-3mwsA:19.6","3d20B-3mwsA:78.79"],["3D20_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.40A","3d20B-3mwsA:19.6","3d20B-3mwsA:78.79"],["3D20_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.33A","3d20B-3mwsA:19.6","3d20B-3mwsA:78.79"],["3EBZ_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.45A","3ebzA-3mwsA:19.3","3ebzA-3mwsA:48.48"],["3EBZ_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.27A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EBZ_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.48A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EBZ_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.27A","3ebzB-3mwsA:19.4","3ebzB-3mwsA:48.48"],["3EKP_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.84A","3ekpB-3mwsA:19.2","3ekpB-3mwsA:74.75"],["3EKP_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.34A","3ekpB-3mwsA:19.2","3ekpB-3mwsA:74.75"],["3EKP_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.48A","3ekpB-3mwsA:19.2","3ekpB-3mwsA:74.75"],["3EKP_C_478C200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.86A","3ekpC-3mwsA:19.8","3ekpC-3mwsA:74.75"],["3EKP_C_478C200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.31A","3ekpC-3mwsA:19.8","3ekpC-3mwsA:74.75"],["3EKP_C_478C200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","3ekpC-3mwsA:19.8","3ekpC-3mwsA:74.75"],["3EKP_C_478C200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.76A","3ekpD-3mwsA:19.8","3ekpD-3mwsA:74.75"],["3EKP_C_478C200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  84","None","1.26A","3ekpD-3mwsA:19.8","3ekpD-3mwsA:74.75"],["3EKP_C_478C200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;ILE A  84","None","0.43A","3ekpD-3mwsA:19.8","3ekpD-3mwsA:74.75"],["3EKQ_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.99A","3ekqA-3mwsA:19.6","3ekqA-3mwsA:74.75"],["3EKQ_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.32A","3ekqA-3mwsA:19.6","3ekqA-3mwsA:74.75"],["3EKQ_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.65A","3ekqA-3mwsA:19.6","3ekqA-3mwsA:74.75"],["3EKQ_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.39A","3ekqA-3mwsA:19.6","3ekqA-3mwsA:74.75"],["3EKQ_A_ROCA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;VAL A  32;ILE A  50;PRO A  81","None","0.95A","3ekqB-3mwsA:19.2","3ekqB-3mwsA:74.75"],["3EKQ_A_ROCA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.63A","3ekqB-3mwsA:19.2","3ekqB-3mwsA:74.75"],["3EKT_B_017B200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.82A","3ektA-3mwsA:19.8","3ektA-3mwsA:74.75"],["3EKT_B_017B200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.26A","3ektA-3mwsA:19.8","3ektA-3mwsA:74.75"],["3EKT_B_017B200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50","None","0.46A","3ektA-3mwsA:19.8","3ektA-3mwsA:74.75"],["3EKT_B_017B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.41A","3ektB-3mwsA:19.8","3ektB-3mwsA:74.75"],["3EKT_B_017B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.87A","3ektB-3mwsA:19.8","3ektB-3mwsA:74.75"],["3EKT_B_017B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","3ektB-3mwsA:19.8","3ektB-3mwsA:74.75"],["3EKT_D_017D200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.84A","3ektC-3mwsA:19.3","3ektC-3mwsA:74.75"],["3EKT_D_017D200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","1.22A","3ektC-3mwsA:19.3","3ektC-3mwsA:74.75"],["3EKT_D_017D200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.43A","3ektC-3mwsA:19.3","3ektC-3mwsA:74.75"],["3EKT_D_017D200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.76A","3ektD-3mwsA:19.3","3ektD-3mwsA:74.75"],["3EKT_D_017D200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.38A","3ektD-3mwsA:19.3","3ektD-3mwsA:74.75"],["3EKV_A_478A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.68A","3ekvA-3mwsA:19.8","3ekvA-3mwsA:77.78"],["3EKV_A_478A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.27A","3ekvA-3mwsA:19.8","3ekvA-3mwsA:77.78"],["3EKV_A_478A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.37A","3ekvA-3mwsA:19.8","3ekvA-3mwsA:77.78"],["3EKV_A_478A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.41A","3ekvA-3mwsA:19.8","3ekvA-3mwsA:77.78"],["3EKV_A_478A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.49A","3ekvB-3mwsA:19.5","3ekvB-3mwsA:77.78"],["3EKV_A_478A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.92A","3ekvB-3mwsA:19.5","3ekvB-3mwsA:77.78"],["3EKW_B_DR7B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;ASP A  25;ALA A  28;ILE A  47;PRO A  81","None","0.69A","3ekwA-3mwsA:19.9","3ekwA-3mwsA:74.75"],["3EKW_B_DR7B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  48;PRO A  81;ILE A  84","None","0.92A","3ekwA-3mwsA:19.9","3ekwA-3mwsA:74.75"],["3EKW_B_DR7B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.37A","3ekwA-3mwsA:19.9","3ekwA-3mwsA:74.75"],["3EKW_B_DR7B100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.26A","3ekwA-3mwsA:19.9","3ekwA-3mwsA:74.75"],["3EKW_B_DR7B100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.48A","3ekwB-3mwsA:19.4","3ekwB-3mwsA:74.75"],["3EKX_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;THR A  80;PRO A  81;ILE A  84","None","0.91A","3ekxA-3mwsA:19.3","3ekxA-3mwsA:77.78"],["3EKX_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;THR A  80;PRO A  81;ILE A  84","None","0.68A","3ekxA-3mwsA:19.3","3ekxA-3mwsA:77.78"],["3EKX_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;THR A  80;ILE A  84","None","0.55A","3ekxA-3mwsA:19.3","3ekxA-3mwsA:77.78"],["3EKX_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;THR A  80;PRO A  81;ILE A  84","None","0.65A","3ekxA-3mwsA:19.3","3ekxA-3mwsA:77.78"],["3EKX_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.70A","3ekxB-3mwsA:19.9","3ekxB-3mwsA:77.78"],["3EKX_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.41A","3ekxB-3mwsA:19.9","3ekxB-3mwsA:77.78"],["3EKX_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.60A","3ekxB-3mwsA:19.9","3ekxB-3mwsA:77.78"],["3EKX_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.56A","3ekxB-3mwsA:19.9","3ekxB-3mwsA:77.78"],["3EKY_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.93A","3ekyA-3mwsA:19.9","3ekyA-3mwsA:77.78"],["3EKY_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.43A","3ekyA-3mwsA:19.9","3ekyA-3mwsA:77.78"],["3EKY_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.56A","3ekyA-3mwsA:19.9","3ekyA-3mwsA:77.78"],["3EKY_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.60A","3ekyB-3mwsA:19.2","3ekyB-3mwsA:77.78"],["3EL0_A_1UNA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;ILE A  84","None","0.50A","3el0A-3mwsA:19.0","3el0A-3mwsA:74.75"],["3EL0_A_1UNA201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.55A","3el0B-3mwsA:19.9","3el0B-3mwsA:74.75"],["3EL1_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.46A","3el1A-3mwsA:19.5","3el1A-3mwsA:76.77"],["3EL1_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.53A","3el1A-3mwsA:19.5","3el1A-3mwsA:76.77"],["3EL1_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.80A","3el1B-3mwsA:19.8","3el1B-3mwsA:76.77"],["3EL1_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.69A","3el1B-3mwsA:19.8","3el1B-3mwsA:76.77"],["3EL4_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.87A","3el4A-3mwsA:19.2","3el4A-3mwsA:75.76"],["3EL4_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;THR A  80;PRO A  81","None","0.72A","3el4A-3mwsA:19.2","3el4A-3mwsA:75.76"],["3EL4_A_ROCA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;PRO A  81","None","0.68A","3el4A-3mwsA:19.2","3el4A-3mwsA:75.76"],["3EL4_A_ROCA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81","None","0.83A","3el4B-3mwsA:19.6","3el4B-3mwsA:75.76"],["3EL4_A_ROCA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.44A","3el4B-3mwsA:19.6","3el4B-3mwsA:75.76"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;ASP A  29;ILE A  50;THR A  80","None","1.14A","3el5A-3mwsA:19.9","3el5A-3mwsA:74.75"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.07A","3el5A-3mwsA:19.9","3el5A-3mwsA:74.75"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.29A","3el5A-3mwsA:19.9","3el5A-3mwsA:74.75"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81","None","0.63A","3el5A-3mwsA:19.9","3el5A-3mwsA:74.75"],["3EL5_B_1UNB201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.33A","3el5A-3mwsA:19.9","3el5A-3mwsA:74.75"],["3EL5_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.39A","3el5B-3mwsA:19.3","3el5B-3mwsA:74.75"],["3EL5_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;THR A  80;PRO A  81","None","0.57A","3el5B-3mwsA:19.3","3el5B-3mwsA:74.75"],["3EL5_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;THR A  80;PRO A  81","None","0.52A","3el5B-3mwsA:19.3","3el5B-3mwsA:74.75"],["3EL5_B_1UNB201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;THR A  80;PRO A  81","None","0.90A","3el5B-3mwsA:19.3","3el5B-3mwsA:74.75"],["3EL9_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","0.45A","3el9A-3mwsA:19.2","3el9A-3mwsA:74.75"],["3EL9_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  48;PRO A  81","None","1.13A","3el9B-3mwsA:20.1","3el9B-3mwsA:74.75"],["3EL9_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;PRO A  81","None","0.59A","3el9B-3mwsA:20.1","3el9B-3mwsA:74.75"],["3EL9_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.30A","3el9B-3mwsA:20.1","3el9B-3mwsA:74.75"],["3EM3_B_478B200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;VAL A  82;ILE A  84","None","0.82A","3em3A-3mwsA:19.9","3em3A-3mwsA:75.76"],["3EM3_B_478B200_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  49;VAL A  82;ILE A  84","None","0.56A","3em3A-3mwsA:19.9","3em3A-3mwsA:75.76"],["3EM3_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.97A","3em3B-3mwsA:20.0","3em3B-3mwsA:75.76"],["3EM3_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.43A","3em3B-3mwsA:20.0","3em3B-3mwsA:75.76"],["3EM3_B_478B200_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.44A","3em3B-3mwsA:20.0","3em3B-3mwsA:75.76"],["3EM4_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.95A","3em4A-3mwsA:19.7","3em4A-3mwsA:74.75"],["3EM4_A_DR7A100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.43A","3em4A-3mwsA:19.7","3em4A-3mwsA:74.75"],["3EM4_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;VAL A  82","None","0.92A","3em4B-3mwsA:19.6","3em4B-3mwsA:74.75"],["3EM4_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;ASP A  25;ALA A  28;GLY A  49;PRO A  81","None","0.64A","3em4B-3mwsA:19.6","3em4B-3mwsA:74.75"],["3EM4_A_DR7A100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.51A","3em4B-3mwsA:19.6","3em4B-3mwsA:74.75"],["3EM4_V_DR7V100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","1.28A","3em4U-3mwsA:20.0","3em4U-3mwsA:74.75"],["3EM4_V_DR7V100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.39A","3em4U-3mwsA:20.0","3em4U-3mwsA:74.75"],["3EM4_V_DR7V100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ASP A  29;GLY A  49;VAL A  82;ILE A  84","None","1.00A","3em4V-3mwsA:19.7","3em4V-3mwsA:74.75"],["3EM4_V_DR7V100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ASP A  29;ILE A  47;GLY A  48;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","3em4V-3mwsA:19.7","3em4V-3mwsA:74.75"],["3EM6_A_017A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.44A","3em6B-3mwsA:19.9","3em6B-3mwsA:74.75"],["3EM6_A_017A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.99A","3em6B-3mwsA:19.9","3em6B-3mwsA:74.75"],["3GGU_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.92A","3gguA-3mwsA:20.2","3gguA-3mwsA:69.70"],["3GGU_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.30A","3gguA-3mwsA:20.2","3gguA-3mwsA:69.70"],["3GGU_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81","None","0.49A","3gguA-3mwsA:20.2","3gguA-3mwsA:69.70"],["3GGU_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.28A","3gguA-3mwsA:20.2","3gguA-3mwsA:69.70"],["3GGU_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.85A","3gguB-3mwsA:20.1","3gguB-3mwsA:69.70"],["3GGU_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.23A","3gguB-3mwsA:20.1","3gguB-3mwsA:69.70"],["3GGU_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","None","0.50A","3gguB-3mwsA:20.1","3gguB-3mwsA:69.70"],["3JVY_B_017B401_1","GAG-POL POLYPROTEIN;GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.83A","3jvyA-3mwsA:20.0","3jvyA-3mwsA:78.79"],["3JVY_B_017B401_1","GAG-POL POLYPROTEIN;GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.36A","3jvyA-3mwsA:20.0","3jvyA-3mwsA:78.79"],["3JVY_B_017B401_2","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.34A","3jvyB-3mwsA:19.4","3jvyB-3mwsA:78.79"],["3JW2_A_017A401_1","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.35A","3jw2A-3mwsA:20.3","3jw2A-3mwsA:78.79"],["3JW2_A_017A401_1","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;VAL A  82;ILE A  84","None","1.03A","3jw2A-3mwsA:20.3","3jw2A-3mwsA:78.79"],["3JW2_A_017A401_1","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.97A","3jw2A-3mwsA:20.3","3jw2A-3mwsA:78.79"],["3JW2_A_017A401_1","GAG-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.36A","3jw2A-3mwsA:20.3","3jw2A-3mwsA:78.79"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.96A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.48A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.41A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","1.34A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.63A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;VAL A  32;THR A  80","None","0.67A","3k4vA-3mwsA:19.6","3k4vA-3mwsA:79.80"],["3K4V_B_ROCB201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.89A","3k4vB-3mwsA:19.6","3k4vB-3mwsA:79.80"],["3K4V_B_ROCB201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.44A","3k4vB-3mwsA:19.6","3k4vB-3mwsA:79.80"],["3K4V_B_ROCB201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.57A","3k4vB-3mwsA:19.6","3k4vB-3mwsA:79.80"],["3K4V_B_ROCB201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3k4vB-3mwsA:19.6","3k4vB-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.75A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  30;VAL A  32;PRO A  81;VAL A  82","None","0.59A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;VAL A  32;ILE A  50;PRO A  81;VAL A  82","None","0.78A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.28A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.54A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.52A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"GLY A  27;ASP A  29;GLY A  48;THR A  80","None","0.43A","3k4vC-3mwsA:19.6","3k4vC-3mwsA:79.80"],["3K4V_D_ROCD201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.31A","3k4vD-3mwsA:19.5","3k4vD-3mwsA:79.80"],["3K4V_D_ROCD201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.59A","3k4vD-3mwsA:19.5","3k4vD-3mwsA:79.80"],["3K4V_D_ROCD201_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3k4vD-3mwsA:19.5","3k4vD-3mwsA:79.80"],["3KEE_D_30BD500_2","GENOME POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"PHE A  89;TYR A  59;VAL A  10;LEU A  23","None","1.49A","3keeD-3mwsA:undetectable","3keeD-3mwsA:24.07"],["3LZS_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3lzsA-3mwsA:20.1","3lzsA-3mwsA:79.80"],["3LZS_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.29A","3lzsA-3mwsA:20.1","3lzsA-3mwsA:79.80"],["3LZS_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.44A","3lzsB-3mwsA:20.1","3lzsB-3mwsA:79.80"],["3LZS_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.25A","3lzsB-3mwsA:20.1","3lzsB-3mwsA:79.80"],["3LZU_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.77A","3lzuA-3mwsA:20.2","3lzuA-3mwsA:78.79"],["3LZU_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.42A","3lzuA-3mwsA:20.2","3lzuA-3mwsA:78.79"],["3LZU_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.21A","3lzuA-3mwsA:20.2","3lzuA-3mwsA:78.79"],["3LZU_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.95A","3lzuB-3mwsA:20.1","3lzuB-3mwsA:78.79"],["3LZU_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.35A","3lzuB-3mwsA:20.1","3lzuB-3mwsA:78.79"],["3LZU_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","1.33A","3lzuB-3mwsA:20.1","3lzuB-3mwsA:78.79"],["3LZU_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.21A","3lzuB-3mwsA:20.1","3lzuB-3mwsA:78.79"],["3LZV_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  27;ALA A  28;ASP A  29;GLY A  48;VAL A  82","None","0.82A","3lzvA-3mwsA:19.4","3lzvA-3mwsA:74.75"],["3LZV_A_017A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.51A","3lzvA-3mwsA:19.4","3lzvA-3mwsA:74.75"],["3LZV_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","3lzvB-3mwsA:19.2","3lzvB-3mwsA:74.75"],["3LZV_A_017A200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.98A","3lzvB-3mwsA:19.2","3lzvB-3mwsA:74.75"],["3N3I_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.79A","3n3iA-3mwsA:13.8","3n3iA-3mwsA:39.41"],["3N3I_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  82","None","0.62A","3n3iA-3mwsA:13.8","3n3iA-3mwsA:39.41"],["3N3I_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;VAL A  82","None","0.43A","3n3iA-3mwsA:13.8","3n3iA-3mwsA:39.41"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.92A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.29A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.47A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;ILE A  50;VAL A  82;ILE A  84","None","0.67A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.67A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.42A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.53A","3ndtA-3mwsA:19.4","3ndtA-3mwsA:79.80"],["3NDT_A_ROCA101_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.92A","3ndtB-3mwsA:19.6","3ndtB-3mwsA:79.80"],["3NDT_A_ROCA101_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.96A","3ndtB-3mwsA:19.6","3ndtB-3mwsA:79.80"],["3NDT_A_ROCA101_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.91A","3ndtB-3mwsA:19.6","3ndtB-3mwsA:79.80"],["3NDT_A_ROCA101_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.69A","3ndtB-3mwsA:19.6","3ndtB-3mwsA:79.80"],["3NDT_A_ROCA101_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.44A","3ndtB-3mwsA:19.6","3ndtB-3mwsA:79.80"],["3NDT_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.29A","3ndtC-3mwsA:19.6","3ndtC-3mwsA:79.80"],["3NDT_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.61A","3ndtC-3mwsA:19.6","3ndtC-3mwsA:79.80"],["3NDT_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.38A","3ndtC-3mwsA:19.6","3ndtC-3mwsA:79.80"],["3NDT_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.51A","3ndtC-3mwsA:19.6","3ndtC-3mwsA:79.80"],["3NDT_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.95A","3ndtD-3mwsA:19.5","3ndtD-3mwsA:79.80"],["3NDT_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.33A","3ndtD-3mwsA:19.5","3ndtD-3mwsA:79.80"],["3NDT_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.61A","3ndtD-3mwsA:19.5","3ndtD-3mwsA:79.80"],["3NDT_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.30A","3ndtD-3mwsA:19.5","3ndtD-3mwsA:79.80"],["3NDU_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.31A","3nduA-3mwsA:19.5","3nduA-3mwsA:79.80"],["3NDU_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.57A","3nduA-3mwsA:19.5","3nduA-3mwsA:79.80"],["3NDU_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","3nduA-3mwsA:19.5","3nduA-3mwsA:79.80"],["3NDU_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81","None","0.93A","3nduB-3mwsA:19.7","3nduB-3mwsA:79.80"],["3NDU_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.34A","3nduB-3mwsA:19.7","3nduB-3mwsA:79.80"],["3NDU_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.58A","3nduB-3mwsA:19.7","3nduB-3mwsA:79.80"],["3NDU_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3nduB-3mwsA:19.7","3nduB-3mwsA:79.80"],["3NDU_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.55A","3nduC-3mwsA:19.6","3nduC-3mwsA:79.80"],["3NDU_D_ROCD100_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.51A","3nduC-3mwsA:19.6","3nduC-3mwsA:79.80"],["3NDU_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.30A","3nduD-3mwsA:19.1","3nduD-3mwsA:79.80"],["3NDU_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.60A","3nduD-3mwsA:19.1","3nduD-3mwsA:79.80"],["3NDU_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.42A","3nduD-3mwsA:19.1","3nduD-3mwsA:79.80"],["3NDU_D_ROCD100_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.43A","3nduD-3mwsA:19.1","3nduD-3mwsA:79.80"],["3NDW_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.80A","3ndwA-3mwsA:19.5","3ndwA-3mwsA:79.80"],["3NDW_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  50;VAL A  82;ILE A  84","None","0.54A","3ndwA-3mwsA:19.5","3ndwA-3mwsA:79.80"],["3NDW_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.42A","3ndwA-3mwsA:19.5","3ndwA-3mwsA:79.80"],["3NDW_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.65A","3ndwA-3mwsA:19.5","3ndwA-3mwsA:79.80"],["3NDW_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  48;VAL A  82;ILE A  84","None","0.85A","3ndwB-3mwsA:19.6","3ndwB-3mwsA:79.80"],["3NDW_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.52A","3ndwB-3mwsA:19.6","3ndwB-3mwsA:79.80"],["3NDW_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;VAL A  82;ILE A  84","None","1.46A","3ndwB-3mwsA:19.6","3ndwB-3mwsA:79.80"],["3NDX_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None","0.50A","3ndxA-3mwsA:19.5","3ndxA-3mwsA:79.80"],["3NDX_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.40A","3ndxA-3mwsA:19.5","3ndxA-3mwsA:79.80"],["3NDX_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","0.69A","3ndxA-3mwsA:19.5","3ndxA-3mwsA:79.80"],["3NDX_A_RITA100_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.67A","3ndxA-3mwsA:19.5","3ndxA-3mwsA:79.80"],["3NDX_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30","None","0.68A","3ndxB-3mwsA:19.7","3ndxB-3mwsA:79.80"],["3NDX_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82;ILE A  84","None","0.84A","3ndxB-3mwsA:19.7","3ndxB-3mwsA:79.80"],["3NDX_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;VAL A  82;ILE A  84","None","1.45A","3ndxB-3mwsA:19.7","3ndxB-3mwsA:79.80"],["3NDX_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;VAL A  82;ILE A  84","None","0.72A","3ndxB-3mwsA:19.7","3ndxB-3mwsA:79.80"],["3NDX_A_RITA100_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.53A","3ndxB-3mwsA:19.7","3ndxB-3mwsA:79.80"],["3NU3_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","3nu3A-3mwsA:20.3","3nu3A-3mwsA:79.80"],["3NU3_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.92A","3nu3A-3mwsA:20.3","3nu3A-3mwsA:79.80"],["3NU3_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81","None","0.81A","3nu3B-3mwsA:19.2","3nu3B-3mwsA:79.80"],["3NU3_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.67A","3nu3B-3mwsA:19.2","3nu3B-3mwsA:79.80"],["3NU3_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.30A","3nu3B-3mwsA:19.2","3nu3B-3mwsA:79.80"],["3NU3_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.54A","3nu3B-3mwsA:19.2","3nu3B-3mwsA:79.80"],["3NU3_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.44A","3nu3B-3mwsA:19.2","3nu3B-3mwsA:79.80"],["3NU4_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.57A","3nu4A-3mwsA:20.2","3nu4A-3mwsA:78.79"],["3NU4_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.92A","3nu4A-3mwsA:20.2","3nu4A-3mwsA:78.79"],["3NU4_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.26A","3nu4B-3mwsA:19.2","3nu4B-3mwsA:78.79"],["3NU4_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  84","None","0.52A","3nu4B-3mwsA:19.2","3nu4B-3mwsA:78.79"],["3NU4_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;GLY A  49;ILE A  50;ILE A  84","None","0.38A","3nu4B-3mwsA:19.2","3nu4B-3mwsA:78.79"],["3NU5_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.03A","3nu5A-3mwsA:20.2","3nu5A-3mwsA:78.79"],["3NU5_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.48A","3nu5A-3mwsA:20.2","3nu5A-3mwsA:78.79"],["3NU5_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81","None","0.51A","3nu5B-3mwsA:19.5","3nu5B-3mwsA:78.79"],["3NU5_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49","None","1.37A","3nu5B-3mwsA:19.5","3nu5B-3mwsA:78.79"],["3NU5_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.58A","3nu5B-3mwsA:19.5","3nu5B-3mwsA:78.79"],["3NU5_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  84","None","0.38A","3nu5B-3mwsA:19.5","3nu5B-3mwsA:78.79"],["3NU6_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.53A","3nu6A-3mwsA:19.9","3nu6A-3mwsA:78.79"],["3NU6_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.61A","3nu6A-3mwsA:19.9","3nu6A-3mwsA:78.79"],["3NU6_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.96A","3nu6A-3mwsA:19.9","3nu6A-3mwsA:78.79"],["3NU6_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.31A","3nu6B-3mwsA:19.6","3nu6B-3mwsA:78.79"],["3NU6_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;VAL A  82;ILE A  84","None","0.50A","3nu6B-3mwsA:19.6","3nu6B-3mwsA:78.79"],["3NU6_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.47A","3nu6B-3mwsA:19.6","3nu6B-3mwsA:78.79"],["3NU9_A_478A401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.46A","3nu9A-3mwsA:19.8","3nu9A-3mwsA:78.79"],["3NU9_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50","None","1.01A","3nu9B-3mwsA:19.7","3nu9B-3mwsA:78.79"],["3NU9_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;VAL A  82","None","0.53A","3nu9B-3mwsA:19.7","3nu9B-3mwsA:78.79"],["3NU9_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.46A","3nu9B-3mwsA:19.7","3nu9B-3mwsA:78.79"],["3NUJ_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","3nujA-3mwsA:20.2","3nujA-3mwsA:78.79"],["3NUJ_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.92A","3nujA-3mwsA:20.2","3nujA-3mwsA:78.79"],["3NUJ_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.83A","3nujB-3mwsA:19.5","3nujB-3mwsA:78.79"],["3NUJ_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","3nujB-3mwsA:19.5","3nujB-3mwsA:78.79"],["3NUJ_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.51A","3nujB-3mwsA:19.5","3nujB-3mwsA:78.79"],["3NUJ_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.40A","3nujB-3mwsA:19.5","3nujB-3mwsA:78.79"],["3NUO_B_478B478_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.56A","3nuoA-3mwsA:20.2","3nuoA-3mwsA:78.79"],["3NUO_B_478B478_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.94A","3nuoA-3mwsA:20.2","3nuoA-3mwsA:78.79"],["3NUO_B_478B478_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.86A","3nuoB-3mwsA:19.3","3nuoB-3mwsA:78.79"],["3NUO_B_478B478_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","3nuoB-3mwsA:19.3","3nuoB-3mwsA:78.79"],["3NUO_B_478B478_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.51A","3nuoB-3mwsA:19.3","3nuoB-3mwsA:78.79"],["3NUO_B_478B478_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.41A","3nuoB-3mwsA:19.3","3nuoB-3mwsA:78.79"],["3OGP_A_017A200_1","FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.60A","3ogpA-3mwsA:15.8","3ogpA-3mwsA:28.45"],["3OGP_A_017A200_2","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  49;ILE A  50","None","0.51A","3ogpB-3mwsA:16.1","3ogpB-3mwsA:28.45"],["3OGP_A_017A200_2","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;VAL A  82","None","0.69A","3ogpB-3mwsA:16.1","3ogpB-3mwsA:28.45"],["3OGP_B_017B200_1","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ALA A  28;GLY A  48;VAL A  82","None","0.90A","3ogpA-3mwsA:15.8","3ogpA-3mwsA:28.45"],["3OGP_B_017B200_1","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ALA A  28;GLY A  49;ILE A  50","None","0.57A","3ogpA-3mwsA:15.8","3ogpA-3mwsA:28.45"],["3OGP_B_017B200_1","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ALA A  28;ILE A  50;VAL A  82","None","0.81A","3ogpA-3mwsA:15.8","3ogpA-3mwsA:28.45"],["3OGP_B_017B200_2","FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  48","None","0.80A","3ogpB-3mwsA:16.1","3ogpB-3mwsA:28.45"],["3OGP_B_017B200_2","FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.36A","3ogpB-3mwsA:16.1","3ogpB-3mwsA:28.45"],["3OGQ_A_AB1A200_1","FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  48","None","0.93A","3ogqA-3mwsA:15.9","3ogqA-3mwsA:28.45"],["3OGQ_A_AB1A200_1","FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50","None","0.59A","3ogqA-3mwsA:15.9","3ogqA-3mwsA:28.45"],["3OGQ_A_AB1A200_2","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  50","None","0.47A","3ogqB-3mwsA:16.1","3ogqB-3mwsA:28.45"],["3OGQ_A_AB1A200_2","FIV PROTEASE;FIV PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.45A","3ogqB-3mwsA:16.1","3ogqB-3mwsA:28.45"],["3OXC_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.88A","3oxcA-3mwsA:18.5","3oxcA-3mwsA:79.80"],["3OXC_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.62A","3oxcA-3mwsA:18.5","3oxcA-3mwsA:79.80"],["3OXC_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.37A","3oxcA-3mwsA:18.5","3oxcA-3mwsA:79.80"],["3OXC_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.56A","3oxcB-3mwsA:18.9","3oxcB-3mwsA:79.80"],["3OXC_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.48A","3oxcB-3mwsA:18.9","3oxcB-3mwsA:79.80"],["3OXV_A_478A200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"TRP A  42;PRO A  44;ARG A  57;GLY A  78","None","0.40A","3oxvA-3mwsA:19.9","3oxvA-3mwsA:75.76"],["3OXV_B_478B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  82;ILE A  84","None","0.48A","3oxvA-3mwsA:19.9","3oxvA-3mwsA:75.76"],["3OXV_B_478B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;GLY A  49;VAL A  82;ILE A  84","None","0.33A","3oxvA-3mwsA:19.9","3oxvA-3mwsA:75.76"],["3OXV_B_478B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","3oxvB-3mwsA:20.0","3oxvB-3mwsA:75.76"],["3OXV_B_478B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.00A","3oxvB-3mwsA:20.0","3oxvB-3mwsA:75.76"],["3OXV_C_478C200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.44A","3oxvC-3mwsA:19.8","3oxvC-3mwsA:75.76"],["3OXV_C_478C200_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  84","None","0.37A","3oxvC-3mwsA:19.8","3oxvC-3mwsA:75.76"],["3OXV_C_478C200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.50A","3oxvD-3mwsA:19.8","3oxvD-3mwsA:75.76"],["3OXV_C_478C200_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.00A","3oxvD-3mwsA:19.8","3oxvD-3mwsA:75.76"],["3OXW_B_017B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;VAL A  82","None","0.89A","3oxwA-3mwsA:20.0","3oxwA-3mwsA:74.75"],["3OXW_B_017B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;VAL A  82","None","0.45A","3oxwA-3mwsA:20.0","3oxwA-3mwsA:74.75"],["3OXW_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.92A","3oxwB-3mwsA:20.0","3oxwB-3mwsA:74.75"],["3OXW_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.43A","3oxwB-3mwsA:20.0","3oxwB-3mwsA:74.75"],["3OXW_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.44A","3oxwB-3mwsA:20.0","3oxwB-3mwsA:74.75"],["3OXW_D_017D200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.87A","3oxwC-3mwsA:20.1","3oxwC-3mwsA:74.75"],["3OXW_D_017D200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;GLY A  49;VAL A  82","None","0.52A","3oxwC-3mwsA:20.1","3oxwC-3mwsA:74.75"],["3OXW_D_017D200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.96A","3oxwD-3mwsA:20.1","3oxwD-3mwsA:74.75"],["3OXW_D_017D200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.38A","3oxwD-3mwsA:20.1","3oxwD-3mwsA:74.75"],["3OXW_D_017D200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.53A","3oxwD-3mwsA:20.1","3oxwD-3mwsA:74.75"],["3OXX_A_DR7A100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;PRO A  81;ILE A  84","None","0.28A","3oxxA-3mwsA:19.7","3oxxA-3mwsA:74.75"],["3OXX_A_DR7A100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3oxxB-3mwsA:19.9","3oxxB-3mwsA:74.75"],["3OXX_C_DR7C100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.46A","3oxxC-3mwsA:19.5","3oxxC-3mwsA:74.75"],["3OXX_C_DR7C100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;GLY A  48;PRO A  81;ILE A  84","None","0.96A","3oxxD-3mwsA:19.5","3oxxD-3mwsA:74.75"],["3OXX_C_DR7C100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.35A","3oxxD-3mwsA:19.5","3oxxD-3mwsA:74.75"],["3OXX_C_DR7C100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","1.49A","3oxxD-3mwsA:19.5","3oxxD-3mwsA:74.75"],["3OY4_B_017B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;PRO A  81;VAL A  82;ILE A  84","None","1.49A","3oy4A-3mwsA:19.3","3oy4A-3mwsA:76.77"],["3OY4_B_017B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.60A","3oy4A-3mwsA:19.3","3oy4A-3mwsA:76.77"],["3OY4_B_017B200_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.93A","3oy4A-3mwsA:19.3","3oy4A-3mwsA:76.77"],["3OY4_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;VAL A  82","None","0.75A","3oy4B-3mwsA:19.5","3oy4B-3mwsA:76.77"],["3OY4_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.23A","3oy4B-3mwsA:19.5","3oy4B-3mwsA:76.77"],["3OY4_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82","None","0.58A","3oy4B-3mwsA:19.5","3oy4B-3mwsA:76.77"],["3OY4_B_017B200_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.53A","3oy4B-3mwsA:19.5","3oy4B-3mwsA:76.77"],["3PWM_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.94A","3pwmA-3mwsA:20.2","3pwmA-3mwsA:78.79"],["3PWM_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49","None","1.43A","3pwmA-3mwsA:20.2","3pwmA-3mwsA:78.79"],["3PWM_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.54A","3pwmA-3mwsA:20.2","3pwmA-3mwsA:78.79"],["3PWM_B_017B402_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.35A","3pwmA-3mwsA:20.2","3pwmA-3mwsA:78.79"],["3PWM_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.69A","3pwmB-3mwsA:19.7","3pwmB-3mwsA:78.79"],["3PWM_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.27A","3pwmB-3mwsA:19.7","3pwmB-3mwsA:78.79"],["3PWM_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.46A","3pwmB-3mwsA:19.7","3pwmB-3mwsA:78.79"],["3PWM_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.44A","3pwmB-3mwsA:19.7","3pwmB-3mwsA:78.79"],["3PWM_B_017B402_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.54A","3pwmB-3mwsA:19.7","3pwmB-3mwsA:78.79"],["3PWR_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.34A","3pwrA-3mwsA:19.8","3pwrA-3mwsA:78.79"],["3PWR_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.65A","3pwrA-3mwsA:19.8","3pwrA-3mwsA:78.79"],["3PWR_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.35A","3pwrA-3mwsA:19.8","3pwrA-3mwsA:78.79"],["3PWR_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3pwrA-3mwsA:19.8","3pwrA-3mwsA:78.79"],["3PWR_A_ROCA401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;VAL A  32;THR A  80","None","0.65A","3pwrA-3mwsA:19.8","3pwrA-3mwsA:78.79"],["3PWR_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.36A","3pwrB-3mwsA:19.6","3pwrB-3mwsA:78.79"],["3PWR_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;VAL A  82;ILE A  84","None","0.52A","3pwrB-3mwsA:19.6","3pwrB-3mwsA:78.79"],["3PWR_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.37A","3pwrB-3mwsA:19.6","3pwrB-3mwsA:78.79"],["3S43_A_478A401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;ILE A  84","None","0.46A","3s43A-3mwsA:20.1","3s43A-3mwsA:76.77"],["3S43_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.27A","3s43B-3mwsA:19.3","3s43B-3mwsA:76.77"],["3S43_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;ILE A  84","None","0.55A","3s43B-3mwsA:19.3","3s43B-3mwsA:76.77"],["3S43_A_478A401_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;GLY A  49;ILE A  50;ILE A  84","None","0.35A","3s43B-3mwsA:19.3","3s43B-3mwsA:76.77"],["3S45_B_478B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.05A","3s45A-3mwsA:19.2","3s45A-3mwsA:48.48"],["3S45_B_478B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.56A","3s45A-3mwsA:19.2","3s45A-3mwsA:48.48"],["3S45_B_478B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None","0.48A","3s45B-3mwsA:19.1","3s45B-3mwsA:48.48"],["3S45_B_478B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","0.40A","3s45B-3mwsA:19.1","3s45B-3mwsA:48.48"],["3S53_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.72A","3s53A-3mwsA:18.7","3s53A-3mwsA:76.77"],["3S53_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.29A","3s53A-3mwsA:18.7","3s53A-3mwsA:76.77"],["3S53_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","3s53B-3mwsA:20.0","3s53B-3mwsA:76.77"],["3S53_B_017B203_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"TRP A  42;PRO A  44;ARG A  57;GLY A  78","None","0.27A","3s53B-3mwsA:20.0","3s53B-3mwsA:76.77"],["3S54_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","1.37A","3s54A-3mwsA:20.1","3s54A-3mwsA:76.77"],["3S54_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.55A","3s54A-3mwsA:20.1","3s54A-3mwsA:76.77"],["3S54_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.94A","3s54A-3mwsA:20.1","3s54A-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.37A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.89A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.24A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","1.38A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.57A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S54_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.31A","3s54B-3mwsA:19.7","3s54B-3mwsA:76.77"],["3S56_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81","None","0.60A","3s56A-3mwsA:19.1","3s56A-3mwsA:76.77"],["3S56_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;THR A  80;PRO A  81","None","0.49A","3s56A-3mwsA:19.1","3s56A-3mwsA:76.77"],["3S56_A_ROCA201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.91A","3s56A-3mwsA:19.1","3s56A-3mwsA:76.77"],["3S56_A_ROCA201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.84A","3s56B-3mwsA:19.3","3s56B-3mwsA:76.77"],["3S56_A_ROCA201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.19A","3s56B-3mwsA:19.3","3s56B-3mwsA:76.77"],["3S56_A_ROCA201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ASP A  30;PRO A  81;ILE A  84","None","0.58A","3s56B-3mwsA:19.3","3s56B-3mwsA:76.77"],["3S56_A_ROCA201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","3s56B-3mwsA:19.3","3s56B-3mwsA:76.77"],["3SM2_A_478A126_2","GAG-PRO-POL POLYPROTEIN;GAG-PRO-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;GLY A  48;LEU A  76;PRO A  81","None","1.02A","3sm2B-3mwsA:11.7","3sm2B-3mwsA:27.41"],["3SM2_A_478A126_2","GAG-PRO-POL POLYPROTEIN;GAG-PRO-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;VAL A  32;GLY A  49;LEU A  76","None","0.71A","3sm2B-3mwsA:11.7","3sm2B-3mwsA:27.41"],["3SM2_A_478A126_2","GAG-PRO-POL POLYPROTEIN;GAG-PRO-POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;VAL A  32;LEU A  76;PRO A  81","None","0.74A","3sm2B-3mwsA:11.7","3sm2B-3mwsA:27.41"],["3SO9_A_017A100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.71A","3so9B-3mwsA:18.9","3so9B-3mwsA:71.72"],["3SO9_A_017A100_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.68A","3so9B-3mwsA:18.9","3so9B-3mwsA:71.72"],["3SPK_A_TPVA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;ASP A  30;ILE A  47;PRO A  81","None","0.74A","3spkA-3mwsA:19.7","3spkA-3mwsA:71.72"],["3SPK_A_TPVA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.42A","3spkA-3mwsA:19.7","3spkA-3mwsA:71.72"],["3SPK_A_TPVA100_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.75A","3spkA-3mwsA:19.7","3spkA-3mwsA:71.72"],["3SPK_B_TPVB100_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81","None","0.78A","3spkA-3mwsA:19.7","3spkA-3mwsA:71.72"],["3SPK_B_TPVB100_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.84A","3spkB-3mwsA:19.8","3spkB-3mwsA:71.72"],["3SPK_B_TPVB100_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;PRO A  81","None","0.62A","3spkB-3mwsA:19.8","3spkB-3mwsA:71.72"],["3SPK_B_TPVB100_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.44A","3spkB-3mwsA:19.8","3spkB-3mwsA:71.72"],["3SPK_B_TPVB100_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;LEU A  23;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.60A","3spkB-3mwsA:19.8","3spkB-3mwsA:71.72"],["3T3C_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.53A","3t3cA-3mwsA:19.7","3t3cA-3mwsA:69.70"],["3T3C_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  50","None","0.31A","3t3cA-3mwsA:19.7","3t3cA-3mwsA:69.70"],["3T3C_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.40A","3t3cB-3mwsA:20.0","3t3cB-3mwsA:69.70"],["3TKG_B_ROCB801_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.33A","3tkgA-3mwsA:19.6","3tkgA-3mwsA:79.80"],["3TKG_B_ROCB801_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.62A","3tkgA-3mwsA:19.6","3tkgA-3mwsA:79.80"],["3TKG_B_ROCB801_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.38A","3tkgA-3mwsA:19.6","3tkgA-3mwsA:79.80"],["3TKG_B_ROCB801_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  30;PRO A  81;VAL A  82","None","0.63A","3tkgB-3mwsA:19.5","3tkgB-3mwsA:79.80"],["3TKG_B_ROCB801_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.31A","3tkgB-3mwsA:19.5","3tkgB-3mwsA:79.80"],["3TKG_B_ROCB801_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.54A","3tkgB-3mwsA:19.5","3tkgB-3mwsA:79.80"],["3TKG_B_ROCB801_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3tkgB-3mwsA:19.5","3tkgB-3mwsA:79.80"],["3TKG_C_ROCC901_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.62A","3tkgC-3mwsA:19.2","3tkgC-3mwsA:79.80"],["3TKG_C_ROCC901_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.50A","3tkgC-3mwsA:19.2","3tkgC-3mwsA:79.80"],["3TKG_C_ROCC901_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.89A","3tkgC-3mwsA:19.2","3tkgC-3mwsA:79.80"],["3TKG_C_ROCC901_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;VAL A  82;ILE A  84","None","0.50A","3tkgD-3mwsA:19.5","3tkgD-3mwsA:79.80"],["3TKG_C_ROCC901_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.29A","3tkgD-3mwsA:19.5","3tkgD-3mwsA:79.80"],["3TKG_C_ROCC901_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;THR A  80;PRO A  81","None","0.30A","3tkgD-3mwsA:19.5","3tkgD-3mwsA:79.80"],["3TKW_B_017B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82;ILE A  84","None","0.50A","3tkwA-3mwsA:20.1","3tkwA-3mwsA:79.80"],["3TKW_B_017B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.41A","3tkwA-3mwsA:20.1","3tkwA-3mwsA:79.80"],["3TKW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.90A","3tkwB-3mwsA:18.7","3tkwB-3mwsA:79.80"],["3TKW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.35A","3tkwB-3mwsA:18.7","3tkwB-3mwsA:79.80"],["3TKW_B_017B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.44A","3tkwB-3mwsA:18.7","3tkwB-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.95A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.41A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.47A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","1.33A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.65A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.42A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ARG A   8;VAL A  32;THR A  80","None","0.69A","3tl9A-3mwsA:19.8","3tl9A-3mwsA:79.80"],["3TL9_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ALA A  28;VAL A  32;GLY A  49;PRO A  81;VAL A  82","None","0.63A","3tl9B-3mwsA:18.7","3tl9B-3mwsA:79.80"],["3TL9_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.95A","3tl9B-3mwsA:18.7","3tl9B-3mwsA:79.80"],["3TL9_A_ROCA401_3","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.41A","3tl9B-3mwsA:18.7","3tl9B-3mwsA:79.80"],["3TTP_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.40A","3ttpA-3mwsA:19.9","3ttpA-3mwsA:73.74"],["3TTP_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.34A","3ttpA-3mwsA:19.9","3ttpA-3mwsA:73.74"],["3TTP_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.85A","3ttpA-3mwsA:19.9","3ttpA-3mwsA:73.74"],["3TTP_A_017A201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.37A","3ttpA-3mwsA:19.9","3ttpA-3mwsA:73.74"],["3TTP_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.38A","3ttpB-3mwsA:19.9","3ttpB-3mwsA:73.74"],["3TTP_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.36A","3ttpB-3mwsA:19.9","3ttpB-3mwsA:73.74"],["3TTP_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.85A","3ttpB-3mwsA:19.9","3ttpB-3mwsA:73.74"],["3TTP_A_017A201_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.37A","3ttpB-3mwsA:19.9","3ttpB-3mwsA:73.74"],["3U7S_A_017A201_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.83A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A201_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A201_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.47A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A201_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.31A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A201_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.42A","3u7sB-3mwsA:20.2","3u7sB-3mwsA:69.70"],["3U7S_A_017A201_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81","None","1.01A","3u7sB-3mwsA:20.2","3u7sB-3mwsA:69.70"],["3U7S_A_017A201_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.60A","3u7sB-3mwsA:20.2","3u7sB-3mwsA:69.70"],["3U7S_A_017A202_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;ILE A  47;GLY A  48;PRO A  81","None","0.88A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A202_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81","None","1.25A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A202_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;ILE A  47;PRO A  81","None","0.49A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A202_1","POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.57A","3u7sA-3mwsA:19.7","3u7sA-3mwsA:69.70"],["3U7S_A_017A202_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.90A","3u7sB-3mwsA:20.2","3u7sB-3mwsA:69.70"],["3U7S_A_017A202_2","POL POLYPROTEIN;POL POLYPROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;ILE A  50","None","0.49A","3u7sB-3mwsA:20.2","3u7sB-3mwsA:69.70"],["3UCB_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.38A","3ucbA-3mwsA:20.3","3ucbA-3mwsA:70.71"],["3UCB_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.41A","3ucbB-3mwsA:20.2","3ucbB-3mwsA:70.71"],["3UCB_B_017B202_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"TRP A  42;PRO A  44;MET A  46;ARG A  57;GLY A  78;PRO A  79","None","0.43A","3ucbB-3mwsA:20.2","3ucbB-3mwsA:70.71"],["3UFN_A_ROCA401_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;GLY A  48;THR A  80;PRO A  81","None","0.85A","3ufnA-3mwsA:20.0","3ufnA-3mwsA:70.71"],["3UFN_A_ROCA401_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  48;GLY A  49;ILE A  50;THR A  80;PRO A  81","None","0.40A","3ufnA-3mwsA:20.0","3ufnA-3mwsA:70.71"],["3UFN_A_ROCA401_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;GLY A  27;ALA A  28;GLY A  49;THR A  80","None","0.85A","3ufnA-3mwsA:20.0","3ufnA-3mwsA:70.71"],["3UFN_A_ROCA401_2","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"ASP A  25;GLY A  49;ILE A  50;VAL A  82","None","0.45A","3ufnB-3mwsA:19.7","3ufnB-3mwsA:70.71"],["3WSJ_A_MK1A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;VAL A  32;LEU A  76;ILE A  84","None","0.81A","3wsjA-3mwsA:13.1","3wsjA-3mwsA:35.34"],["3WSJ_A_MK1A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ILE A  84","None","0.52A","3wsjB-3mwsA:13.1","3wsjB-3mwsA:35.34"],["3WSJ_A_MK1A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  25;VAL A  56;ILE A  84","None","1.32A","3wsjB-3mwsA:13.1","3wsjB-3mwsA:35.34"],["4AC9_B_DXCB1473_0","MJ0495-LIKE PROTEIN","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ILE A  64;ASP A  65;ILE A  66;GLY A  68;GLY A  94","None","0.89A","4ac9B-3mwsA:undetectable;4ac9C-3mwsA:undetectable","4ac9B-3mwsA:13.76;4ac9C-3mwsA:13.76"],["4DQB_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.49A","4dqbA-3mwsA:19.7","4dqbA-3mwsA:79.80"],["4DQB_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.57A","4dqbA-3mwsA:19.7","4dqbA-3mwsA:79.80"],["4DQB_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.94A","4dqbA-3mwsA:19.7","4dqbA-3mwsA:79.80"],["4DQB_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.64A","4dqbB-3mwsA:19.7","4dqbB-3mwsA:79.80"],["4DQB_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.18A","4dqbB-3mwsA:19.7","4dqbB-3mwsA:79.80"],["4DQB_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82","None","0.48A","4dqbB-3mwsA:19.7","4dqbB-3mwsA:79.80"],["4DQB_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.46A","4dqbB-3mwsA:19.7","4dqbB-3mwsA:79.80"],["4DQC_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.54A","4dqcA-3mwsA:19.4","4dqcA-3mwsA:77.78"],["4DQC_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.99A","4dqcA-3mwsA:19.4","4dqcA-3mwsA:77.78"],["4DQC_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.63A","4dqcB-3mwsA:19.9","4dqcB-3mwsA:77.78"],["4DQC_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.19A","4dqcB-3mwsA:19.9","4dqcB-3mwsA:77.78"],["4DQC_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.39A","4dqcB-3mwsA:19.9","4dqcB-3mwsA:77.78"],["4DQC_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50","None","0.30A","4dqcB-3mwsA:19.9","4dqcB-3mwsA:77.78"],["4DQE_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.45A","4dqeA-3mwsA:19.6","4dqeA-3mwsA:77.78"],["4DQE_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","4dqeA-3mwsA:19.6","4dqeA-3mwsA:77.78"],["4DQE_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.01A","4dqeA-3mwsA:19.6","4dqeA-3mwsA:77.78"],["4DQE_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.70A","4dqeB-3mwsA:19.9","4dqeB-3mwsA:77.78"],["4DQE_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.19A","4dqeB-3mwsA:19.9","4dqeB-3mwsA:77.78"],["4DQE_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82","None","0.45A","4dqeB-3mwsA:19.9","4dqeB-3mwsA:77.78"],["4DQE_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.44A","4dqeB-3mwsA:19.9","4dqeB-3mwsA:77.78"],["4DQF_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","4dqfA-3mwsA:18.6","4dqfA-3mwsA:77.78"],["4DQF_B_017B101_1","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.97A","4dqfA-3mwsA:18.6","4dqfA-3mwsA:77.78"],["4DQF_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82;ILE A  84","None","0.71A","4dqfB-3mwsA:19.6","4dqfB-3mwsA:77.78"],["4DQF_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.22A","4dqfB-3mwsA:19.6","4dqfB-3mwsA:77.78"],["4DQF_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  82;ILE A  84","None","0.57A","4dqfB-3mwsA:19.6","4dqfB-3mwsA:77.78"],["4DQF_B_017B101_2","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.51A","4dqfB-3mwsA:19.6","4dqfB-3mwsA:77.78"],["4DQH_B_017B101_1","WILD-TYPE HIV-1 PROTEASE DIMER;WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81","None","1.46A","4dqhA-3mwsA:19.7","4dqhA-3mwsA:79.80"],["4DQH_B_017B101_1","WILD-TYPE HIV-1 PROTEASE DIMER;WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.58A","4dqhA-3mwsA:19.7","4dqhA-3mwsA:79.80"],["4DQH_B_017B101_1","WILD-TYPE HIV-1 PROTEASE DIMER;WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.01A","4dqhA-3mwsA:19.7","4dqhA-3mwsA:79.80"],["4DQH_B_017B101_2","WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.69A","4dqhB-3mwsA:19.8","4dqhB-3mwsA:79.80"],["4DQH_B_017B101_2","WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.20A","4dqhB-3mwsA:19.8","4dqhB-3mwsA:79.80"],["4DQH_B_017B101_2","WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82","None","0.44A","4dqhB-3mwsA:19.8","4dqhB-3mwsA:79.80"],["4DQH_B_017B101_2","WILD-TYPE HIV-1 PROTEASE DIMER","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.45A","4dqhB-3mwsA:19.8","4dqhB-3mwsA:79.80"],["4HLA_A_017A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.52A","4hlaA-3mwsA:20.1","4hlaA-3mwsA:78.79"],["4HLA_A_017A200_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.43A","4hlaA-3mwsA:20.1","4hlaA-3mwsA:78.79"],["4HLA_A_017A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.47A","4hlaB-3mwsA:20.1","4hlaB-3mwsA:78.79"],["4HLA_A_017A200_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.45A","4hlaB-3mwsA:20.1","4hlaB-3mwsA:78.79"],["4J5J_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82","None","0.97A","4j5jB-3mwsA:20.2","4j5jB-3mwsA:70.71"],["4J5J_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.55A","4j5jB-3mwsA:20.2","4j5jB-3mwsA:70.71"],["4J5J_B_478B402_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"TRP A  42;PRO A  44;ARG A  57;PRO A  79","None","0.47A","4j5jB-3mwsA:20.2","4j5jB-3mwsA:70.71"],["4JEC_B_478B401_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.44A","4jecB-3mwsA:19.9","4jecB-3mwsA:79.80"],["4JEC_B_478B401_3","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"ASP A  29;LEU A  76;VAL A  82","None","0.52A","4jecB-3mwsA:19.9","4jecB-3mwsA:79.80"],["4L1A_A_AB1A101_1","MDR769 HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.52A","4l1aA-3mwsA:18.3","4l1aA-3mwsA:72.73"],["4L1A_A_AB1A101_1","MDR769 HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81","None","0.52A","4l1aA-3mwsA:18.3","4l1aA-3mwsA:72.73"],["4LL3_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.88A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.25A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  48;ILE A  84","None","1.48A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.45A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.22A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A202_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.85A","4ll3A-3mwsA:20.1","4ll3A-3mwsA:78.79"],["4LL3_A_017A202_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","1.21A","4ll3A-3mwsA:20.1","4ll3A-3mwsA:78.79"],["4LL3_A_017A202_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.46A","4ll3A-3mwsA:20.1","4ll3A-3mwsA:78.79"],["4LL3_A_017A202_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.21A","4ll3A-3mwsA:20.1","4ll3A-3mwsA:78.79"],["4LL3_A_017A202_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ASP A  25;ALA A  28;ASP A  29;GLY A  49;PRO A  81;ILE A  84","None","1.47A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A202_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.59A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A202_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ASP A  25;ALA A  28;VAL A  32;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.47A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4LL3_A_017A202_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.85A","4ll3B-3mwsA:20.2","4ll3B-3mwsA:78.79"],["4NJT_B_017B101_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.95A","4njtA-3mwsA:19.8","4njtA-3mwsA:70.71"],["4NJT_B_017B101_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.45A","4njtA-3mwsA:19.8","4njtA-3mwsA:70.71"],["4NJT_B_017B101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.77A","4njtB-3mwsA:19.7","4njtB-3mwsA:70.71"],["4NJT_B_017B101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.20A","4njtB-3mwsA:19.7","4njtB-3mwsA:70.71"],["4NJT_B_017B101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.49A","4njtB-3mwsA:19.7","4njtB-3mwsA:70.71"],["4NJT_B_017B101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50","None","0.37A","4njtB-3mwsA:19.7","4njtB-3mwsA:70.71"],["4NJT_D_017D101_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","4njtC-3mwsA:19.8","4njtC-3mwsA:70.71"],["4NJT_D_017D101_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.97A","4njtC-3mwsA:19.8","4njtC-3mwsA:70.71"],["4NJT_D_017D101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.47A","4njtD-3mwsA:19.7","4njtD-3mwsA:70.71"],["4NJT_D_017D101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  50","None","0.44A","4njtD-3mwsA:19.7","4njtD-3mwsA:70.71"],["4NJU_A_TPVA500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.92A","4njuA-3mwsA:19.9","4njuA-3mwsA:70.71"],["4NJU_A_TPVA500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.60A","4njuA-3mwsA:19.9","4njuA-3mwsA:70.71"],["4NJU_A_TPVA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.84A","4njuB-3mwsA:19.7","4njuB-3mwsA:70.71"],["4NJU_A_TPVA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.64A","4njuB-3mwsA:19.7","4njuB-3mwsA:70.71"],["4NJU_C_TPVC500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","0.92A","4njuC-3mwsA:19.8","4njuC-3mwsA:70.71"],["4NJU_C_TPVC500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.60A","4njuC-3mwsA:19.8","4njuC-3mwsA:70.71"],["4NJU_C_TPVC500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;ALA A  28;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.84A","4njuD-3mwsA:19.7","4njuD-3mwsA:70.71"],["4NJU_C_TPVC500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.64A","4njuD-3mwsA:19.7","4njuD-3mwsA:70.71"],["4NJV_A_RITA500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","4njvA-3mwsA:19.7","4njvA-3mwsA:70.71"],["4NJV_A_RITA500_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  51;ILE A  50;PRO A  81;THR A  80;ILE A  54","None","1.01A","4njvA-3mwsA:19.7","4njvA-3mwsA:70.71"],["4NJV_A_RITA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","1.35A","4njvB-3mwsA:19.3","4njvB-3mwsA:70.71"],["4NJV_A_RITA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ASP A  29;ASP A  30;VAL A  32;GLY A  49;PRO A  81;ILE A  84","None","0.66A","4njvB-3mwsA:19.3","4njvB-3mwsA:70.71"],["4NJV_A_RITA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.63A","4njvB-3mwsA:19.3","4njvB-3mwsA:70.71"],["4NJV_A_RITA500_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"GLY A  27;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.96A","4njvB-3mwsA:19.3","4njvB-3mwsA:70.71"],["4NJV_D_RITD500_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.46A","4njvC-3mwsA:19.8","4njvC-3mwsA:70.71"],["4NJV_D_RITD500_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;ILE A  84","None","0.30A","4njvD-3mwsA:19.4","4njvD-3mwsA:70.71"],["4NJV_D_RITD500_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.54A","4njvD-3mwsA:19.4","4njvD-3mwsA:70.71"],["4Q1W_A_017A104_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.74A","4q1wA-3mwsA:19.8","4q1wA-3mwsA:76.77"],["4Q1W_A_017A104_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.24A","4q1wA-3mwsA:19.8","4q1wA-3mwsA:76.77"],["4Q1W_A_017A104_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  82","None","0.60A","4q1wA-3mwsA:19.8","4q1wA-3mwsA:76.77"],["4Q1W_A_017A104_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;VAL A  82","None","0.48A","4q1wA-3mwsA:19.8","4q1wA-3mwsA:76.77"],["4Q1W_A_017A104_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  38;GLY A  73;GLY A  86;ILE A  85;VAL A  77","None","1.03A","4q1wA-3mwsA:19.8","4q1wA-3mwsA:76.77"],["4Q1W_A_017A104_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","4q1wB-3mwsA:19.5","4q1wB-3mwsA:76.77"],["4Q1W_A_017A104_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.06A","4q1wB-3mwsA:19.5","4q1wB-3mwsA:76.77"],["4Q1X_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.75A","4q1xA-3mwsA:19.7","4q1xA-3mwsA:76.77"],["4Q1X_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.24A","4q1xA-3mwsA:19.7","4q1xA-3mwsA:76.77"],["4Q1X_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;VAL A  82","None","0.63A","4q1xA-3mwsA:19.7","4q1xA-3mwsA:76.77"],["4Q1X_A_017A101_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.54A","4q1xA-3mwsA:19.7","4q1xA-3mwsA:76.77"],["4Q1X_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.57A","4q1xB-3mwsA:19.6","4q1xB-3mwsA:76.77"],["4Q1X_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ARG A   8;LEU A  23;ILE A  54;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","1.49A","4q1xB-3mwsA:19.6","4q1xB-3mwsA:76.77"],["4Q1X_A_017A101_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.93A","4q1xB-3mwsA:19.6","4q1xB-3mwsA:76.77"],["4Q1Y_A_017A106_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;VAL A  82","None","0.77A","4q1yA-3mwsA:20.0","4q1yA-3mwsA:76.77"],["4Q1Y_A_017A106_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.25A","4q1yA-3mwsA:20.0","4q1yA-3mwsA:76.77"],["4Q1Y_A_017A106_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  82","None","0.60A","4q1yA-3mwsA:20.0","4q1yA-3mwsA:76.77"],["4Q1Y_A_017A106_1","ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;VAL A  82","None","0.47A","4q1yA-3mwsA:20.0","4q1yA-3mwsA:76.77"],["4Q1Y_A_017A106_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.85A","4q1yB-3mwsA:19.9","4q1yB-3mwsA:76.77"],["4Q1Y_A_017A106_2","ASPARTYL PROTEASE;ASPARTYL PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.46A","4q1yB-3mwsA:19.9","4q1yB-3mwsA:76.77"],["4Q5M_A_ROCA1101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"GLY A  27;ASP A  29;ILE A  47;ILE A  50;THR A  80;PRO A  81;VAL A  82","None","0.51A","4q5mA-3mwsA:16.8","4q5mA-3mwsA:39.90"],["4Q5M_A_ROCA1101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"GLY A  27;ASP A  29;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.60A","4q5mA-3mwsA:16.8","4q5mA-3mwsA:39.90"],["4QGI_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;VAL A  82","None","0.93A","4qgiA-3mwsA:19.7","4qgiA-3mwsA:77.78"],["4QGI_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  47;THR A  80;VAL A  82","None","0.62A","4qgiA-3mwsA:19.7","4qgiA-3mwsA:77.78"],["4QGI_A_ROCA101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;VAL A  82","None","0.54A","4qgiA-3mwsA:19.7","4qgiA-3mwsA:77.78"],["4QGI_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.67A","4qgiB-3mwsA:19.3","4qgiB-3mwsA:77.78"],["4QGI_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.63A","4qgiB-3mwsA:19.3","4qgiB-3mwsA:77.78"],["4QGI_A_ROCA101_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;ALA A  28;VAL A  32;ILE A  47;GLY A  49;PRO A  81;VAL A  82;ILE A  84","None","0.72A","4qgiB-3mwsA:19.3","4qgiB-3mwsA:77.78"],["4RVJ_B_478B101_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.58A","4rvjA-3mwsA:19.9","4rvjA-3mwsA:70.71"],["4RVJ_B_478B101_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;GLY A  48;PRO A  81;ILE A  84","None","1.07A","4rvjA-3mwsA:19.9","4rvjA-3mwsA:70.71"],["4RVJ_B_478B101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.82A","4rvjB-3mwsA:19.2","4rvjB-3mwsA:70.71"],["4RVJ_B_478B101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.28A","4rvjB-3mwsA:19.2","4rvjB-3mwsA:70.71"],["4RVJ_B_478B101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.50A","4rvjB-3mwsA:19.2","4rvjB-3mwsA:70.71"],["4RVJ_B_478B101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.48A","4rvjB-3mwsA:19.2","4rvjB-3mwsA:70.71"],["4RVJ_D_478D101_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.57A","4rvjC-3mwsA:19.9","4rvjC-3mwsA:70.71"],["4RVJ_D_478D101_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;GLY A  48;PRO A  81;ILE A  84","None","1.08A","4rvjC-3mwsA:19.9","4rvjC-3mwsA:70.71"],["4RVJ_D_478D101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;ILE A  84","None","0.81A","4rvjD-3mwsA:19.3","4rvjD-3mwsA:70.71"],["4RVJ_D_478D101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.28A","4rvjD-3mwsA:19.3","4rvjD-3mwsA:70.71"],["4RVJ_D_478D101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  84","None","0.49A","4rvjD-3mwsA:19.3","4rvjD-3mwsA:70.71"],["4RVJ_D_478D101_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.47A","4rvjD-3mwsA:19.3","4rvjD-3mwsA:70.71"],["5AJQ_A_DB8A800_2","SERINE\/THREONINE-PROTEIN KINASE 10","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"VAL A  13;ILE A  33;ASN A  88;VAL A  62","None","1.25A","5ajqA-3mwsA:undetectable","5ajqA-3mwsA:17.83"],["5E5J_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;ILE A  84","None","0.43A","5e5jA-3mwsA:19.5","5e5jA-3mwsA:76.77"],["5E5J_A_017A201_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;ILE A  84","None","0.32A","5e5jA-3mwsA:19.5","5e5jA-3mwsA:76.77"],["5E5J_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.42A","5e5jB-3mwsA:19.9","5e5jB-3mwsA:76.77"],["5E5J_A_017A201_2","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;GLY A  48;PRO A  81;ILE A  84","None","0.92A","5e5jB-3mwsA:19.9","5e5jB-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.42A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","0.83A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.21A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;PRO A  81;ILE A  84","None","1.43A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.54A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_1","HIV-1 PROTEASE;HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.41A","5e5kA-3mwsA:19.5","5e5kA-3mwsA:76.77"],["5E5K_B_017B201_2","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.39A","5e5kB-3mwsA:19.9","5e5kB-3mwsA:76.77"],["5KQX_A_ROCA101_1","PROTEASE E35D-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.95A","5kqxA-3mwsA:19.5","5kqxA-3mwsA:77.78"],["5KQX_A_ROCA101_1","PROTEASE E35D-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.69A","5kqxA-3mwsA:19.5","5kqxA-3mwsA:77.78"],["5KQX_A_ROCA101_1","PROTEASE E35D-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"GLY A  27;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80;VAL A  82;ILE A  84","None","0.58A","5kqxA-3mwsA:19.5","5kqxA-3mwsA:77.78"],["5KQX_A_ROCA101_1","PROTEASE E35D-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"GLY A  27;ALA A  28;ASP A  29;ILE A  47;THR A  80;PRO A  81;VAL A  82;ILE A  84","None","0.54A","5kqxA-3mwsA:19.5","5kqxA-3mwsA:77.78"],["5KQX_A_ROCA101_2","PROTEASE E35D-SQV;PROTEASE E35D-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.74A","5kqxB-3mwsA:19.3","5kqxB-3mwsA:77.78"],["5KQY_B_017B101_1","PROTEASE E35D-DRV;PROTEASE E35D-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.97A","5kqyA-3mwsA:19.9","5kqyA-3mwsA:77.78"],["5KQY_B_017B101_1","PROTEASE E35D-DRV;PROTEASE E35D-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.51A","5kqyA-3mwsA:19.9","5kqyA-3mwsA:77.78"],["5KQY_B_017B101_2","PROTEASE E35D-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"ALA A  28;ASP A  29;ASP A  30;GLY A  48","None","0.67A","5kqyB-3mwsA:19.6","5kqyB-3mwsA:77.78"],["5KQY_B_017B101_2","PROTEASE E35D-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",4,"GLY A  27;ALA A  28;ASP A  29;ASP A  30","None","0.47A","5kqyB-3mwsA:19.6","5kqyB-3mwsA:77.78"],["5KQY_B_017B101_2","PROTEASE E35D-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","0.26A","5kqyB-3mwsA:19.6","5kqyB-3mwsA:77.78"],["5KR0_A_478A101_1","PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","5kr0A-3mwsA:19.8","5kr0A-3mwsA:77.78"],["5KR0_A_478A101_1","PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.93A","5kr0A-3mwsA:19.8","5kr0A-3mwsA:77.78"],["5KR0_A_478A101_2","PROTEASE E35D-APV;PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  30;VAL A  32;GLY A  48;VAL A  82","None","0.76A","5kr0B-3mwsA:19.3","5kr0B-3mwsA:77.78"],["5KR0_A_478A101_2","PROTEASE E35D-APV;PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;GLY A  27;ALA A  28;ASP A  30;VAL A  32;VAL A  82","None","0.53A","5kr0B-3mwsA:19.3","5kr0B-3mwsA:77.78"],["5KR0_A_478A101_2","PROTEASE E35D-APV;PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;GLY A  27;ALA A  28;VAL A  32;GLY A  49;ILE A  50;VAL A  82","None","0.58A","5kr0B-3mwsA:19.3","5kr0B-3mwsA:77.78"],["5KR0_A_478A101_2","PROTEASE E35D-APV;PROTEASE E35D-APV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  38;GLY A  73;GLY A  86;ILE A  85;VAL A  77","None","1.01A","5kr0B-3mwsA:19.3","5kr0B-3mwsA:77.78"],["5KR1_B_017B101_1","PROTEASE PR5-DRV;PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;ALA A  28;ASP A  30;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.69A","5kr1A-3mwsA:19.4","5kr1A-3mwsA:76.77"],["5KR1_B_017B101_1","PROTEASE PR5-DRV;PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  30;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.37A","5kr1A-3mwsA:19.4","5kr1A-3mwsA:76.77"],["5KR1_B_017B101_1","PROTEASE PR5-DRV;PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;ILE A  54;GLY A  49;ILE A  50;ILE A  84","None","1.46A","5kr1A-3mwsA:19.4","5kr1A-3mwsA:76.77"],["5KR1_B_017B101_2","PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.62A","5kr1B-3mwsA:19.7","5kr1B-3mwsA:76.77"],["5KR1_B_017B101_2","PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32","None","0.47A","5kr1B-3mwsA:19.7","5kr1B-3mwsA:76.77"],["5KR1_B_017B101_2","PROTEASE PR5-DRV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50","None","0.46A","5kr1B-3mwsA:19.7","5kr1B-3mwsA:76.77"],["5KR2_A_ROCA101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.94A","5kr2A-3mwsA:19.0","5kr2A-3mwsA:76.77"],["5KR2_A_ROCA101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;ILE A  47;THR A  80;PRO A  81","None","0.81A","5kr2A-3mwsA:19.0","5kr2A-3mwsA:76.77"],["5KR2_A_ROCA101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80","None","0.59A","5kr2A-3mwsA:19.0","5kr2A-3mwsA:76.77"],["5KR2_A_ROCA101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.70A","5kr2B-3mwsA:19.2","5kr2B-3mwsA:76.77"],["5KR2_A_ROCA101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;ASP A  30;PRO A  81;VAL A  82","None","1.10A","5kr2B-3mwsA:19.2","5kr2B-3mwsA:76.77"],["5KR2_A_ROCA101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.55A","5kr2B-3mwsA:19.2","5kr2B-3mwsA:76.77"],["5KR2_A_ROCA101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.57A","5kr2B-3mwsA:19.2","5kr2B-3mwsA:76.77"],["5KR2_A_ROCA101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.51A","5kr2B-3mwsA:19.2","5kr2B-3mwsA:76.77"],["5KR2_C_ROCC101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;GLY A  48;THR A  80;PRO A  81","None","0.94A","5kr2C-3mwsA:19.2","5kr2C-3mwsA:76.77"],["5KR2_C_ROCC101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;ILE A  47;THR A  80","None","0.86A","5kr2C-3mwsA:19.2","5kr2C-3mwsA:76.77"],["5KR2_C_ROCC101_1","PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;THR A  80","None","0.64A","5kr2C-3mwsA:19.2","5kr2C-3mwsA:76.77"],["5KR2_C_ROCC101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ARG A   8;LEU A  23;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.65A","5kr2D-3mwsA:19.5","5kr2D-3mwsA:76.77"],["5KR2_C_ROCC101_2","PROTEASE PR5-SQV;PROTEASE PR5-SQV","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.44A","5kr2D-3mwsA:19.5","5kr2D-3mwsA:76.77"],["5T2Z_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"LEU A  23;ASP A  25;ASP A  29;GLY A  49;PRO A  81","None","1.08A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.52A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.47A","5t2zA-3mwsA:19.5","5t2zA-3mwsA:73.74"],["5T2Z_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","1.24A","5t2zB-3mwsA:19.4","5t2zB-3mwsA:73.74"],["5T2Z_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;ILE A  84","None","1.43A","5t2zB-3mwsA:19.4","5t2zB-3mwsA:73.74"],["5T2Z_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;ILE A  84","None","0.74A","5t2zB-3mwsA:19.4","5t2zB-3mwsA:73.74"],["5T2Z_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  49;PRO A  81;ILE A  84","None","0.51A","5t2zB-3mwsA:19.4","5t2zB-3mwsA:73.74"],["5T2Z_B_017B201_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.44A","5t2zB-3mwsA:19.4","5t2zB-3mwsA:73.74"],["5T8H_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;PRO A  81;ILE A  84","None","0.51A","5t8hA-3mwsA:19.3","5t8hA-3mwsA:76.77"],["5T8H_B_478B401_1","PROTEASE;PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.50A","5t8hA-3mwsA:19.3","5t8hA-3mwsA:76.77"],["5T8H_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.40A","5t8hB-3mwsA:20.0","5t8hB-3mwsA:76.77"],["5T8H_B_478B401_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;GLY A  48;PRO A  81;ILE A  84","None","0.95A","5t8hB-3mwsA:20.0","5t8hB-3mwsA:76.77"],["6DGX_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.64A","6dgxA-3mwsA:20.0","6dgxA-3mwsA:75.00"],["6DGX_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.19A","6dgxA-3mwsA:20.0","6dgxA-3mwsA:75.00"],["6DGX_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82;ILE A  84","None","0.49A","6dgxA-3mwsA:20.0","6dgxA-3mwsA:75.00"],["6DGX_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.53A","6dgxA-3mwsA:20.0","6dgxA-3mwsA:75.00"],["6DGX_A_017A101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.80A","6dgxB-3mwsA:19.8","6dgxB-3mwsA:75.00"],["6DGX_A_017A101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;LEU A  76;PRO A  81;VAL A  82;ILE A  84","None","0.47A","6dgxB-3mwsA:19.8","6dgxB-3mwsA:75.00"],["6DH0_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.62A","6dh0A-3mwsA:19.9","6dh0A-3mwsA:75.00"],["6DH0_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.20A","6dh0A-3mwsA:19.9","6dh0A-3mwsA:75.00"],["6DH0_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;VAL A  82","None","0.57A","6dh0A-3mwsA:19.9","6dh0A-3mwsA:75.00"],["6DH0_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82","None","0.53A","6dh0A-3mwsA:19.9","6dh0A-3mwsA:75.00"],["6DH0_A_017A101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;GLY A  49;ILE A  50;LEU A  76;PRO A  81;VAL A  82","None","0.38A","6dh0B-3mwsA:20.0","6dh0B-3mwsA:75.00"],["6DH0_A_017A101_2","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",3,"LEU A  23;ASP A  29;ILE A  47","None","0.51A","6dh0B-3mwsA:20.0","6dh0B-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.64A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;GLY A  49;ILE A  50","None","1.19A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  84","None","0.36A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;ILE A  84","None","0.40A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;ILE A  84","None","0.48A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"LEU A  23;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.50A","6dh3A-3mwsA:19.9","6dh3A-3mwsA:75.00"],["6DH3_A_017A101_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;ILE A  84","None","0.44A","6dh3B-3mwsA:19.8","6dh3B-3mwsA:75.00"],["6DH6_A_017A104_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;VAL A  82;ILE A  84","None","0.54A","6dh6A-3mwsA:19.9","6dh6A-3mwsA:73.75"],["6DH6_A_017A104_0","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;VAL A  82;ILE A  84","None","0.47A","6dh6A-3mwsA:19.9","6dh6A-3mwsA:73.75"],["6DH6_A_017A104_1","PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;ASP A  30;VAL A  32;ILE A  47;GLY A  49;LEU A  76;PRO A  81;ILE A  84","None","0.49A","6dh6B-3mwsA:19.8","6dh6B-3mwsA:73.75"],["6DIF_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ARG A   8;LEU A  23;GLY A  49;ILE A  50;PRO A  81","None","0.60A","6difA-3mwsA:20.0","6difA-3mwsA:76.25"],["6DIF_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;PRO A  81;VAL A  82;ILE A  84","None","0.60A","6difA-3mwsA:20.0","6difA-3mwsA:76.25"],["6DIF_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","6difA-3mwsA:20.0","6difA-3mwsA:76.25"],["6DIF_B_TPVB201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",9,"ARG A   8;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.67A","6difB-3mwsA:19.5","6difB-3mwsA:76.25"],["6DIF_B_TPVB201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;VAL A  82;ILE A  84","None","0.56A","6difB-3mwsA:19.5","6difB-3mwsA:76.25"],["6DIL_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81;VAL A  82","None","0.97A","6dilA-3mwsA:19.9","6dilA-3mwsA:75.00"],["6DIL_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81","None","0.73A","6dilA-3mwsA:19.9","6dilA-3mwsA:75.00"],["6DIL_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ARG A   8;LEU A  23;ASP A  25;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81","None","0.59A","6dilA-3mwsA:19.9","6dilA-3mwsA:75.00"],["6DIL_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;ASP A  30;VAL A  32;PRO A  81;VAL A  82","None","0.66A","6dilA-3mwsA:19.9","6dilA-3mwsA:75.00"],["6DIL_B_TPVB201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"LEU A  23;ASP A  25;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.49A","6dilA-3mwsA:19.9","6dilA-3mwsA:75.00"],["6DIL_B_TPVB201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;VAL A  32;GLY A  48;PRO A  81;VAL A  82","None","0.86A","6dilB-3mwsA:19.5","6dilB-3mwsA:75.00"],["6DIL_B_TPVB201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;LEU A  23;ASP A  25;GLY A  27;ALA A  28;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.72A","6dilB-3mwsA:19.5","6dilB-3mwsA:75.00"],["6DJ1_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;ALA A  28;ASP A  29;GLY A  48;GLY A  49;ILE A  50","None","1.38A","6dj1A-3mwsA:20.1","6dj1A-3mwsA:76.25"],["6DJ1_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;VAL A  82","None","0.61A","6dj1A-3mwsA:20.1","6dj1A-3mwsA:76.25"],["6DJ1_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",11,"ASP A  25;GLY A  27;ALA A  28;ASP A  29;VAL A  32;GLY A  48;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.47A","6dj1A-3mwsA:20.1","6dj1A-3mwsA:76.25"],["6DJ1_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ASP A  25;GLY A  27;ALA A  28;ASP A  30;GLY A  48;VAL A  82","None","0.72A","6dj1A-3mwsA:20.1","6dj1A-3mwsA:76.25"],["6DJ1_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;GLY A  27;ALA A  28;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.72A","6dj1A-3mwsA:20.1","6dj1A-3mwsA:76.25"],["6DJ1_B_AB1B201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",5,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48","None","0.80A","6dj1B-3mwsA:19.6","6dj1B-3mwsA:76.25"],["6DJ1_B_AB1B201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.54A","6dj1B-3mwsA:19.6","6dj1B-3mwsA:76.25"],["6DJ2_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",8,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","0.94A","6dj2A-3mwsA:20.1","6dj2A-3mwsA:75.00"],["6DJ2_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",10,"ASP A  25;ALA A  28;ASP A  29;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82;ILE A  84","None","0.55A","6dj2A-3mwsA:20.1","6dj2A-3mwsA:75.00"],["6DJ2_B_AB1B201_0","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",7,"ASP A  25;ALA A  28;ASP A  30;GLY A  48;PRO A  81;VAL A  82;ILE A  84","None","1.34A","6dj2A-3mwsA:20.1","6dj2A-3mwsA:75.00"],["6DJ2_B_AB1B201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",6,"ALA A  28;ASP A  29;ASP A  30;VAL A  32;GLY A  48;PRO A  81","None","1.11A","6dj2B-3mwsA:19.4","6dj2B-3mwsA:75.00"],["6DJ2_B_AB1B201_1","HIV-1 PROTEASE","3mws","HIV-1 PROTEASE","Human immunodeficiency virus 1",12,"ARG A   8;ASP A  25;GLY A  27;ALA A  28;ASP A  29;ASP A  30;VAL A  32;ILE A  47;GLY A  49;ILE A  50;PRO A  81;VAL A  82","None","0.57A","6dj2B-3mwsA:19.4","6dj2B-3mwsA:75.00"]]